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Summary
Orally-administered controlled-release drug delivery systems are associated with the short-
comings of relatively short residence times in the human stomach as well as highly variable
gastrointestinal (GI) transit times. Thus, considerable intra-individual and inter-individual
di erences in the bioavailability of drugs are observable. There are numerous drug substances
which may benefit from prolonged and controlled GI passage times. As a solution to the problem,
gastroretentive drug delivery systems (GRDDS), which feature an enhanced gastric residence
time (GRT), were developed. Several gastric retention approaches, such as flotation, have been
proposed and analyzed.
Despite the extensive research performed in the field of GRDDS, the development, the
production, and the evaluation of floating devices are still challenging. The aim of the thesis
was to come up with a formulation strategy which facilitates the design of innovative floating
drug delivery systems (FDDS).
Hydrophilic and lipophilic floating formulations were prepared by wet granulation and melt
granulation, respectively. Tablets with an inherent density of less than unity were compacted
using porous functionalized calcium carbonate (FCC) as matrix-forming component. For the
concurrent assessment of drug release by UV/Vis spectroscopy and floating behavior by visual
observation, a custom-built stomach model method was set up. Our in vitro evaluation method
was combined with in silico dissolution simulations to analyze the floating force as a function
of drug release. To determine the in vivo gastric retention potential of FCC-based FDDS, a
study protocol has been proposed for the assessment of the stomach residence time of floating
tablets and non-floating references in humans.
The production of tablets and mini-tablets, which met the requirements for immediately
floating tablets (i.e. inherently low density accompanied by su cient hardness), was possible
due to the characteristic lamellar structures of the FCC particles. The tablets showed no
floating lag time and remained afloat until complete release of the model drug substance ca eine.
For the hydrophilic formulation, the drug release was erosion-controlled and the flotation
mechanism was a reaction-based erosion mechanism with gelation-layer-forming polymers as
imbibition-inhibiting and gas-entrapping components. In the case of the lipophilic formulations,
flotation was achieved by slowing-down and/or inhibiting the reaction-based erosion of FCC
due to hydrophobization of the particle’s stratum layer [215]; the release of the drug was
vii
SUMMARY
di usion-controlled and erosion-controlled.
A FDDS formulation design tool box (including the novel pharmaceutical excipient FCC,
an in vitro stomach model, an in silico tablet dissolution simulation approach, and an in
vivo clinical study concept) was proposed to assist the future formulation development, the
production, and the analysis of innovative FDDS. We introduced and applied a classification
system, including an “ideal” floating performance (i.e. no floating lag time, maintaining of the
floating force until complete drug release, followed by a decrease of the floating capability) to
categorize experimentally observed flotation behavior. It was shown that FCC is an enabling
excipient for the manufacture of FDDS and the preparation of formulations with an “ideal”
floating behavior was possible. The results of the in vivo experiment provided a first evidence
for the gastric retention potential of FCC-based floating tablets in humans.
viii
1
Introduction
In the following chapter, the anatomy and the physiology of the human stomach are describedin order to illustrate the gastrointestinal (GI) transit of orally-administered pharmaceutical
dosage forms. The concept of gastroretentive drug delivery with focus on floating drug delivery
systems (FDDS) is explained. Furthermore, the current state of research in the field of gastrore-
tentive drug delivery is summarized and shortcomings associated with the manufacture and the
evaluation of floating dosage forms are shown.
1.1 Drug candidates for a gastroretentive delivery approach
The residence time of an orally-administered dosage form in the human stomach and hence of
the drug substance is relatively short compared to the transit time through the rest of the GI
tract [82]. It is reported that orally-administered drugs pass through the stomach to the intestine
within 1 to 2 h [95]; whereas, the residence time in the colon may take 15 up to 48 h [240].
Thus, a reason and a need for a gastroretentive delivery approach are primarily dictated by
physiological necessity. By prolonging the stomach residence time of a pharmaceutical dosage
form, the total GI transit time of the active pharmaceutical ingredient (API) is extended.
Consequently, the bioavailability and the therapeutic e cacy may improve. A reduction of the
dose, as well as of the drug administration frequency, may be possible [226].
The gastroretentive delivery approach o ers new and important therapeutic options for
numerous APIs [168]. An overview of drugs which benefit from a prolonged GI residence time
is given below:
(i) Drugs which are locally active in the stomach, such as antacids [62], antibiotics for the
1
CHAPTER 1. INTRODUCTION
eradication therapy of Helicobacter pylori infections (e.g. amoxicillin, metronidazole) [10],
and misoprostol [161], profit from an extended stomach residence time.
(ii) The gastroretentive drug delivery approach is beneficial for APIs with a narrow ab-
sorption window in the stomach or in the upper part of the small intestine
(e.g. ciprofloxacin [6], cyclosporin [15], furosemide [162], levodopa [94], p-aminobenzoic
acid [103, 104], and riboflavin [94]).
(iii) An extended stomach residence time may be favorable for drugs which exhibit a low
solubility at higher pH values (e.g. chlordiazepoxide [205], diazepam [204], and
verapamil HCl [196]).
(iv) Drugs, such as captopril [156], which are unstable in the intestinal or colonic
environment are possible candidates for a gastroretentive delivery approach.
However, it has to be kept in mind that a prolonged retention in the stomach is not
appropriate for drugs which may cause gastric lesions (e.g. non-steroidal anti-inflammatory
drugs) [226]. The gastroretentive delivery approach is also not convenient for APIs that are
unstable in the acidic stomach environment [220].
1.2 Anatomy and physiology of the stomach
The human stomach is an “J”-shaped organ which is positioned in the left upper part of
the abdomen, behind the liver, part of the diaphragm, and the anterior abdominal wall. The
pancreas, the left kidney, the left adrenal, the spleen, and the colon are situated behind it.
Though, the position, the shape, and the size of the stomach may vary depending on the extent
of the gastric contents [120, 240]. The empty stomach has a volume of approx. 50 mL; in the
filled state, the stomach volume increases up to a maximum of 1500 mL [207].
1.2.1 Structural organization
Figure 1.1 illustrates the structure of the human stomach. The organ is dividable into di erent
anatomical regions, these include the fundus, the body/corpus, and the pylorus (i.e. pyloric
antrum and pyloric canal) [89]. The proximal part of the stomach, which is composed of the
fundus and the upper one-third of the body, functions as a reservoir for ingested food and
liquids [115]. The distal stomach, consisting of the remaining body and the pyloric portion,
is the main region responsible for mixing motions, grinding, and homogenization of gastric
contents. In addition, the gastric emptying of ingested material is regulated in this part by
contraction and propelling actions [122].
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Figure 1.1. Structural organization of the human stomach. Adapted from Washing-
ton et al. [240].
1.2.2 Gastric pH
In general, the gastric pH for the fasted state is reported to range from 1.5 to 2.0 [27]. It is not
uniform within the di erent regions of the human stomach due to variations in the distribution
of the gastric acid-producing parietal cells and due to gastric motility [240]. Dressman et al.
measured a median gastric pH of 1.7 in the case of young, healthy men and women. In the fed
state, following the ingestion of a standard solid and liquid meal, the gastric pH increased to a
median value of 6.7 [55].
Several parameters, including gender and age [187, 240], diseases [139], drugs [27], and
composition of meals [240], were investigated regarding their e ect on the gastric pH. However,
the results of the in vivo evaluation in human are often contradictory. Some studies demonstrate
an influence of the above-mentioned factors on gastric pH; whereas, other trials do not reveal
any e ect.
1.2.3 Gastric motility patterns
Two distinct patterns of GI motility, based on fed or fasted state, are distinguished [64]. The
gastric emptying process occurs in both conditions [43].
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Figure 1.2. Overview of the phases of the MMC; it was first described in human in
1977 by Vantrappen et al. [233]. Adapted from Kong and Singh [122], Luik-
ing et al. [133], Minami and McCallum [145], and Washington et al. [240].
1.2.3.1 Fasted state
In the absence of any digestible material, the stomach and the small intestine return to the
fasted motility pattern, which is their resting condition [240]. The fasted state is characterized
by an interdigestive series of events: the migrating myoelectric complex or migrating
motor complex (MMC) [133]. The contraction pattern cycles through the stomach and the
small intestine in 2 to 3 h [64]. Within an individual and between individuals, the MCC activity
varies significantly [52]. Di erences are observed in the total MMC cycle length, the duration
of the individual phases, and the amplitude of the contractions [114].
Figure 1.2 displays the four consecutive phases of the MMC which are discriminated by
di erent contractile activities. The MMC starts with a quiescent state (Phase I) where no
motor activity or only rare contractions take place in the stomach. It is followed by series of
irregular mixing contractions (Phase II) that begin simultaneously in both the antrum and
the duodenum. The intensity and the frequency of the contractile activity increase during this
period; a contraction strength up to 40 mm Hg is recorded. Phase III is characterized by
powerful and regular contractions at their maximum frequency and amplitude (up to 80 mm Hg)
against an open pylorus also referred to as “housekeeper waves”. Large solid particles are now
emptied from the stomach into the small intestine. Then, the motor activity decreases and is
followed by a resting period (Phase IV).
The cycle repeats until a meal is ingested. The ingestion of food disrupts the fasted state
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motility pattern and initiates the digestive phase of motility [122, 240].
1.2.3.2 Fed state
After the ingestion of a meal, the digestible material is processed in the stomach to chyme. The
chyme is a slurry composed of separate phases of aqueous solution, fats, and solid material [122,
207]. Both mechanical forces and chemical reactions break down the ingested meal into small
food fragments.
The motility pattern of the stomach walls is characterized by two types of contractions [122].
The first type of motor activity is slow and weak, volume-reducing contractions that arise
in the upper part of the stomach [163]. The second type of muscle contractions are series of
peristaltic waves which originate in the corpus and spread distally towards the duodenum with
continuously increasing intensity [65, 240]. The contraction forces are responsible for the mixing
and grinding motions in the stomach and push the antral contents towards the pylorus [122].
They are often referred to as antral contraction waves [65]. The antral contractions progress
towards the duodenum until simultaneous contraction of antrum and pylorus (i.e. antral systole).
After closure of the pylorus, the antral systole mixes solid components with the gastric juice; it
grinds and retropels food particles into the proximal antrum. A “sieving e ect” occurs as large
and dense food fragments get trapped ahead of the constriction [122, 240].
The gastric emptying of meal components (liquids, digestible and indigestible solids) occurs
at di erent rates and not in form of a homogeneous mass. The liquid components empty
exponentially (i.e. first order kinetics) according to the pressure gradient between stomach and
intestine [26]. The stomach empties solid material in a biphasic pattern. A variable lag time,
during which only little material is emptied, is followed by a linear phase of emptying [206].
Solid components are emptied after they were ground, due to grinding and shear forces, to
particles sizes smaller than 1 to 2 mm [122]. The duration of the lag time depends on the size
of the food particles: larger particles need longer digestion times to be broken down into sizes
enabling the emptying through the pylorus.
1.2.4 Gastric emptying process
Numerous factors influence the gastric emptying process and, consequently, the gastric residence
time (GRT) of orally-administered drug delivery systems. The characteristics of a dosage form
a ect its retention in the stomach [151, 240]. The intake of food and the administration of some
drug substances are known to modify the gastric motility pattern [22, 153]. Intra-subject and
inter-subject variability in stomach emptying may be explained by physiological factors [220].
(i) Properties of dosages forms which influence the gastric emptying
The emptying of delivery systems from the stomach depends on the type of dosage form:
the stomach transit time of solutions, capsules, pellets, and tablets varies. Solutions pass
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through the stomach into the duodenum within 18 min; the longest stomach residence
time is observed for tablets with approx. 2.7 h [168]. In addition, the gastric emptying
time of dosage forms is a ected by their density and size. In most cases, it applies: the
larger the size of the system the longer the GRT. Due to the larger size, the stomach
emptying through the pylorus is hindered [5, 35, 75]. Disintegrated tablets are emptied
with the digestible phase of a meal; whereas, tablets that remained in shape are emptied
with the indigestible material [240].
(ii) Pharmaceutical agents which influence the gastric emptying
Prokinetic drugs enhance the gastric motility and promote the transit through the GI
tract [225]. The class of drugs includes, for example: benzamides (e.g. metoclopramide,
cisapride), cholinergic agonists (e.g. bethanecol), dopamine antagonists (e.g. domperi-
done), macrolide antibiotics (e.g. erythromycin), opiate antagonists (e.g. naloxone), and
somatostatin analogs (e.g. octreotide) [131].
In contrast, the GI motility is slowed down by anticholinergic agents (e.g. atropin [179],
propantheline [152]), opioids [150], and tricyclic antidepressants [247].
The anti-parkinsonian drug levodopa alters the gastric emptying [181]. Adrenergics
influence the GI motility: —2-adrenergic agonists (e.g. isoprenaline) retard, whereas,
—2-adrenergic antagonists (e.g. propanolol) accelerate the gastric emptying process [140].
(iii) Influence of food intake on the gastric emptying
The stomach empties liquids more rapid than solid material [115]. And the gastric
emptying of digestible solid meal components occurs faster than of indigestible solids [63].
The size of the ingested meal influences the gastric emptying: the larger the amount of
ingested liquid or solid material, the longer the time period which the stomach remains
in the fed motility pattern [240]. There is only little evidence provided to support the
hypothesis that the meal consistency has an impact [99]. However, the nutritive density
and the food composition (carbohydrates, proteins, fat) are reported to influence the
gastric emptying rate [235].
(iv) Physiological factors which influence the gastric emptying
The gastric emptying follows the circadian rhythm. The emptying of solids occurs in the
morning faster than in the afternoon and evening. In the case of liquids, no di erences in
the gastric emptying depending on the time of day are observed [79, 240].
The age does not seem to have an e ect on the gastric emptying. It was reported to be
similar for young and elderly persons; although, the secretion of hydrochloric acid (HCl)
and pepsin decreases in elderly people [135]. Contradictory study results were obtained
by Moore et al. They reported di erences in the stomach emptying of liquids for aged
men compared to young subjects [149].
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Healthy women exhibit significantly prolonged GRT of solid material compared to men;
but, no significant di erence is observed in the gastric emptying of liquid meals [14]. In
contrast, Datz et al. discovered that females empty both, solids and liquids, slower than
men [38]. The menstrual cycle and pregnancy are known to alter the gastric motility
patterns [19, 237].
Study results regarding the e ect of the body mass index on the gastric motility are
contradictory [18]. There are reports providing evidence that obesity is associated with
increased gastric emptying rates [109]. However, obese subjects were also found to exhibit
similar or depressed stomach emptying rates compared to normal weight subjects [97, 236].
In order to evaluate the influence of the body position on the stomach emptying, subjects
were studied in lying, sitting, standing, and combined sitting-standing postures. The
lying body position delays the gastric emptying process in comparison to the other body
positions [148].
(v) Diseases which influence the gastric emptying
Diseases which alter the stomach emptying process and the gastric motility are primarily
disorders of the GI tract [240]. Gastric ulcerations reduce the antral motility; therefore,
the stomach emptying is delayed [144]. In contrast, ulcerations in the duodenum are
reported to promote the gastric motility [127]. Patients su ering from diseases, such as
atrophic gastritis, Crohn’s disease, and pernicious anaemia, show delayed emptying of food
components [40, 126, 154]. The e ect of gastro-esophageal reflux on the emptying process
of solid material and liquids has been evaluated. In some patients, gastro-esophageal
reflux slowed down the gastric emptying, whereas, in a number of patients the gastric
motility patterns remained una ected [138].
Diabetic patients are known to exhibit altered GI motility patterns and drastically delayed
gastric emptying rates [98].
The study data regarding the impact of bulimia nervosa on the GI motility patterns
are contradictory. On the one hand, the gastric emptying was found to be una ected in
patients and, on the other hand, abnormal gastric motility patterns and emptying rates
were observed. Anorexia nervosa is associated with delayed stomach emptying of liquid
and solid meal components [51, 182].
During migraine attacks, the gastric emptying process is depressed in patients [17].
1.3 Gastroretentive drug delivery systems
Oral controlled-release pharmaceutical dosage forms are known to have limitations due to
relatively short and unpredictable GI transit times. The interest in innovative pharmaceutical
7
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drug delivery systems which exhibit prolonged GRT has significantly increased during the
last decades [176, 195]. Gastroretentive drug delivery systems (GRDDS) were developed to
overcome the drawback associated with conventional dosage forms [33]. GRDDS are designed to
remain in the stomach for an extended and controlled period of time [168]. Due to a prolonged
stomach residence time, the total GI transit time of the drug substance is extended and the
bioavailability may improve [5].
1.3.1 Approaches to prolong gastric retention
Researchers have proposed various mechanisms to retain drug delivery systems in the stomach
for an extended period of time [168, 226]. An overview of the di erent techniques is given in
Figure 1.3.
1.3.1.1 Co-administration of (pharmacologically active) substances
A prolonged GRT of drug delivery systems is achievable by the simultaneous administration of
(pharmacologically active) substances which slow down the gastric motility [50]. The passage-
controlling excipients may be incorporated in the dosage form and when the substances are
released, they delay the GI transit of the drug delivery device.
An in vivo study has demonstrated that the GI transit time can be modulated by the
administration of drug substances. The pre-treatment with metoclopramide enhances; whereas,
the pre-treatment with propantheline delays the gastric emptying process. The e ect of the
GI-motility-altering APIs has been investigated on the absorption of subsequently-administered
metformin in human subjects [136].
Dietary components (e.g. certain amino acids, fats, peptides) are known to prolong the time
period that a dosage form remains in the gastric region [42]. For example, the co-administration
of fatty acid salts (e.g. salts of myristic acid) delayed the gastric emptying in humans. The e ect
of ammonium myristate was studied in vivo following the administration of a commercially
available sustained-release nitrofurantoin capsule formulation. The renal nitrofurantoin excretion
was assessed in order to investigate indirectly the influence of ammonium myristate on the
absorption of the API. The addition of a GI-passage-controlling agent was found to improve
the drug bioavailability and to reduce the inter-individual variations [87, 88].
1.3.1.2 Bioadhesive and mucoadhesive systems
Bioadhesive (i.e. immobilization at intestinal surfaces) and mucoadhesive (i.e. immobilization
restricted to the mucus layer) systems prolong the relatively short GRT of orally-administered
drug delivery systems by adherence of the dosage form to the mucous membrane of the stomach
or the epithelial surface of the remaining GI tract [166, 173, 226]. There are di erent theories
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GRDDS
Co-
administration
of substances
Combination
systemsDensity-
controlled
systems
High-density
systems
Floating
systems
Bio/mucoadhesive
systems
Size-increasing
systems
Modified-
shape
systems
Expanding,
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systems
Figure 1.3. Overview of di erent approaches to prolong gastric retention. The most
commonly used and the more rarely used mechanisms are colored in light
gray and dark gray, respectively [220, 242].
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to explain the mechanism of bio/mucoadhesion: the electronic theory, the adsorption theory,
the wetting theory, and the di usion-interlocking theory [10].
Several polymers have been analyzed regarding their bio/mucoadhesive potential. Chitosan,
cholestyramine, poly(acrylic acid) (e.g. Carbopol®, polycarbophil), Gantrez® (polymethyl vinyl
ether/maleic anhydride copolymers), cross-linked dextran gel (e.g. Sephadex®), dextran, hydrox-
ypropyl methylcellulose (HPMC), polyethylene glycol, sodium alginate, sucralfate, tragacanth,
poly(alkyl cyanoacrylate), and polylactic acid are used for preparation of bio/mucoadhesive
systems [10, 81, 242].
The gastroretentive potential of bio/mucoadhesive GRDDS has been evaluated in vivo in
human. Using “-scintigraphy, the influence of polycarbophil on the GRT of a pellet formulation
was investigated in fasted subjects. The pellets were found to be rapidly emptied from the
stomach [117].
Akiyama et al. compared the GI transit time of sustained-release adhesive and non-adhesive
microspheres in fed and fasted volunteers. The GI transit was pharmacokinetically assessed by
analyzing the furosemide plasma concentrations and the riboflavin concentrations in urinary
excretions. The microspheres, based on the bioadhesive substance carboxyvinyl polymer, showed
an extended gastric retention due to the adherence of the dosage form to the gastric and/or
intestinal mucosa [1].
The in vivo “-scintigraphic studies of Säkkinen et al. did not provide a clear evidence
whether formulations containing microcrystalline chitosan can be used as gastroretentive
delivery platform. In a few volunteers the microcrystalline chitosan granules were retained in
the GI tract for an extended time period compared to the reference formulation of lactose
granules [188].
It is di cult to target specifically the GI walls. The use of bio/mucoadhesive substances
bears the risk of the dosage forms to attach to the esophageal walls. This results in injuries or
possible occlusion of the esophagus [168]. Another challenge is the high gastric mucus turnover
rate [3]. Due to the regular renewal of the mucosal surface, the adhesion duration is limited [173].
In the stomach and the intestine, the mucus is constantly secreted and digested from the luminal
surface. In the human stomach, the turnover time from the production to the removal of the
mucus layer is estimated to range from 4 to 5 h [240]. The bio/mucoadhesive drug delivery
systems may be encased by a mucus shell. In addition, the e cacy of the delivery approach is
influenced by the gastric peristalsis because it may hinder the adhesion of the dosage forms to
the GI walls [3].
1.3.1.3 Size-increasing systems
The size-increasing GRDDS are based on the principle of expansion of the pharmaceutical
dosage form in the stomach to dimensions larger than the pyloric sphincter [220]. Consequently,
the gastric emptying of the drug delivery system through the pylorus is retarded [176].
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The size-increasing systems exhibit three configurations. The initial size of the dosage form
should be small to facilitate swallowing (“collapsed” configuration) [176]. The delivery approach
bears the risk of causing severe injuries or obstruction of the esophagus due to a premature
expansion of the dosage form during swallowing [110]. After contact with the gastric juice,
the size of the device increases rapidly to prevent uncontrolled stomach emptying through the
pylorus [220]. The diameter of the human pyloric sphincter is reported to be 12.8±7 mm [120,
189]. It is thought about establishing a threshold value for the size of dosage forms above which
a significant gastric retention may be observable. Researchers have suggested to set a minimum
tablet size of 13 mm as cut-o  value [120, 220]. The cut-o  value is supported by experimental
observations: it was discovered that non-disintegrating tablets with a size of 13 mm were
retained in the stomach for a prolonged time period compared to 7 mm tablets [118]. The
expanded dosage form needs to be rigid enough to withstand the mechanical destruction forces
acting in the stomach. On the other hand, the device should not e ect the gastric motility,
inhibit the gastric emptying, or show local adverse e ects (e.g. puncture of the GI walls) [120].
After release of the API, the GRDDS need to be present again in a small configuration to
allow clearance from the stomach in order to prevent a permanent stomach retention [168]. The
delivery approach has the potential risk of life-threatening complications due to the occlusion
of the pylorus or due to the accumulation of dosage forms after multiple administrations.
The size-increase of dosage forms is achievable by di erent principles. They are explained
and illustrated, by means of examples, in the section below:
(i) Expanding, swelling systems
In the stomach, the expanding, swelling systems increase in size to such an extend that
their passage through the pyloric sphincter into the intestine is prevented and their GRT
is prolonged. Due to their tendency to remain stuck at the pyloric sphincter, the dosage
forms are referred to as “plug-type-systems” [200].
Enzyme-digestible hydrogels, based on polyvinylpyrrolidone (PVP) cross-linked with
functionalized albumin, have been prepared to extend the GRT of APIs. The swelling and
degradation properties of the system were controllable by the albumin cross-linker content
and by adjusting the degree of albumin alkylation [198, 199]. The concept of hydrogels
has been further investigated and superporous hydrogels, which exhibit gastroretentive
properties due to rapid swelling of the delivery system, were developed. The fast swelling of
the superporous hydrogels to equilibrium size within minutes is achieved by liquid uptake
due to capillary wetting through inter-connected pores. The addition of composite material
(e.g. croscarmellose sodium) during the synthesis improves the mechanical properties of
the hydrogels [29–32]. Omidian et al. have invented novel superporous hydrogel hybrids
with advanced mechanical, elastic, and swelling properties [158, 159].
A GRDDS composed of a swellable tablet core which is coated with a porous membrane
11
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has been investigated. The inner core consisted of the API, the expanding agents (e.g. PVP,
Carbopol®), and calcium carbonate. For the permeable tablet coating, di erent ratios and
types of Eudragit® were studied regarding su cient elasticity to withstand the expansion
pressure during swelling and to allow the disintegration of the dosage form after drug
release [47, 48].
An expanding system, which exhibits a very high swelling ratio (2 to 50-fold volume
increase), has been patented by Theeuwes et al. Due to its large size, the device was, on the
one hand, retained in the stomach for an extended time period and, on the other hand, it
influenced the gastric motility pattern. The GRDDS are supposed to maintain the stomach
in the fed state and thereby delay the onset of the “housekeeper waves” which would
empty the dosage form from the stomach. The device consists of tiny, drug-containing
pills with a release-controlling wall dispersed within a hydrogel reservoir. The stomach
emptying is enabled due to erosion of the device [228].
A complex mechanism of action to increase the dimensions of a drug delivery system and
to achieve its gastric retention has been described by Mamajek and Moyer (Figure 1.4).
The outer polymer envelope, which is permeable for both, drug and body fluids, contains
an expanding agent and a drug metering device. After contact with the gastric contents,
the expanding agent causes the expansion of the envelope by osmotic pressure. As a result,
the dosage form is retained in the stomach while the drug metering mean releases the
API in a controlled manner [134].
Gröning et al. developed compressed collagen sponges which expand after contact with
the gastric fluids. The in vivo gastric retention capability of the devices has been studied
in healthy human subjects following the oral administration of collagen tablets and small
sustained-release reference tablets. In the case of the expanding devices, the renal excretion
of riboflavin was enhanced; hence, providing evidence for the applicability of the collagen
sponges as a drug delivery platform featuring a prolonged GI transit time [85, 86].
(ii) Modified-shape systems
Several unfolding GRDDS with di erent geometry, size, erodibility, and mechanical
properties have been patented. For example, the dosage forms exhibit the following
geometries: cloverleaf, planar disc, planar multilobe, pellet/sphere, ring, solid stick, and
string (Figure 1.5). For a convenient oral administration, the devices are packed into
gelatin capsules. In the stomach, the capsule dissolves and releases the drug delivery
device. It unfolds to a su ciently large size preventing the emptying through the pylorus.
The developed GRDDS are claimed to exhibit su cient resistance to the forces present in
the GI tract. After a predetermined period of time, the erosion of the device occurs; thus,
enabling the stomach emptying of the dosage form [23–25]. The in vivo performance of
2 cm-arms tetrahedrons has been studied in human. In the fasting state, the administered
12
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Figure 1.4. Schematic representation of expanding delivery devices proposed by Mamajek
and Moyer [134]. (a.) The dosage form consists of a polymer envelope (A)
which contains drug and expanding excipients (B). (b.) The system is based
on a drug mixture (D) which is enclosed by a first polymer envelope (E),
surrounded by expanding excipients (F), and packed into another polymer
envelope (G). (c.) The drug delivery device is composed of the drug mixture (I)
embedded into expanding excipients (J), and enclosed by an outer polymer
envelope (K). Release of the drug substance is indicated by (C).
13
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Figure 1.5. Schematic representation of unfolding devices proposed by Caldwell et al.
The carrier gelatin capsule contains a drug delivery system in the compressed
state. In the stomach, the delivery device unfolds. Adapted from Bardon-
net et al. [10].
tetrahedrons exhibited a median GRT of 3 h. But, the stomach residence time was found
to be highly variable, ranging from 0.5 to 6 h. Under fed conditions, the median GRT
increased to 6.5 h. The retention time of the dosage form in the human stomach, after
the regular ingestion of meals, varied from 3.5 to 12 h [67].
The unfolding GRDDS are often associated with the disadvantages that the devices
are complex and expensive from the manufacturing point of view. Another problem
of the above-described modified-shape systems is the degradation of their elastic and
mechanical properties after relatively short time. Long storage times and the stress
thereby applied to the dosage forms a ect negatively the ability of the devices to expand
in the stomach [120, 168]. This drawback was addressed by Pogany and Zentner. They
invented bioerodible, thermoset, covalently-crosslinked, elastomeric poly (ortho esters).
The material, being referred to as “prolonged mechanical shape memory material”, extends
the time period after which the dosage forms start loosing their unfolding capability [172].
In order to extend the GRT of drug substances, Sonobe et al. developed modified-shape
systems composed of at least three coplanar limbs which extend from the center of the
device (Figure 1.6). The GRDDS are prepared of a molding of “prolonged shape memory
material” combined with eroding excipients. The API is mixed with the erodible material;
it defines the stomach residence time of the dosage form by its degradation rate [211].
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Figure 1.6. Schematic representation of unfolding dosage forms proposed
by Sonobe et al [211]. The devices (e.g. Y-shape, cruciform) are con-
structed of so-called “shape memory material” (A), erodible material serving
as drug reservoir (B), and connection pieces (C).
Figure 1.7. Schematic representation of a gastroretentive dosage form proposed by Cura-
tolo and Lo [37]. The device is composed of four retention arms (B) connected
to a receptacle (A) which contains a controlled-release tablet (C).
An unfolding spiral or coil configuration was proposed by Curatolo and Lo to delay the
GI transit time of drug substances (Figure 1.7). It consists of a drug reservoir in form
of a capsule or tablet and at least one retention arm attached to the drug container.
In the stomach, the fiber-shaped or ribbon-shaped retention arms should unfold, uncoil
or unroll to reach cross-sections of at minimum 3 cm. After complete API release, the
gastric emptying of the receptacle is enabled due to softening, disintegration, dissolution
or detachment of the retention arms [37].
The successful in vivo performance of an unfolding multilayer (“sandwich-type”) polymeric
GRDDS was demonstrated by Klausner et al. After oral administration of the drug
delivery device to healthy subjects, a significant prolongation of the absorption phase was
observed for drugs with a narrow absorption window in the GI tract (e.g. furosemide,
levodopa) [71, 119, 121].
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1.3.1.4 Magnetic systems
The magnetic systems are composed of a dosage form, containing a small internal magnet or
a mass of magnetic material, and an extra-corporal magnet to control the GI transit of the
dosage form [72, 84].
The concept of magnetic drug delivery systems has been evaluated in human. By using a
magnetic model dosage form which consists of small magnets attached to a pH-telemetring
capsule (Heidelberg capsule), it was demonstrated that due to an external magnet the GRT
of the model dosage form could be significantly extended [83]. In addition, magnetic depot
tablets have been analyzed. They were retained in the stomach region for a prolonged period
of time; hence, an extension of the acyclovir absorption after peroral administration of a
sustained-release magnetic drug delivery platform was achieved [84].
Despite the promising results of the in vivo studies, the magnetic drug delivery systems
exhibit a major shortcoming: the external magnet needs to be placed with a high degree of
precision; therefore, a good patient compliance is required.
1.3.1.5 High-density systems
Orally-administered pharmaceutical dosage forms with a density higher than the density of the
gastric contents (1.004-1.01 g/cm3 [174]) sink down to the bottom of the greater curvature of
the stomach, in case the patient is in an upright position, and get entrapped in the folds of the
antrum. The devices are located on a level lower than the pylorus away from the antral mixing.
Consequently, the gastric emptying is supposed to be delayed [13]. High-density systems are
prepared by the incorporation of heavy inert material, such as barium sulfate, iron powder,
titanium dioxide, and zinc oxide [10, 184].
Contradictory results were obtained regarding the influence of density on the GI passage
time of dosage forms. The in vivo gastric emptying rates of pellets with densities of 0.94 g/cm3
and 1.96 g/cm3 did not di er significantly in “-scintigraphy studies [44]. The observation is
supported by the finding that pellets with densities of 1.29 g/cm3 and 1.92 g/cm3 did not vary
in gastric emptying times [35].
In contrast, Bechgaard and Ladefoged have reported prolonged average GI transit times in
ileostomy subjects after increasing the density of a multiparticulate formulation from 1 g/cm3
to 1.6 g/cm3 [13]. The clinical study of Simoni et al. showed that the administration of an
enteric-coated sinking ursodeoxycholic acid tablet formulation (density>1 g/cm3) to healthy
subjects resulted in a better bioavailability of ursodeoxycholic acid compared to an enteric-coated
floating tablet and a hard gelatin capsule [208].
Above a threshold value of 2.4-2.8 g/cm3, the high-density delivery systems are reported to
be retained in the rugae at the bottom of the stomach [36]. A significantly prolonged stomach
residence time was found for pellets with a density of 2.6 g/cm3 [36] and 2.8 g/cm3 [49] in
comparison to control pellets with a density of 1.5 g/cm3.
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Up to now, there is no high-density GRDDS available on the market. A drawback of the
dosage forms is the limited drug loading capacity. High amounts of heavy inert material need to
be added to the formulations in order to achieve and maintain a su ciently high density. The
porosity of high-density devices is low, resulting in a slow drug release speed and in di culties
controlling the drug release kinetics.
1.3.1.6 Floating systems
The concept of tablets which have a density less than unity was first described in 1968 by Davis.
His invention was aimed to solve the problem of gagging and choking experienced by some
people when swallowing a pharmaceutical dosage form. Due to a density less than unity, the
medicinal pill floats on liquid surfaces. The intake with a certain volume of water is supposed
to facilitate swallowing of the dosage form [41].
FDDS are pharmaceutical dosage forms exhibiting a density lower than the gastric fluids
(1.004-1.01 g/cm3) [201]. Due to its density less than unity, the dosage form floats on the
gastric contents and is retained in the stomach while releasing the API [168]. FDDS o er the
advantage that they do not influence the gastric emptying process [209]. But, the filling state of
the stomach is important; a certain amount of liquid is required for floating delivery platforms.
Single-unit FDDS (e.g. tablets, capsules) are associated with the problem of “all-or-nothing”
gastric emptying [10]. Therefore, high inter-subject and intra-subject variability in GI transit
time and in bioavailability are observed. However, most floating devices described in literature
are single-unit dosage forms [209]. The design of multiple-unit FDDS o ers the possibility to
overcome the shortcomings of single-unit devices [212]. Multiple-unit floating dosage forms
spread over the gastric contents and they are gradually emptied from the stomach. The drug
release profiles are supposed to be more predictable and inter-individual as well as intra-
individual di erences in bioavailability are claimed to be reduced [168].
Di erent mechanisms are known to achieve flotation: floating systems due to swelling of
excipients [205], non-e ervescent systems with an inherently low density [220], and
e ervescent systems which float due to the generation and entrapment of gas [8].
(i) Non-e ervescent drug delivery systems with flotation due to swelling
One of the first floating GRDDS described in literature is the so-called hydrodynamically
balanced system (HBSTM). It is a single-unit floating gelatin capsule which contains a
mixture of drug substance and one (or more) gel-forming hydrophilic polymers [205]. For
example, agar, alginic acid, carrageenans, hydroxyethylcellulose, HPMC, hydroxypropyl-
cellulose, and sodium carboxymethylcellulose have been studied as gelation-layer-forming
excipients [168]. Upon contact with the gastric fluids, the gelatin capsule shell dissolves;
hydration and swelling of the polymers occur. A buoyant mucus body with a density of
less than unity is formed. At the surface, the gelatinous barrier erodes constantly and a
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new hydrated layer is generated. The API release is controlled by di usion and by erosion
of the hydrated gel barrier. The principle of HBSTM is also applied for the preparation of
floating gastroretentive tablets [202, 203] and mini-tablets [185].
Kumar et al. has studied the use of glycerol monooleate (GMO) matrices for the manu-
facture of floating, swelling GRDDS. The API was added to molten GMO under stirring.
Then, the molten mass was transferred into cylindrical molds and frozen. The swelling and
flotation performance of the devices has been evaluated in vitro. The authors concluded
that GMO matrices are suitable for oral controlled-release floating GRDDS [125].
(ii) Non-e ervescent floating drug delivery systems with inherently low density
The preparation of FDDS featuring an inherently low density (i.e. the devices are im-
mediately floating on the gastric contents) is favored. The systems have a reduced risk
of unpredictable, premature gastric emptying because the flotation mechanism does not
need to be activated in the stomach [220]. Long floating lag times increase the possibility
of premature gastric emptying of the dosage forms by the “housekeeper waves” before
flotation starts. An inherently low density may be achieved by the entrapment of air
and/or the incorporation of low-density material [220]. Such kind of low-density material
includes, for example, fatty components or oils [213], porous material [57], and foamed
powders [217].
Krögel and Bodmeier proposed HPMC tablets in combination with a hollow, impermeable
cylinder. Each HPMC tablet closes one of the ends of the cylinder in a way that an
air-filled compartment is created providing an inherently low density to the delivery
system. But, the flotation of the device is terminated as soon as at least one of the tablets
has dissolved [124].
A delivery platform (Dome Matrix®) based on hydrophilic matrices which are prepared
by “release modules assemblage” technology has been presented by Losi et al. The device
is constructed of units having the shape of a disc with one convex and one concave
base. For FDDS, two di erent base-shaped matrices (i.e. “male” and “female” module)
are interlocked in “void configuration”. The internal void space provides an inherently
low density to the dosage form [132, 157, 221, 222]. Strusi et al. evaluated the in vivo
performance of a FDDS based on the Dome matrix® technology in humans. The “-
scintigraphy proofed a significantly-prolonged GRT for the floating device compared to
the non-floating control system [222].
A single-unit floating delivery device with an inherently low density was developed by
Watananbe et al. The system consists of a hollow core (e.g. empty hard gelatin capsule,
polystyrene foam, pop rice grain) coated subsequently with two layers: a subcoat of cellulose
acetate phtalate and an outer API-containing coating of ethylcellulose/HPMC [241]. FDDS
based on highly porous foamed powder, which provides an inherently low density, have
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been proposed. Tablets were compacted of propylene foamed powder, matrix-forming
polymers, API, and optional a filler material [218]. The highly porous foamed powder
was also used for the preparation of multiparticulate FDDS [217, 219].
Multiple-unit hollow microspheres (microballoons; size ranging from 1 up to 1000 µm)
consisting of enteric polymers, combined optionally with hydrophilic or hydrophobic
polymers, and containing the API in the outer polymeric shell were prepared by emulsion-
solvent di usion method [60, 112, 113, 192]. Lee et al. introduced a non-volatile oil as core
material to optimize the drug release kinetics from the devices [128]. The drug delivery
platform has been investigated following oral administration of riboflavin-containing
microballoons and non-floating controls to healthy human volunteers. The GI behavior
was studied by “-scintigraphy and by urinary excretion of riboflavin. In the fed state,
the floating microspheres were dispersed in the upper part of the stomach and were
retained for a prolonged period of time (up to 5 h) compared to the non-floating reference
formulation. Based on the in vivo results, the authors concluded that floating microballons
are suitable for improving the drug bioavailability and for sustaining the pharmacological
action [193].
An alternative technique for the design of multiple-unit FDDS featuring an inherently
low density was proposed by Iannucelli et al. [100, 101]. The individual units with a
size of 4-7 mm consist of a calcium alginate core and a calcium alginate (or calcium
alginate/polyvinyl alcohol) membrane with an air compartment between core and outer
layer. The authors reported excellent in vitro buoyancy properties of the FDDS. The
behavior of the air-compartment multiple-unit GRDDS was also investigated in human
subjects. In the fasted state, the floating and non-floating dosage forms did not di er in
their gastric emptying time. In contrast, the GI passage time was found to vary under fed
conditions: the FDDS were retained in the stomach for a prolonged time period [102]. The
findings were supported by the study results of Whitehead et al. In the case of floating
calcium alginate beads, the “-scintigraphic evaluation in humans in the fed state showed
extended gastric transit times compared to the non-floating controls [245].
(iii) E ervescent drug delivery systems with flotation due to gas generation and
entrapment
The flotation of dosage forms may be achieved by gas generation, upon contact with
body fluids, and entrapment of the gas bubbles in a swollen matrix [220]. For example,
carbon dioxide is generated by carbonates or bicarbonates reacting with acidic compo-
nents (i.e. gastric acid, citric or tartaric acid added to the formulation) [10]. E ervescent
floating devices have been prepared by intermixing carbon-dioxide-producing excipi-
ents with matrix components and compacting the mixture into tablets [39, 106, 107].
Rouge et al. selected the approach for the preparation of floating mini-tablets containing
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sodium bicarbonate as gas-generating agent [186].
As they o er the possibility to formulate and optimize the API and the flotation-promoting
excipients individually, bilayer [105, 178] and multilayer [248, 249] floating tablets have
been proposed. The gas-generating layer contains e ervescent substances and, maybe in
addition, acidic excipients. Upon contact with the acidic gastric fluids, carbon dioxide is
generated and gets entrapped within a gelling hydrocolloid; thus, providing buoyancy to
the dosage form. Additionally, capsules that are based on the same flotation mechanism
were evaluated [129, 130]. For example, Umezawa et al. patented floating mini-capsules
with a diameter in the range of 0.1-2.0 mm. The mini-capsules consisted of a sodium
bicarbonate core coated with an inner HPMC layer and an outer pepstatin layer [232].
A balloon-like, multiple-unit dosage form which floated due to carbon dioxide generation
was developed and evaluated by Ichikawa et al. The system is constructed of a core-shell
structure, i.e. the sustained-release core is coated with two subsequent layers: an inner
e ervescent (e.g. sodium bicarbonate and tartaric acid) layer and an outer swellable
membrane containing polyvinyl acetate and shellac [104].
The applicability of ion-exchange resin beads for the preparation of e ervescent FDDS was
studied in vitro and in vivo by Atyabi et al. The resin beads are loaded with bicarbonate
which, upon exposure to acidic gastric fluids, releases carbon dioxide. The delivery system
floats due to entrapment of the gas within a semipermeable membrane that surrounds the
resin beads. The “-scintigraphic evaluation in human volunteers showed a significantly-
prolonged GRT of the coated resin beads compared to non-coated controls [7, 8].
An alternative approach to provide flotation to dosage forms by gas formation is the use
of matrices containing a gas with a boiling point below 37 ¶C (e.g. cyclopentane, diethyl
ether) [220]. The gas is incorporated in the device in solid or liquid form at ambient
temperature. It evaporates at physiological temperature and inflates the dosage form.
Several drug delivery systems have been patented using this floating mechanism [11, 12,
142, 143, 171]. Though, the approach is mainly interesting from scientific point of view as
the manufacture of the complex devices is expected to be challenging [220].
Buoyancy due to gas generation and entrapment is associated with the disadvantage of
floating lag times because the gas needs to be produced first. Therefore, the delivery
device may undergo a premature stomach emptying before it starts floating on the gastric
contents [168].
1.3.1.7 Combination systems
This kind of system combines di erent gastroretentive approaches to extend the GRT of drug
delivery platforms; thus, is allows to overcome the drawbacks of the individual concepts. It
is common to combine the working principles of flotation and bio/mucoadhesion [108, 210,
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231, 234, 250]. The joint application of swelling and bio/mucoadhesion for gastroretentive drug
delivery was also investigated [28].
The introduction section illustrates that various techniques have been invented to prolong the
GI transit time of drug delivery systems. But, the summary reveals that the manufacturability
of GRDDS is challenging and some of the gastroretentive approaches cannot be generally
considered as “safe” for administration to humans.
1.3.2 Marketed gastroretentive drug delivery systems
During the last decades, considerable research has been done in the field of GRDDS: a number
of patents were filed and a few products were launched. An overview of commercially available
gastroretentive dosage forms is provided in Table 1.1.
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1.3.3 Methods for the analysis of floating systems
1.3.3.1 In vitro techniques for the analysis of flotation
The density, the floating lag time (i.e. time period which a dosage form requires to rise
to the surface of the dissolution medium after being immersed into the liquid [164]), the
floating duration (i.e. time period which the dosage form floats constantly in the experimental
setup [201]), and the floating kinetics (i.e. resultant force) are considered as parameters that
are essential for the characterization of FDDS.
A simple measurement approach to study the flotation of FDDS was applied by Jimenez et al.
They placed the dosage forms in individual flasks containing 400 mL 0.1 N HCl. The floating
lag time and the total buoyancy time were visually assessed [108]. The described method brings
the disadvantages along that the test setup is non-dynamic and it does not mimic the motility
of the GI tract.
To take into account the gastric motility, El-Gibaly used a water bath shaker (shaking
speed: 100 oscillations per minute) for the evaluation of microparticles. The floating lag time
and the floating duration were visually determined by soaking 50 microparticles in 100 mL
dissolution medium at 37 ¶C [59].
Numerous researchers combine drug release measurements with floating time measurements:
they observe visually the flotation characteristics of FDDS during United States Pharmacopoeia
(USP) II (paddle) dissolution testing [164]. However, the approach is associated with several
problems. For example, the floating device may stick to the paddle shaft; hence, incorrect
results for drug release and flotation are obtained [170].
The above-described techniques do not enable a quantification of the floating capability of
FDDS. Additionally, they are restricted in terms of floating behavior comparison of di erent
formulations. To overcome the drawbacks, Moës and Timmermans have invented an apparatus
to monitor the resultant force which acts vertically on an object being immersed into liquid
(i.e. resultant-weight of an object). The direction and magnitude of the resultant force is used
to quantify floating and non-floating performance of FDDS. The proposed evaluation method
allows studying the floating capability of a dosage form as a function of time [147, 230]. Some
researchers applied the resultant-weight measurement apparatus for the formulation design and
optimization of FDDS [53, 80, 90, 129].
1.3.3.2 In vitro techniques for the analysis of drug release
The USP dissolution apparatus I (basket) and II (paddle), depending on the type of floating
dosage form, are commonly used for the assessment of drug release. The measurements are
performed in 0.1 N HCl with/without enzymes and surfactants or in simulated gastric fluids
to mimic the in vivo GI conditions [164]. The volume of dissolution liquid, required for the
conventional USP I and II dissolution tests (approx. 900-1000 mL), is relatively large compared
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to the volume of gastric fluids available in the GI tract (20-30 mL mucus in the fasted state
stomach [54]).
The USP methods exhibit limitations regarding the evaluation of drug release from floating
devices and the correlation between in vitro and in vivo data is often poor [78].
The USP apparatus I o ers the advantage that the FDDS is entirely immersed into the
dissolution medium. But, the device may stick to the mesh of the basket; or in case of a heavily
swelling system, the device may completely occupy the basket [164]. Consequently, the correct
analysis of swelling properties and drug release may not be feasible.
In case the dissolution tests are performed using the USP paddle apparatus, the tablets
tend to float on the surface of the medium. The incomplete exposure of the dosage form to the
dissolution liquid a ects drug release and floating kinetics [57]. The position of the drug delivery
system in the dissolution vessel plays an important role as the complex hydrodynamics and the
three-dimensional fluid flow pattern, generated by the UPS paddle, vary significantly within the
di erent parts of the vessel. A dosage form floating on the liquid surface is less a ected by the
paddle rotation and there is a potential risk of non-homogeneous distribution of the API [170].
To overcome the shortcoming, Burns et al. modified the conventional USP apparatus II by
positioning the paddle blades in the upper part of the dissolution vessel [20, 21]. The United
States Pharmacopeial Convention recommends the attachment of a helical wire sinker to dosage
forms, that tend to float, in order to immerse them completely into the dissolution medium [229].
However, a sinker may influence or prevent the swelling process of heavily swelling dosage units
and eroding or disintegrating devices are assumed to escape the wire sinker.
Various modifications of the USP methods have been proposed and innovative measurement
systems were invented in order to achieve more reliable and reproducible in vitro dissolution
data for FDDS.
For example, di erent ring mesh assemblies have been introduced to entirely submerge the
floating dosage form into the liquid of the dissolution vessel [20, 56, 170]. Aoki et al. stated
that mechanical destruction forces or frictional forces are necessary elements of the in vitro
dissolution test setup. Therefore, they developed the so-called “paddle-beads” method: it
describes a USP II method with polystyrene beads which are added to the dissolution liquid [4].
As the conventional USP dissolution methods and the above-described modifications do
not take into account the gastric emptying process and the gastric acid secretion rate, novel
methods to analyze the behavior of FDDS under conditions closer to the in vivo situation have
been proposed. Bajpai and Dubey as well as Gohel et al. introduced test systems to study
the performance of floating dosage forms based on the Rossett-Rice apparatus [9, 78]. Further
optimization of the experimental setup has been done by Parikh et al.: they came up with a
multi-compartment dissolution apparatus which is supposed to mimic in vivo stomach and
intestine conditions [165].
And finally, there exist several complex model systems for the human GI tract [146, 246].
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Kong and Singh proposed a “Human Gastric Simulator”. The apparatus is designed in a
way that it mimics the physiological conditions of the GI tract, including the continuous
peristaltic contractions of the stomach walls, the gastric acid secretion, and the gastric emptying
process [123].
1.3.3.3 In vivo techniques for the analysis of gastric retention
Although, animal studies may proof the in vivo gastric retention potential of a drug delivery
system; the clinical evaluation in human often fails to confirm the results [242]. A reason for
the di erent outcomes is the significant species di erentiation between humans and common
laboratory animals, which includes: metabolic di erences, as well as anatomical, physiological,
and biochemical di erences in the GI tract [111]. For example, the in vivo analysis of FDDS is
associated with the drawback that quadrupeds do not maintain a floating dosage form in the
stomach at a level higher than the pyloric sphincter. Animal experiments may be used for a
screening approach and they may provide a first evidence for the gastric retention capability
of dosage forms; but, in order to assess adequately the in vivo performance of FDDS, the
evaluation in human is required [242].
Independent of the species, an appropriate reference system (i.e. non-buoyant, controlled-
release formulation) has to be selected. In some clinical trials, the in vivo behavior of GRDDS
was compared with immediate-release formulations; hence, suggesting an extended GRT of the
investigated GRDDS in comparison to the selected controls [93, 137, 196].
Another important point to be considered is whether the evaluation of the GRT is performed
under fed or fasted conditions. In vivo studies are often carried out in fed state, though, the
GRT of non-disintegrating tablets shows a linear correlation with the caloric content of food.
The intake of high-caloric meals with 850 kcal results in a significantly-prolonged GRT of
approx. 7 h [242].
Di erent analytical methods are used to track the GI passage of orally-administered
pharmaceutical dosage forms and to determine their GRT:
(i) For “-scintigraphy, a stable “-emitting radioisotope (e.g. 111Indium, 99mTechnetium)
is co-formulated in a low amount within the delivery system. In comparison to other
marker-based methods, the “-scintigraphic evaluation requires only small changes of the
formulation [164]. Nonetheless, it is associated with the shortcomings of low resolution,
limited topographic information, ionization radiation, as well as complicated and expansive
manufacture [168]. The highly-sensitive technique is considered as “gold standard” for
the assessment of GI transit [169].
(ii) Radiology is a more simple and cost e ective method with an excellent spatial resolution.
High amounts (Ø40%) of contrasting agent, such as barium sulfate, need to be incorporated
into the delivery device for an optimum evaluation. Hence, the formulations are modified
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and the GI passage of the systems may be a ected. Due to x-ray exposure of the study
subjects the application of this analytical technique is not favored (average e ective dose
for computed tomography of the abdomen: 8 mSv [141]). For GI transit studies, the
health risk increases as series of images are recorded [164, 244].
(iii) In recent years, the interest in magnetic resonance imaging (MRI) techniques has
increased. The non-invasive imaging method is shown to be a valuable analytical tool for
the investigation of the in vivo behavior of dosage forms. To label the delivery device, the
contrast agents Fe3O4 and Gd-DOTA (gandoteric acid) are feasible as MRI markers. MRI
features the advantages of high soft tissue contrast, high temporal and spatial resolution,
as well as the absence of x-ray radiation [214].
(iv) It is possible to mark magnetically dosage forms by the incorporation of small amounts
of ferromagnetic material into the formulations and to acquire images by biomagentic
measurement systems. The addition of high-density iron powder may a ect the GI
behavior of the delivery device. In comparison to the above-described techniques, the
magnetic marker monitoring system is less hazardous because it does not employ
any radiation [243].
(v) Another visual observation method is gastroscopy: an endoscope is used to assess the
behavior of dosage forms in the GI tract. The approach features the advantages that is
does not require a modification of the formulation (e.g. addition of marker substances)
and that the dosage form can be withdrawn from the stomach during the measurement.
However, food particles remaining in the gastric region may complicate the assessment of
the GRT. At predetermined time points, the endoscope has to be administered to the
study subject; the inconvenient procedure limits the application of gastroscopy to assess
stomach residence times [168].
(vi) As an alternative imaging technique, which is not yet routinely used for the in vivo
evaluation of GRDDS, the application of ultrasonography is discussed [168].
(vii) The 13C-labeled octanoic acid breath test o ers a non-invasive measurement ap-
proach to assess the stomach residence time of dosage forms. The 13C-labeled octanoic
acid, a medium chain fatty acid, is co-formulated within the dosage form. The substance
is absorbed in the upper part of the small intestine and transported to the liver. Due
to mitochondrial oxidation, carbon dioxide is generated and exhaled in the breath. It
indicates the transit of the dosage form through the small intestine and marks the gastric
emptying of the delivery device from the stomach. The presence of 13C-labeled carbon
dioxide in the expired air is measured by isotope-ratio mass spectrometry [164].
(viii) Pharmacokinetic parameters, such as the maximum plasma concentration of drug
(cmax), the time to reach the maximum plasma concentration (tmax), and the area
27
CHAPTER 1. INTRODUCTION
under the plasma concentration-time curve (AUC) are evaluated. Based on the results,
conclusions are drawn regarding the GI transit behavior: some researchers assume that
an improved bioavailability of the API is linked with a prolonged GRT of the dosage
form [242]. However, the pharmacokinetik analysis does not enable the direct assessment
of the stomach residence time of a drug delivery system.
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Aim of the thesis
Following the analysis above, the interest in drug delivery systems which are retained in theGI tract for a predictable and prolonged period of time persists. As it was shown, various
approaches for the design of GRDDS have been proposed and analyzed. The mechanism of
flotation is considered as the most straightforward approach. Despite considerable research, the
development, the manufacture, as well as the in vitro and in vivo evaluation of FDDS remains
challenging.
The main aim of the thesis was to address the shortcomings associated with gastroretentive
FDDS and to propose a strategy which facilitates the formulation development.
(i) Preparation and in vitro evaluation of gastroretentive FDDS
Until recently, there was no pharmaceutical excipient commercially available that allowed
the compaction of floating tablets with an inherently low density and a su cient hardness.
Functionalized calcium carbonate (FCC), which was originally developed for the use in
paper industry [74], was identified as a material that may be suitable for the manufacture
of tablets featuring the above-mentioned characteristics. FCC was invented and patented
by OMYA Development AG (Oftringen, Switzerland). The material is prepared by
decomposition under acidic conditions and re-crystallization. The starting material, ground
natural calcium carbonate, is treated with one or more water-soluble acids (e.g. phosphoric
acid) and gaseous carbon dioxide is provided [76, 77]. Depending on the reaction conditions,
di erent particle shapes and particle size distributions are obtained [216].
The objective of the thesis was to investigate the applicability of FCC for the preparation
of instantly floating GRDDS in form of floating tablets and floating mini-tablets. The in
vitro USP dissolution methods exhibit limitations regarding the assessment of drug release
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and flotation behavior of FDDS. Therefore, it was important to introduce a custom-built
stomach model method for the analysis of floating dosage forms.
(ii) In vitro and in silico evaluation of gastroretentive FDDS
Up to now, it does not exist an in vitro evaluation method to determine simultaneously drug
release and floating force of FDDS; thus, complicating the preparation, the optimization,
and the comparison of floating formulations. The objective was to propose a formulation
strategy for the development of floating tablets with desired drug release and flotation
performance using a combination of in vitro and in silico techniques. The in silico tablet
dissolution simulations provided a tool to assess tablet density and resultant force during
drug release.
(iii) In vivo evaluation of gastroretentive FDDS
The objective was to analyze the gastric retention capability of FCC-based FDDS in
human volunteers. Therefore, the stomach residence time of FCC-based floating tablets
was compared to the residence time of non-floating reference tablets.
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3.1. DESIGN AND IN VITRO EVALUATION OF HYDROPHILIC FLOATING SYSTEMS
3.1 Design and in vitro evaluation of hydrophilic floating
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Introduction: Gastroretentive drug delivery systems (GRDDS) play an important role in the delivery of
drug substances to the upper part of the gastrointestinal tract; they offer a possibility to overcome the
limited gastric residence time of conventional dosage forms.
Aims: The aim of the study was to understand drug-release and floatation mechanisms of a floating
GRDDS based on functionalized calcium carbonate (FCC). The inherently low apparent density of the
excipient (approx. 0.6 g/cm3) enabled a mechanism of floatation. The higher specific surface of FCC
(approx. 70 m2) allowed sufficient hardness of resulting compacts. The floating mechanism of GRDDS
was simulated in silico under simulated acidic and neutral conditions, and the results were compared
to those obtained in vitro.
Methods: United States Pharmacopeia (USP) dissolution methods are of limited usefulness for evaluating
floating behavior and drug release of floating dosage forms. Therefore, we developed a custom-built
stomach model to simultaneously analyze floating characteristics and drug release. In silico dissolution
and floatation profiles of the FCC-based tablet were simulated using a three-dimensional cellular
automata-based model.
Results: In simulated gastric fluid, the FCC-based tablets showed instant floatation. The compacts stayed
afloat during the measurement in 0.1 N HCl and eroded completely while releasing the model drug sub-
stance. When water was used as dissolution medium, the tablets had no floating lag time and sank down
during the measurement, resulting in a change of release kinetics.
Conclusions: Floating dosage forms based on FCC appear promising. It was possible to manufacture float-
ing tablets featuring a density of less than unity and sufficient hardness for further processing. In silico
dissolution simulation offered a possibility to understand floating behavior and drug-release mechanism.
! 2014 Elsevier B.V. All rights reserved.
1. Introduction
Compared to conventional dosage forms, gastroretentive drug
delivery systems (GRDDS) are designed to remain in the stomach
for a prolonged, predictable time. Consequently, gastric residence
time of drug substances is extended and bioavailability improved
(Arora et al., 2005). GRDDS are suitable for a number of drugs,
including substances whose sites of action are in the stomach
(Bardonnet et al., 2006) (e.g. antibiotics such as metronidazole
used for the eradication of Helicobacter pylori (Adebisi and Conway,
2013)) and drugs that exhibit a narrow absorption window in the
stomach or the upper part of the small intestine (Streubel et al.,
2006a) (e.g. simvastatin (Jagdale et al., 2013) and norfloxacin
(Guguloth et al., 2011)). Moreover, GRDDS are suited for drugs de-
graded in the intestinal or colonic environment (e.g. captopril (Nur
and Zhang, 2000)), as well as substances that are poorly soluble in
alkaline media (e.g. diazepam (Sheth and Tossounian, 1984)).
Various approaches have been proposed to achieve gastric reten-
tion and avoid unpredictable gastric emptying of dosage forms.
These approaches include co-administration of drugs or pharma-
ceutical excipients that influence the gastric motility pattern and
thereby delay gastric emptying (Gröning and Heun, 1989, 1984),
magnetic systems (Fujimori et al., 1995), muco-adhesive systems
http://dx.doi.org/10.1016/j.ejps.2014.03.001
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(Dhaliwal et al., 2008), systems that increase in size due to swelling
(Deshpande et al., 1997) or unfolding (Michaels, 1974), density-con-
trolled systems that either float on gastric contents (Baumgartner
et al., 2000; Stops et al., 2008) or sediment (Devereux et al., 1990),
and combination systems (Jiménez-Castellanos et al., 1994). How-
ever, despite the multitude of options, the broad application of
GRDDS remains an unsatisfied need.
Pawar et al. considered floating drug delivery systems (FDDS) a
logical approach developing GRDDS (Pawar et al., 2011). FDDS are
low-density systems with a density less than that of gastric fluids
(approx. 1.004 g/cm3) (Pawar et al., 2011). Therefore, dosage forms
float on gastric contents and are retained in the stomach while
releasing drug (Singh and Kim, 2000).
According to literature data, enhanced gastric residence times
of floating pharmaceutical dosage forms are achievable under
fasted conditions (Babu and Khar, 1990; Desai and Bolton, 1993;
Xu et al., 1991). Since the introduction of the concept of floating
tablets by Davis (1968), many research groups have invented vary-
ing strategies to prepare FDDS. Floatation is achieved by incorpo-
rating low-density materials (Streubel et al., 2002), by swelling
(Sheth and Tossounian, 1978), or by generation and entrapment
of gas (Atyabi et al., 1996). Because excipients with a density <1
provide immediate floatation of the delivery device, their use is
highly favored for formulation development (Streubel et al.,
2006b). However, design of floating dosage forms is technically
demanding. First, traditional in vitro dissolution methods are not
able to predict in vivo behavior with a sufficiently high accuracy
(Pawar et al., 2012). Neither the European Pharmacopeia nor the
American Food and Drug Administration (FDA) describe any spe-
cific methods to assess dissolution behavior and floating character-
istics of FDDS. Second, methods for preparation of FDDS are often
cumbersome and expensive. Third, cost-effective large-scale pro-
duction of FDDS remains a challenge.
Optimal floating tablets must feature two, often self-excluding
characteristics: high porosity to promote floatation on stomach
contents, but also sufficient hardness to withstand destruction by
gastric peristalsis. A novel pharmaceutical excipient that exhibits
a highly porous meshwork with a lamellar surface structure to
interlock particles tightly was identified in the paper industry
(Stirnimann et al., 2013). Due to its unique properties, functional-
ized calcium carbonate (FCC) holds promise in the preparation of
FDDS. It offers the possibility to compact tablets that can be further
processed at a relative density <1.
The objective of this work was to design an FDDS using the no-
vel excipient FCC and the model drug caffeine. To overcome the
drawbacks of existing dissolution methods, we introduced a cus-
tom-built stomach model to simultaneously evaluate drug release
and floating characteristics of dosage forms. Using a 3D cellular
automata-based computational model, an attempt was made to
evaluate in silico the floating characteristics and drug release. The
theoretical background of the cellular automata-based software
is described in the next section.
2. Mathematical model: cellular automata-based dissolution
model for floating tablets
Use of cellular automata (CA) for modeling drug release profiles
from solid dosage forms has previously been described for poly-
mer-containing formulations (Zygourakis and Markenscoff,
1996). In this study, the standard three-dimensional CA dissolution
model (Kimura, 2013; Puchkov et al., 2013) with extended rule set
was used to account for medium absorption kinetics by porous
materials. In addition, output statistics were collected to obtain
information about every automaton state at every sampling inter-
val. This allowed calculation of tablet density during in silico exper-
imentation and thus assessment of tablet floatation. Tablet
densities >1 g/cm3 indicated that the dissolving tablet sank. Gen-
eral automata rules used in this study can be split into 3 main cat-
egories: rules for active pharmaceutical ingredients (API), rules for
polymers, and rules for porous FCC material.
2.1. CA rules for active pharmaceutical ingredients
Fig. 1a displays the dissolution of non-hydrophobic API cells.
Solvation of the solid is controlled by a C1 constant of an automa-
ton. This primary constant defines the number of iterations needed
to change the ‘‘solid’’ state of the API cell into a ‘‘liquid’’ state. Each
‘‘liquid’’ cell in the 3D Moore neighborhood (Kari, 2005) of an API
cell subtracts one unity at a time from the C1 value of the API cell.
Automaton changes its state at reaching the C1 value of zero and
irreversibly converts itself into a ‘‘liquid’’ cell. Physical meaning
of the C1 value is the reciprocal of the product of solid–liquid inter-
face surface and diffusion coefficient divided by the thickness of
the boundary layer. In other words, the C1 value is reciprocal to
the constant term of the Noyes–Whitney equation (Noyes and
Whitney, 1897). This basic rule applies to all automaton states
except the ‘‘liquid’’ state.
2.2. CA rules for polymer component
Spatial changes of the hydrated materials, i.e. swelling, require
separate governing rules and control parameters. In this study, the
C2 constant was used for polymer materials to control the degree of
swelling.
The swelling cell state mimics the properties of a component
which shows an increase in volume after contact with the dissolu-
tion medium (see Fig. 1b). The ‘‘liquid’’ cells in the 3DMoore neigh-
borhood of the swelling compound are converted into ‘‘hydrated’’
polymer cells and obtain a C1 value which is calculated by dividing
C1 by the C2 value. Therefore, the higher the C2 value, the lower is
the swelling capacity of a component. From the physical point of
view, the relationship between C1 and C2 constants of the swelling
polymer component can be expressed as the logarithm of C1 of
base C2 (Eq. (1)):
q ¼ 1þ logC2C1 ð1Þ
where q is the volumetric swelling ratio q ¼ Volume of swollen gelVolume of dry gel
! "
.
Solving Eq. (1) for C2 yields the following relationship:
C2 ¼ C
1
q%1
1 ð2Þ
When applying Eq. (2), the values for C2 can be obtained exper-
imentally for different polymers or gels in different media.
2.3. CA rules for porous materials such as FCC
Unlike swelling, liquid sorption into porous particles does not
result in spatial changes but requires dedicated governing rules
and a control parameter. In this case, C2 is the constant responsible
for the rate of liquid sorption into porous particle meshwork.
Fig. 1c and d shows the behavior of porous state cells after con-
tact with dissolution medium. Division of the C2 value by the num-
ber of surrounding ‘‘liquid’’ cells gives the number of iterations
needed to change a porous ‘‘dry’’ state cell into a ‘‘wet’’ state,
respecting the 3D Moore neighborhood. Considering the physical
meaning of the value for C2, it is possible to experimentally obtain
this constant for different materials and media by liquid sorption
measurements.
To obtain experimental values for the C1 constant of the poly-
mer components and C2 constant of porous FCC, the liquid sorption
kinetics have to be determined. The sorption rate is the slope
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coefficient of the linear part of a sorption curve, which is measured
in gram per second. To determine the time in seconds needed to fill
a volume which is equal to the volume of one automaton cell (i.e.
3.94 & 105 lm3 for the cell volume used in this study), the volume
of one cell layer (i.e. 6.95 & 109 lm3 in this study) at the surface of
the virtual tablet has to be divided by the rate of sorption. It is
Fig. 1. (a) Dissolution of non-hydrophobic API cells with C1 = 18. (b) Behavior of a hydrophilic swelling cell with C1 = 40 and C2 = 4. (c and d) Liquid absorption of FCC with
C2 = 3500.
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important to note that water density of 1.00 g/cm3 is assumed for
this calculation. Another assumption is that the skeleton volume of
the porous material is significantly smaller than the volume of the
voids in the particles; hence it is neglected.
To assess the number of neighbor cells with assigned state of
‘‘liquid’’ or ‘‘liquid-filled porous material’’ per ‘‘wet’’ polymer or
‘‘wet’’ FCC cell, the average number of ‘‘liquid’’ neighbors per cell
has to be calculated. Therefore, the total number of ‘‘liquid’’ and
‘‘liquid-filled’’ cells as well as the number of ‘‘wet’’ polymer cells
was recorded after every iteration during in silico dissolution. In
3D Moore neighborhood of a ‘‘wet’’ polymer component, an aver-
age of 13 cells had a state of ‘‘liquid’’ or ‘‘liquid-containing’’ mate-
rial. This implies a necessity of multiplying the time needed for one
cell to occupy the polymer or FCC cell by a factor of 13. The result-
ing product is the C1 or C2 constant for the polymer compound or
the porous material, respectively.
3. Materials and methods
3.1. Materials
FCC (VP-DP141 S04, Omya, Oftringen, Switzerland) (Stirnimann
et al., 2013) was used as the matrix to prepare the floating tablets.
Water-soluble polyethylene oxide (Polyox™ WSR 301, The Dow
Chemical Company, Midland, Michigan) and hydroxypropyl
methylcellulose (Methocel" K100 Premium LV, Sandoz Pharma
AG, Basel, Switzerland) were selected as gelation-layer forming
polymers. Citric acid (Acid citricum monohydr. pulvis, Hänseler
AG, Herisau, Switzerland) was chosen as the effervescent excipient.
Forwet-granulation, ethanol 96% (Schweizerhall Chemie AG, Flawil,
Switzerland) was used. Caffeine (Coffeinum WSF, Böhringer-
Ingelheim, Ingelheim, Germany) served as the model drug.
3.2. Methods
3.2.1. Preparation of FCC-based floating formulation
The floating formulation used for the study was prepared
according to Table 1. It contained highly porous FCC, which al-
lowed manufacture of tablets with an inherently low density.
The gelation-layer forming polymers, Polyox™ WSR 301 and
Methocel" K100 Premium LV, were included in the formulation
to slow down penetration of liquid into the tablet during dissolu-
tion; entrapped air in the porous FCC particles should ensure low
density of the tablet and provide floatation of the dosage form.
Moreover, the swelling polymers should retard the release of the
model substance (caffeine) from the tablet.
The required amounts of FCC, Polyox™ WSR 301, Methocel"
K100 Premium LV, citric acid, and caffeine were weighed and
mixed in a tumbling mixer (Turbula type T2C, Willy A. Bachofen,
Switzerland) for 10 min. The speed of the tumbling mixer was kept
at the default value of 30 rpm. Afterwards, ethanol 96% was added
to the mixture to form a paste. The obtained slurry was dried and
extruded through a sieve (1000 lm).
3.2.2. Preparation of FCC-based floating tablets
Floating tablets of 400 mg were compacted using a single-
punch eccentric press (EK0, Korsch, Germany) equipped with
11 mm round flat tooling. The resulting tablet height of 5 mm
was calculated to yield a tablet density of 0.8 g/cm3. For the com-
paction process, the punch gap was set to the calculated value.
3.2.3. Characterization of FCC-based floating tablets
Mean tablet weight (n = 30) was determined with an electronic
balance (AX204 Delta Range, Mettler Toledo, Switzerland). Deter-
mination of tablet diameter (n = 30) and tablet thickness (n = 30)
was done using a dial indicator (CD-15CPX, Mitutoyo, Japan).
Helium pycnometry (AccuPyc 1330, Micromeritics, USA) was
performed to measure the apparent true density. Porosity e of
flat-faced tablets was calculated according to Eq. (3):
e ¼ 1%mq '
1
V
ð3Þ
where volume V is V = p ' r2 ' h, m is tablet weight (g), q is true den-
sity of the powder mixture (g/cm3), r is tablet radius (mm), and h is
tablet height (mm).
A hardness tester (Tablet Tester 8 M, Dr. Schleuniger Pharma-
tron, Switzerland) was used to analyze tablet breaking strength
(n = 10). Afterwards, tablet tensile strength rt was calculated
according to Eq. (4):
rt ¼ 2 ' Fp ' d ' h ð4Þ
where F is diametrical crushing force (N), d is tablet diameter (mm),
and h is tablet height (mm).
3.2.4. Evaluation of in vitro floating behavior and drug release
To simultaneously assess the in vitro floating characteristics and
drug release of tablets (n = 12), a modified dissolution apparatus
(AT7smart, Sotax, Switzerland) was used. The experimental setup
(Fig. 2) consisted of four polycarbonate Erlenmeyer flasks
(500 ml) fixed to the carriage of a water-bath shaker (TB VS-02,
Heto InterMed, Germany; Kobrin scientific precision centigrade
temperature processor 345, Switzerland). The carriage moved hor-
izontally at a rotation speed of 75 rpm and an amplitude of 50 mm.
The tests were carried out in 400 ml 0.1 N HCl and distilled water
as the media at a temperature of 37 #C.
For comparison, floating behavior and drug release (n = 15)
were also analyzed using the USP dissolution apparatus II (AT7s-
mart, Sotax, Switzerland) in 900 ml 0.1 N HCl with a paddle rota-
tion of 100 rpm and a temperature of 37 #C.
Drug content in the dissolution media was analyzed at prede-
termined time intervals using a UV/Vis spectrophotometer (Lamb-
da 25, Perkin Elmer, USA) at 272 nm. Floating lag time, defined as
the time a tablet required to rise to the surface of the test medium
after being placed in the medium, and floating duration were visu-
ally inspected.
Table 1
Composition of the FCC-based floating formulation.
Component Apparent true density (g/cm3) Tablet composition
Experimental (%, w/w) Experimental (mg) In silico (%, w/w) In silico (%, v/v) In silico (mg)
Caffeine 1.4489 25.000 100.000 25.013 14.510 100.000
FCC 0.6350 (2.9090a) 56.250 225.000 56.227 74.425 224.792
Polyox™ WSR-301 1.2332 7.500 30.000 7.504 5.114 30.000
Methocel" K100 Premium LV 1.5901 10.875 43.500 10.881 5.751 43.500
Citric acid 1.5827 0.375 1.500 0.375 0.199 1.500
a For crystalline material (skeletal density).
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3.2.5. Evaluation of mechanical stability of FCC-based floating tablets
after incubation in dissolution media
A texture analyzer (FMT-310 Force Tester, Alluris, Germany)
was used in order to evaluate the mechanical properties of the
FCC-based tablets. The floating tablets were placed in the Erlen-
meyer flasks of the custom-built stomach model for 30 min using
distilled water (n = 3) and 0.1 N HCl (n = 3) as dissolution media.
Afterwards, the required force to break the tablets at a certain dis-
placement of the force gauge was assessed.
3.2.6. Kinetics of liquid absorption
A tensiometer (Krüss Processor Tensiometer K100MK2) was
used to characterize liquid sorption kinetics. Powder samples were
filled in a glass tube which had a ceramic filter bottom. The tubes
were sealed at the top to prevent mass loss due to evaporation. The
sample holder was attached to the microbalance of the tensiome-
ter and immersed to a depth of 4 mm into a beaker with distilled
water thermostated at 37 #C. The beaker was covered with a plastic
paraffin film to minimize evaporation. The tensiometer software
plotted mass gain against time. During the measurement, the glass
tube contributed to the recorded mass gain. Therefore, the mass
gain of the empty glass tube was subtracted from the recoded data
of the powder samples at every time point. The slope coefficient of
the linear part of the water sorption curves was calculated; values
for the sampling points at 200–600 s (20–60 s in the case of FCC
powder) were included.
3.2.7. Cellular automata-based tablet model setup and parameters
The cellular automata-based dissolution model was used from
software package F-CAD v.2.0 (CINCAP GmbH, Switzerland)
(Puchkov et al., 2013). For computer simulation, a flat-faced tablet
with a diameter of 11 mm and a thickness of 5 mm was defined as
a geometric object which consists of unit cubes with an individual
unit cube side length of 73.3 lm. This transformation is done using
the ray-casting discretization algorithm. In brief, the rays penetrate
the cubic matrix in x- and y-direction and the coordinates of the
intersection points of the rays and the tablet matrix are detected.
The matrix around the virtual tablet is filled with unit cubes, while
the tablet remains as hollow space. Then, the matrix is inverted,
resulting in a discrete cubic grid in a shape of a tablet. This grid
was filled at random with components in the particle arrangement
and compaction (PAC) module. The resulting 3D tablet matrix
(Fig. 3a and b) contained the components of the floating formula-
tion (Table 1).
3.2.8. Evaluation of in silico floating behavior and drug release
Floating characteristics and drug release from the virtual tablet
were investigated in silico using the dissolution simulation module
of the F-CAD software. Table 2 shows the component types and
codes, as well as the parameters used for caffeine release simula-
tion. At predetermined time points, the number of remaining unit
cubes of each component type in the tablet matrix was recorded in
order to calculate the density of the virtual tablet and drug release.
Density of the simulated tablet was calculated as the total sum
of individual weights of the cells, divided by the total volume of the
cells assuming no disintegration of the tablet. The density of ‘‘hy-
drated’’ polymer cells was assumed to be = 1, and the density of
the ‘‘liquid-containing’’ FCC particles was assumed to be 1.6 g/cm3.
4. Results
4.1. Characterization of FCC-based floating tablets
Table 3 summarizes the properties of the prepared tablets. Tab-
let height was set to achieve tablet densities <1 g/cm3 in order to
ensure floatation on the gastric fluids. Despite their high porosity
of approx. 60%, FCC-based floating compacts were hard enough
Fig. 2. Schematic representation of a single unit of the proposed stomach model to evaluate in vitro floating behavior and drug release.
Fig. 3. (a) Cross-section of the prepared 3D tablet matrix. The outer rim (5 units
thick) was kept free of cells with swelling properties to account for the initial
‘‘burst’’-effect. (b) 3D tablet matrix.
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to be processed further. For computer simulation, the tablet had a
porosity of 0% and a density <1 g/cm3.
4.2. In vitro evaluation of floating behavior and drug release in 0.1 N
HCl
Fig. 4a compares caffeine release from floating tablets measured
in 0.1 N HCl using the custom-built stomach model with that ob-
tained with the conventional USP dissolution apparatus II. The tab-
lets floated immediately when introduced into liquid. In the
stomach model, the compacts stayed afloat for approx. 300 min.
Within this period, they eroded completely while releasing caf-
feine. Caffeine was entirely released after 295 min, and the drug re-
lease mechanism was classified as erosion-controlled.
Dissolution testing by the USP paddle method resulted in a
slowdown of caffeine release: 100% of caffeine was released after
500 min. During dissolution measurement, the FCC-based tablets
floated on the surface of the test medium and rotated around the
paddle shaft. In the stomach model, the floating tablets were fully
immersed in the dissolution medium throughout the test. Due to
the horizontal movements of the water-bath shaker, drying of
the tablets’ surfaces was prevented.
4.3. Experimental determination of simulation constants
Table 4 displays the obtained water sorption rates of polymer
components, FCC, and floating formulation. In line with the
Table 2
F-CAD component types, codes, and constants used for simulation of the dissolution runs. C1 and C2 values of caffeine and citric acid were taken from the F-CAD database.
Component Type ID Component code Dissolution run in HCl Dissolution run in water
C1 value C2 value C1 value C2 value
Caffeine 1 API 800 – 800 –
Citric acid 12 Non-swelling soluble filler 10 – 10 –
Polyox™ WSR-301 41 Hydrophilic swelling matrix 2500 4 2500 4
Methocel" K100 Premium LV 42 Hydrophilic swelling matrix 5000 12 5000 12
FCC 80 Porous material 1800 3500 4000 3500
Table 3
Properties of the experimental and simulated FCC-based floating tablets. Discrepancies between virtual and experimental parameters were explained by discretization error.
Mechanical stability of tablets cannot be simulated by the current version of the software.
Tablet
formulation
Weight
(mg)
Diameter
(mm)
Thickness
(mm)
Tensile
strength
(N/mm2)
Porosity
(%, v/v)
Tablet
density
(g/cm3)
Apparent true density
of formulation (g/
cm3)
Experimental 399.65 ± 0.59 11.00 4.99 0.5924 ± 0.0419 58 0.84 2.0101
In silico 399.79 11.07 4.98 – 0 0.99 0.9909
Fig. 4. (a) In vitro drug release profiles of FCC-based floating tablets in 0.1 N HCl tested using the stomach model (h, n = 12) and the USP dissolution apparatus II (s, n = 15).
Each data point is the mean ± standard deviations. In silico caffeine release profile (%) and densities (d) of floating tablet were obtained using dissolution simulation. The
buoyancy of the tablets F (s) is displayed as the vectorial sum of the gravity FGravity and buoyancy FBuoyancy forces. It was calculated as follows: F ¼ qf ' V ' g % qt ' g ' V , where
qf is the density of the fluid (g/cm3), qt is the tablet density (g/cm3), V is the volume of the displaced object (cm3), and g is the gravitational acceleration (m/s2) (Sauzet et al.,
2009). (b) Hydrophilic floating tablet after 0, 10, 100, and 200 min in silico dissolution simulation in 0.1 N HCl. Caffeine and ‘‘dry’’ material are displayed in red and light gray,
respectively. ‘‘Wet’’ material is shown in dark gray and the formed gel-layer in yellow. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
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method described in the theoretical section, the C1 value of the two
polymer components and the C2 value of FCC were determined
using the results of the tensiometer measurements.
4.4. In silico evaluation of floating behavior and drug release in 0.1 N
HCl
Table 2 shows the selected parameters for dissolution simula-
tion of the FCC-based floating tablet under acidic conditions.
Fig. 4a displays the resulting in silico caffeine release profile and
tablet densities during dissolution. The virtual compact eroded
completely (as shown in Fig. 4b) while releasing caffeine, and com-
plete drug release was obtained after 308 min. Maximum tablet
density of approx. 1.17 g/cm3 was observed after 279 min.
4.5. In vitro evaluation of floating behavior and drug release in distilled
water
Additionally, caffeine release and floatation were analyzed in
distilled water to provide additional data for in silico simulation
and elucidation of the floatation mechanism. Fig. 5a shows drug re-
lease from floating tablets in distilled water using the custom-built
stomach model. The FCC-based tablets exhibited no floating lag
time, similar to the behavior in simulated gastric fluid. However,
unlike in HCl, the compacts sank to the bottom of the Erlenmeyer
flasks at approx. 90 min. The drug release profile showed a signif-
icant change in the speed of caffeine release at this time point.
Complete caffeine release was measured after approx. 18 h, and
tablet matrices remained at the bottom of the flasks after 100%
drug release.
4.6. In silico evaluation of floating behavior and drug release in
distilled water
The solid line in Fig. 5a displays the in silico caffeine release
from the FCC-based tablet in distilled water. The simulated profile
was obtained using the automaton constants given in Table 2. Caf-
feine was entirely released after 533 min. A linear increase in tablet
density up to 1.47 g/cm3 at 288 min was calculated. After 64 min of
simulated release, the density of the FCC-based compact had
reached values higher than 1.004 g/cm3, which implied that a real
tablet would sink to the bottom. The change in experimental re-
lease profile (Fig. 5a) was observed at a similar time point and
was associated with tablet sinking, which occurred at approx.
90 min and was visually confirmed.
4.7. Evaluation of mechanical stability of FCC-based floating tablets
after incubation in dissolution media
After incubation in 0.1 N HCl, a force of 7 ± 2 N was detected by
the texture analyzer in order to break the tablets. At the same dis-
placement of 0.9 mm, a force of 8 ± 2 N was recorded for the tablets
immersed into distilled water. FCC-based floating tablets which
soaked dissolution medium did not lose their stability.
5. Discussion
The concept of FDDS is not well established, as animal studies
and clinical trials often fail to prove significant gastric retention
Table 4
Calculated C1 and C2 constants based on water sorption measurements.
Component Liquid sorption rate
(g/s)
C1 value C2 value
Polyox™ WSR-301 4.48 & 10%5 2015 –
Methocel" K100 Premium LV 1.23 & 10%5 7340 –
FCC 2.45 & 10%3 – 37
Floating formulation 2.32 & 10%5 – 3883
Fig. 5. (a) In vitro caffeine release profiles of floating tablets in distilled water tested using the stomach model (h, n = 12). Each data point is the mean ± standard deviations.
Drug release profile (%) and densities (d) of the virtual tablet obtained using dissolution simulation. The buoyancy of the tablets F (s) is displayed as the vectorial sum of the
gravity FGravity and buoyancy FBuoyancy forces. It was calculated as follows: F ¼ qf ' V ' g % qt ' g ' V , where qf is the density of the fluid (g/cm3), qt is the tablet density (g/cm3), V
is the volume of the displaced object (cm3), and g is the gravitational acceleration (m/s2) (Sauzet et al., 2009). In the magnification of the initial part of the release profile linear
regression lines and the density of the gastric fluid (approximately 1.004 g/cm3) were added. (b) Hydrophilic floating tablet after 0, 20, 60, and 120 min in silico dissolution
simulation in distilled water. Caffeine and ‘‘dry’’ material is displayed in red and light gray, respectively. ‘‘Wet’’ material is shown in dark gray and the formed gel-layer in
yellow. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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(Waterman, 2007). Although considerable research on floating sys-
tems has been done, only a few products are on the market (Pawar
et al., 2012). One factor contributing to this unsatisfactory situation
is the lack of predictive in vitro test systems to evaluate the perfor-
mance of FDDS. Most scientists carry out in vitro floating tests and
drug release studies of gastroretentive dosage forms without tak-
ing into account anatomical and physiological parameters such
as volume of gastric fluids or stomach pH, gastric motility pattern,
or the gastric emptying process. Research groups primarily use USP
dissolution apparatus II to analyze FDDS drug release, although
this traditional method has a number of limitations. First, the float-
ing tablet surface dries during experiments because it is not im-
mersed in test media. Drying out of the compact surface
artificially prolongs the floating times and slows the release rate
due to constant exposure of the upper part of the tablet to air.
Compared to conventional dosage forms, floating devices are less
exposed to rotational forces during dissolution measurement using
the USP paddle method because the floating tablets rotate around
or may stick to the paddle shaft. Sinkers added to ensure that the
floating device is fully submerged in the dissolution medium were
not considered suitable because floating tablets may undergo
erosion or disintegration during the release experiment. Neither
USP I/IV dissolution apparatuses nor a meshwork to prevent floata-
tion to the surface were used because the floating dosage forms
tend to stick to the mesh structures.
To overcome the drawbacks of USP dissolution methods, we
introduced a custom-built stomach model in the present study to
simultaneously evaluate drug release and floating characteristics
of dosage forms. This method has clear advantages over the USP
dissolution methods. Drying of the floating compact surface was
prevented by the continuous shaker movement and complete
immersion of tablets into medium throughout the test. In addition,
there was no need to force the tablets underneath the liquid sur-
face, hence simplifying the construction of the stomach model.
The volume of test medium was only 400 ml, compared to
900 ml necessary for the USP II dissolution method. Thus, higher
impact forces may act on the floating tablets. As a general observa-
tion, dissolution speed of floating tablets in 0.1 N HCl was higher in
the stomach model than the conventional USP paddle apparatus.
Devices such as the TIM gastrointestinal model (Minekus and
Havenaar, 1996), the human gastric simulator (Kong and Singh,
2010), and the dynamic gastric model (Wickham et al., 2012) pro-
vide realistic and complex simulations of the human stomach.
They mimic continuous peristaltic movements of the stomach
walls, take into account the secretion of gastric acid and enzymes,
and provide a tool to study gastric emptying processes. In contrast,
the custom-built stomach model method is not aimed to evaluate
digestion and gastric emptying of floating dosage forms. It mainly
offers a simplified system to assess in vitro floatation and drug re-
lease of floating tablets. Additionally, due to continuous horizontal
movement of the Erlenmeyer flasks a constant stress to simulate
gastric motility is applied to the floating tablets.
In the case of an ‘‘ideal’’ human stomach simulation device, the
evaluation of the behavior of floating tablets during the complete
interdigestive migrating myoelectric complex (Washington et al.,
2001) including gastric emptying waves would be possible. Addi-
tionally, the effect of the density and the viscosity of the chime
on floatation behavior and the ability of dosage forms to be re-
tained in the stomach could be studied. A minimum required filling
state of the human stomach might be determined which would be
necessary to retain the floating tablet in the stomach without being
emptied through the pylorus by the gastric emptying wave. These
features have been implemented at least in part in other stomach
models (Table 5). If needed, our custom-built stomach model could
be adapted accordingly. However, this was not considered to be
necessary for the present study.
In vitro floating behavior of FCC-based compacts heavily de-
pended on the pH of the dissolution medium. Two pH conditions
were studied: pH 1.1 and pH 7.0. In 0.1 N HCl, the tablets were
floating during the entire dissolution measurement while eroding.
However, in water the floating tablets sank to the bottom of the
Erlenmeyer flasks after approx. 90 min. Erosion of the FCC-based
tablet was observed in vitro when using HCl as dissolution med-
ium. After contact with liquid, swelling of the polymers and forma-
tion of a gelation layer took place; thus penetration of the test
medium into the porous structure of the floating tablet was lim-
ited. After erosion of the outer tablet layer due to formation of sol-
uble CaCl2, the dissolution medium penetrated further into the
tablet, and a new gel layer was generated around the tablet. This
process was visualized using a computer simulation. A correspond-
ing video file is provided as Supplementary material. After contact
with water, the polymers also swelled, and a gel layer formed
around the tablet. Thus, liquid penetration into the compact was
slowed down in a manner similar to that seen when using simu-
lated gastric fluid as the medium. However, the porous FCC did
not react with water to form a soluble salt. Thus, the floating tab-
lets did not erode but gained weight, and floatation was stopped.
This process was as well visualized using a computer simulation.
A corresponding video file is provided as Supplementary material.
Thereafter, dissolution continued, however at much lower rate.
This was clearly observed after 90 min of drug release (Fig. 5a).
The slowed release rate was associated with a reduction of tablet
surface exposed to the dissolution medium. Thus, it can be ex-
pected that in the case of neutral pH of the gastric content the gas-
tric retention due to floatation of the dosage form might not be
sufficient.
The evaluation of the mechanical properties of the floating tab-
lets showed that the tablets after incubation in both dissolution
media still exhibited sufficient hardness and might withstand
destruction due to gastric peristalsis. The contraction forces in
the stomach range between 0.2 and 1.89 N depending on the fast-
ing or fed state (Kong and Singh, 2010).
These hypothesized floating mechanisms and drug release
properties were tested in in silico dissolution simulation. The vir-
tual tablet was designed with an outer layer devoid of any swell-
ing, gelation-layer forming polymer particles. Thus, simulation of
initial, rapid caffeine release (‘‘burst’’ effect) as observed in the
in vitro dissolution profiles was possible. The in silico model simu-
lated drug release from a tablet completely immersed in the disso-
lution medium. Thus, in silico dissolution results were in better
agreement with the in vitro profiles obtained in the stomach model
than those obtained in the USP test.
By varying the C1 value, the different behavior of FCC in HCl and
water was taken into account during dissolution simulation. The
primary constant C1 defines the number of iterations necessary
to convert a cell occupied by a solid into a liquid cell. For in silico
Table 5
Features and overview of available stomach models.
Custom-built
stomach
model
Available devices to
simulate the human
gastrointestinal
tracta
Evaluation of floatation behavior
(e.g. floating lag time, floating
duration)
Implemented Not possible
Evaluation of drug dissolution Implemented Implemented
Simulation of acid and enzyme secretion Possible Implemented
Simulation of different prandial states Possible Implemented
Simulation of gastric emptying Not possible Implemented
pH range 1.1–7.0 1.1–9.0
a Kong and Singh (2010), Minekus and Havenaar (1996) and Wickham et al.
(2012).
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dissolution of the tablet in acidic medium, a low C1 value was se-
lected, as FCC reacted with HCl. Because the tablet did not erode
when using distilled water as dissolution medium, the C1,FCC value
was increased for the in silico evaluation. The calculated tablet den-
sities obtained from in silico dissolution simulation support the
in vitro observations. Compact density increased to slightly higher
than 1 g/cm3 during dissolution simulation in HCl, while the exper-
imental tablets floated during the entire in vitro measurement.
Time difference between the visually observed sinking of the
floating tablets during in vitro evaluation and the calculated time
point according to in silico data might be due to incomplete
assumptions of densities for ‘‘hydrated’’ swollen components and
‘‘wet’’ FCC used to calculate simulation profiles of tablet densities.
Water sorption measurement of powder samples of the floating
formulation (powder blend) resulted in a secondary constant for in
silico dissolution modeling. In the case of pure FCC, a low C2 con-
stant (implying high porosity of the material and thus a fast mass
transfer) was obtained compared to the powder blend constant.
Penetration of liquid into porous FCC particles was slowed down
due to gelation-layer formation of the polymer substances after
contact with water.
Summing up the experimental and simulated data, the concept
of floatation of FCC-based tablets can be defined as a competition
between rates of erosion and imbibition. The different erosion
kinetics (i.e., fast erosion in simulated gastric fluid and infinitely
slow erosion in a neutral medium) govern the mechanism of floa-
tation: prevalence of imbibition induced the sinking of the tablet
after a certain time. Such description of the observed phenomenon
of sinking and reduction of dissolution speed in the case of distilled
water as test medium is well supported by the computer-based
calculations. During the computer experiments, imbibition front
thickness was significantly larger in neutral (Fig. 5b) than acidic
(Fig. 4b) media.
It has to be kept in mind that conventional modeling of such
propagation kinetic is cumbersome and yields non-linear dynamic
models; such models are often difficult to analyze. The modeling
technique used in the presented study allows simulation of the
mass-balance dynamics in the dissolving tablet and assessment
of tablet densities during the dissolution experiment (which is
not possible in reality), avoiding the complexity of conventional
modeling yet providing higher correlation with the data obtained
experimentally.
In this respect, it can be concluded that floating tablet formula-
tion for different APIs, drug loads, formulation components, and
tablet shapes can be optimized on the basis of our findings for the
mechanism of floating behavior. Understanding the behavior of
the key component of the studied formulation, i.e., FCC, is necessary
to keep the tablets afloat throughout the desired drug release time
frame. The mathematical model based on 3D cellular automata
used in the presented study allows taking into account the key
properties of FCC and their influence on the formulation; therefore,
further optimization is possible and can be carried out in silico.
6. Conclusions
FCC is a promising pharmaceutical excipient suitable for the
preparation of floating tablets. Due to its highly porous structure
and lamellar surface, manufacture of compacts that feature a den-
sity <1 and sufficient hardness is feasible. The prepared floating
tablets exhibited no floating lag time, thus lowering the risk of
unpredictable, premature gastric emptying. Furthermore, FCC-
based floating tablets exhibited sufficient hardness to resist
destruction by gastric peristalsis.
Simulated drug release profiles using F-CAD software matched
the experimental data of caffeine release from floating tablets in
the custom-built stomachmodel.Moreover, calculated tablet densi-
ties based on in silico datawere in accordancewith the observations
made during in vitro dissolution testing. Measurement of liquid
sorption kinetics allows determining F-CAD constants of polymer
compounds and porous FCC material based on experimental data.
The in silico drug release and floatation simulations supported the
hypothesis of floating mechanism, i.e. a reaction-based erosion
mechanism with polymers as imbibition-inhibiting components.
The strategy used in the present work facilitates rational design,
in vitro testing, and in silico analysis of floating tablet formulations.
This will be instrumental for future development and optimization
of innovative FDDS.
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3.2 In silico evaluation of multiple-unit lipophilic floating
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Abstract
Context: Development of floating drug delivery systems (FDDS) is challenging. To facilitate this
task, an evaluation method was proposed, which allows for a combined investigation of drug
release and flotation.
Objective: It was the aim of the study to use functionalized calcium carbonate (FCC)-based
lipophilic mini-tablet formulations as a model system to design FDDS with a floating behavior
characterized by no floating lag time, prolonged flotation and loss of floating capability after
complete drug release.
Materials and methods: Release of the model drug caffeine from the mini-tablets was assessed
in vitro by a custom-built stomach model. A cellular automata-based model was used to
simulate tablet dissolution. Based on the in silico data, floating forces were calculated and
analyzed as a function of caffeine release.
Results and discussion: Two floating behaviors were identified for mini-tablets: linear decrease of
the floating force and maintaining of the floating capability until complete caffeine release. An
optimal mini-tablet formulation with desired drug release time and floating behavior was
developed and tested.
Conclusion: A classification system for a range of varied floating behavior of FDDS was
proposed. The FCC-based mini-tablets had an ideal floating behavior: duration of flotation is
defined and floating capability decreases after completion of drug release.
Keywords
Drug release, floating force, flotation,
functionalized calcium carbonate,
mini-tablet formulations
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Introduction
During the last decades, the interest in novel pharmaceutical
dosage forms which are retained in the stomach has increased
significantly, as conventional oral controlled-release dosage forms
are known to exhibit limitations due to relatively short gastro-
intestinal transit times1. The gastroretentive delivery approach
offers new and important therapeutic options for numerous drug
substances2. Various mechanisms were investigated in order to
enhance the stomach residence time of pharmaceutical dosage
forms3,4. The development of floating drug delivery systems
(FDDS) is favored: they do not influence the motility pattern of
the gastrointestinal tract, and immediately floating dosage forms,
due to an inherent low density, reduce the risk of uncontrolled and
premature gastric emptying as no activation mechanism is
needed5,6.
Most floating gastroretentive drug delivery systems
(GRDDSs) reported in the literature are single-unit drug delivery
systems (e.g. tablets and capsules)7. Single-unit delivery devices
have a major drawback: they feature the risk of unpredictable
‘‘all-or-nothing’’ gastric emptying8,9. Consequently, high inter-
and intra-subject variability in gastrointestinal transit time and,
therefore, in bioavailability is observed2.
A possibility to overcome the problem is the development of
multiple-unit drug delivery systems9,10. Multiple-unit FDDS are
evenly spread over the stomach contents due to their density lower
than the gastric fluids (i.e. 1.004–1.01 g/cm3)11 and are gradually
emptied from the gastric region. Consequently, they have more
predictable drug release profiles and inter- as well as intra-
individual differences in drug bioavailability are reduced2. In
addition, multiple-unit dosage forms feature the advantage that
combinations of subunits with different drug release kinetics may
be administered12. Various multiple-unit FDDS, comprising
powder formulations13, granules14,15, microspheres16,17 and
mini-tablets18,19, have been described in literature.
Numerous researchers still use the density of a dosage form
and the visually observed floating behavior (i.e. floating lag time
and floating duration) as the main parameters to characterize,
compare and optimize the in vitro floating capabilities of
FDDS20,21. On the one hand, determination of the density of the
‘‘dry’’ dosage form alone is not a predictor for the changes in the
resulting floating forces acting on the tablet occurring during the
release of the drug substance22. To observe the actual floating
Address for correspondence: Prof. Dr Jo¨rg Huwyler, Department of
Pharmaceutical Sciences, Division of Pharmaceutical Technology,
University of Basel, Klingelbergstr. 50, 4056 Basel, Switzerland. Tel:
+41 061 267 15 13. Fax: +41 061 267 15 16. E-mail: joerg.huwyler@
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visually, on the other hand, does not provide any information
about the magnitude of the floating forces and their effect on the
floating kinetics. Therefore, when using these traditional
approaches the comparison of different FDDS formulations is
limited23.
In order to evaluate the in vitro floating capabilities of buoyant
dosage forms as a function of time more precisely, an apparatus to
measure the resultant-weight of floating systems was proposed24.
The instrument monitors the total resultant force acting vertically
on an immersed object which results from the difference between
the flotation force, i.e. buoyancy (¼displacement volume of
liquid" liquid density), and the force on the object due to gravity.
This force characterizes the resultant-weight of the immersed
object, hence, allows quantification of floating and non-floating
capabilities of drug delivery systems. The resultant-weight
method was used to provide an overview of the floating behavior
of some typical floating formulations22. The development of
FDDS requires the in vitro assessment of drug release profiles as
well as the assessment of the floating behavior of the dosage
forms25. However, it is common to evaluate and optimize these
parameters separately due to the formidable obstacles to simul-
taneously investigate floating properties and drug release. For
example, the measurement conditions of the resultant-weight
method are not comparable to the conditions of the in vitro USP 1
and 2 dissolution measurements, as mechanically stirred hydro-
dynamics will prevent accurate resultant-weight registration. The
measuring principle of the resultant-weight recording apparatus
was also used by Sauzet et al26. They developed a custom-built
apparatus to assess floating capabilities of drug delivery systems;
however, this method does not allow for the determination of drug
release and floating simultaneously.
The general approach for the analysis of dissolution behavior
and floating capabilities of FDDS is to plot drug release and
buoyancy forces separately versus time. However, in order to
develop floating formulations successfully a combined evaluation
of in vitro drug release and floating capabilities is needed27. The
objective of the study was to propose such a combined evaluation
method and investigate its applicability to find a formulation
which has no floating lag time and maintains its floating
capabilities while releasing the drug substance. After complete
drug release, the delivery systems should lose their floating
capability. The loss of floating capability allows gastric emptying
of the FDDS and prevents possible accumulation of tablet remains
in the stomach after multiple administering. Termination of
flotation after complete drug release is supposed to be ideal for
FDDS regarding safe administration in humans. In this study,
functionalized calcium carbonate (FCC)-based lipophilic mini-
tablet formulations were used as a model system to optimize the
final dosage form based on the findings derived from the above
described concepts. Mini-tablets were selected as model dosage
forms as their manufacture is associated with some difficulties:
good flowability of the powder mixtures is required in order to
obtain uniform filling of the die and consequently the preparation
of mini-tablets with acceptable properties (i.e. tablet weight and
content uniformity)28. Larger particle size generally enhances
flowability, however, powder particles are limited in their
maximum size to prevent blockage of the die entry opening
during the compaction process. In the case where mini-tablets are
intended for subsequent coating, they should exhibit sufficient
hardness and friability29.
Materials and methods
Materials
Functionalized calcium carbonate (FCC VP-OM2501 S02, Omya,
Switzerland)30 served as matrix-forming excipient for the
preparation of mini-tablets. For hot-melt granulation, Lubritab!
(JRS Pharma, Germany), a hydrogenated cottonseed oil, was
selected as lipophilic substance. Polyethylene oxide Polyox!
WSR-Coagulant (approximate molecular weight 5 000 000)
(Cimex AG, Switzerland) was added to the formulations as
gelation-layer forming polymer. As a model drug substance,
caffeine (BASF, Ludwigshafen, Germany) was used.
Methods
Preparation of mini-tablet formulations
Table 1 shows the Box–Behnken experimental design generated
by STAVEX 5.0 (Aicos, Switzerland). A Box–Behnken design
was selected as a screening approach that provides sufficient
coverage for the design space. Three mixture factors – concen-
trations of FCC, Lubritab! and Polyox! WSR-Coagulant – were
specified (mixture equation: FCC+Lubritab! +Polyox!¼ 0.83.
For FCC, the factor levels were set to 15, 23, 31, 37, 45, 53 and
59% (w/w). Lubritab! levels and Polyox!WSR-Coagulant levels
were 1, 8, 15, 23, 30, 37 and 45% (w/w).
In cycle 2, a formulation Foptimal was prepared. The criteria set
for the optimization were a caffeine release time of 12 h and the
highest tablet hardness possible for this drug release time. The
composition of Foptimal is displayed in Table 1.
The required amounts of each excipient were weighed.
Caffeine, FCC, Lubritab! and Polyox! WSR-Coagulant were
then mixed in a tumble-action mixer (Turbula type T2C, Willy A.
Bachofen, Switzerland) for 10min. Granulation of the prepared
mixtures was performed using a twin-screw hot-melt extruder
(ZE9, Three Tec, Switzerland). The co-rotating screws had a
diameter of 9mm and a length to diameter (L/D) ratio of 30 D.
During the granulation process, the die plate of the hot-melt
extruder was removed to obtain granules directly.
Prior to compaction, the granules obtained by hot-melt
granulation were sieved. Afterwards, 1% (w/w) Aerosil! 200
and 1% (w/w) magnesium stearate were added. The formulations
were mixed in a Turbula mixer (Turbula type T2C, Willy A.
Bachofen, Switzerland) for 15 and 3min, respectively. For the
preparation of round, convex mini-tablets, a single punch tablet
press (STYL’One, Medel’Pharm, France) equipped with 2mm
(diameter), r1.4 (cap radius 1.4mm) Euro-B multiple tooling
(multiple-tip punch with 12 tips) was used. The mini-tablet weight
was set to 6mg. Mini-tablets were compacted using a mechan-
ically-assisted feed shoe.
Computer simulation parameters for mini-tablet formulations
The computer simulations of drug release and flotation kinetics
were performed using the three-dimensional cellular automata-
based dissolution model from the software package F-CAD v.2.0
(CINCAP GmbH, Switzerland)31. For the in silico dissolution
experiments (n¼ 1), concave-shaped tablet matrices with a
diameter of 2mm and a cap radius of 1.4mm were generated.
The virtual tablet matrices consisted of a discrete cubic grid with
an individual voxel side length of 35.43 lm. Discrepancies
between the experimental and the simulated mini-tablet properties
are due to the discretization error. The absolute average error of
the tablet weight was 0.58mg. The absolute average deviation of
in silico tablet thickness and diameter from the experimental
parameters were 0.02 and 0.14mm, respectively.
Using the particle arrangement and compaction (PAC) module,
the in silico generated grid was filled with the components of the
mini-tablet formulations to 0% simulated tablet porosity. To
assess the deviation in composition of the in silico packed tablet
matrices from the experimentally prepared formulations, the
absolute average errors were calculated for every component.
DOI: 10.3109/03639045.2015.1078350 Optimization of gastroretentive floating mini-tablets 809
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The absolute average errors for Polyox! WSR-Coagulant,
caffeine, Lubritab! and FCC were found to be 1.81% (w/w),
2.24% (w/w), 3.19% (w/w) and 7.17% (w/w), respectively. The
high absolute average error for the FCC component can be
explained by the highly porous structure of the FCC particles and
their ability to accommodate relatively large amounts of other
components within the lamellar structures of the particles. The
computer simulation model accounts only for components with
rigid volumes and the filling of formulation components into
porous FCC cannot be simulated in silico.
Tablet density was less than 1 g/cm3 for all virtual mini-tablet
matrices and the absolute average deviation from the experimental
values was 0.04 g/cm3. The properties of the in silico mini-tablets
are shown in Table 2.
Characterization of experimental mini-tablets
Weight, diameter and height. The weight of the mini-tablets,
using a sample number n¼ 20, was determined using an
electronic balance (AX 204 Delta Range, Mettler Toledo,
Switzerland). Tablet diameter (n¼ 10) and height (n¼ 10) were
assessed by a microscope (Projectina, Switzerland). Use of a slide
caliper gauge was not possible, as the mini-tablets would be
compressed during the measurement resulting in wrong tablet
diameter and thickness values.
True density and porosity. According to Equation (1), the
porosity e of the tablets was calculated
" ¼ 1# m
V $ !
! "
$ 100 ð1Þ
where e is the tablet porosity (%), m is the mass of the mini-tablet
(mg), ! is the true density of the formulation (g/cm3) and V is the
tablet volume (cm3).
Tensile strength. A texture analyzer (FMT-310, Force Tester,
Alluris GmbH & Co. KG, Germany) was used in order to evaluate
the hardness (n¼ 10) of the mini-tablets. The mini-tablet was
placed under the sensor and the zero point of force was
determined. Afterwards, the sensor was moved downwards
0.4mm and a path–force diagram was recorded. The peak value
of the path–force diagram was taken as the hardness of the
Table 1. Composition of the experimental FCC-based mini-tablet formulations according to the generated Box–Behnken design.
Mixture factors
Formulation
Caffeine
(%, w/w)
FCC
(%, w/w)
Lubritab!
(%, w/w)
Polyox! WSR-Coagulant
(%, w/w) FCC Lubritab!
Polyox!
WSR-Coagulant
F1 17.00 53.00 15.00 15.00 +2 #1 #1
F2 17.00 37.00 1.00 45.00 0 #3 +3
F3 17.00 37.00 45.00 1.00 0 +3 #3
F4 17.00 23.00 30.00 30.00 #2 +1 +1
F5 17.00 31.00 37.00 15.00 #1 +2 #1
F6 17.00 15.00 23.00 45.00 #3 0 +3
F7 17.00 59.00 23.00 1.00 +3 0 #3
F8 17.00 45.00 8.00 30.00 +1 #2 +1
F9 17.00 31.00 15.00 37.00 #1 #1 +2
F10 17.00 15.00 45.00 23.00 #3 +3 0
F11 17.00 59.00 1.00 23.00 +3 #3 0
F12 17.00 45.00 30.00 8.00 +1 +1 #2
F13 17.00 37.00 23.00 23.00 0 0 0
Foptimal* 17.00 40.00 43.00 0.00
The experimental design matrix is displayed in uncoded and coded form.
*Preparation of the optimal mini-tablet formulation was done in cycle 2.
Table 2. Composition of the simulated FCC-based mini-tablet formulations and in silico tablet matrix properties.
Formulation
Caffeine
(%, w/w)
FCC
(%, w/w)
Lubritab!
(%, w/w)
Polyox!
WSR-Coagulant
(%, w/w)
Tablet weight
(mg)
Tablet
height
(mm)
Tablet
density (g/cm3)
Calculated inherent
resultant force
~Fr ($10#5 N)
Simulated F1 19.58 45.10 17.66 17.66 5.36 2.84 0.6858 2.408
Simulated F2 18.14 32.77 1.09 48.02 5.62 2.59 0.7985 1.392
Simulated F3 19.54 28.50 51.18 0.78 5.37 2.56 0.7751 1.529
Simulated F4 17.31 19.11 31.79 31.79 5.79 2.42 0.8917 0.689
Simulated F5 18.23 23.71 41.64 16.42 5.76 2.52 0.8299 1.158
Simulated F6 15.90 21.35 21.12 41.63 6.60 2.73 0.8821 0.865
Simulated F7 22.25 47.56 28.90 1.29 4.73 2.62 0.6614 2.375
Simulated F8 18.80 39.31 8.77 33.12 5.59 2.77 0.7356 1.969
Simulated F10 17.40 13.95 45.61 23.04 6.03 2.45 0.9131 0.563
Simulated F11 20.80 50.85 0.79 27.53 5.05 2.77 0.6648 2.497
Simulated F12 21.18 31.94 36.86 10.01 4.96 2.42 0.7643 1.500
Simulated F13 18.15 33.79 24.03 24.03 5.78 2.77 0.7619 1.774
Simulated Foptimal 20.64 27.48 51.89 0.00 5.09 2.42 0.7839 1.376
The diameter of the in silico mini-tablet matrices was 2mm for all formulations. Mechanical stability of tablets cannot be simulated by the current
version of the software.
810 V. A. Eberle et al. Drug Dev Ind Pharm, 2016; 42(5): 808–817
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mini-tablet. The tensile strength "t of the mini-tablets was
calculated according to Equation (2)32
"t ¼ 10P
# $ D2 $ 2:84 $ tD# 0:126 $ tW þ 3:15 $ WD þ 0:01
# $ ð2Þ
where "t is the tensile strength (MPa), P the fracture load (N), D
the tablet diameter (mm), t the tablet thickness (mm) and W the
wall height (mm).
Drug content. Caffeine content of the mini-tablets was mea-
sured for each formulation in triplicate. Each mini-tablet was
ground in a mortar and dissolved in 100ml 0.1N HCl while
stirring. The solution was filtered and the UV/Vis spectrophoto-
metric absorbance was determined (UV/Vis-spectrophotometer,
Jasco V-630, Brechbu¨hler AG, Switzerland) at 272 nm. For the
drug content analysis, a calibration curve (A¼ 50.88# 0.0074;
R2¼ 0.9997, where A is the absorbance and c the concentration
(mg/ml)) was prepared with five measurement points in the
concentration range from 0.005 to 0.015mg/ml.
In vitro evaluation of drug release
A custom-built stomach model was used to assess in vitro drug
release behavior of mini-tablet formulations27. In brief, dissol-
ution was measured in a volume of 400ml of 0.1N HCl on a
horizontally shaking platform. For simultaneous and precise
placement into the Erlenmeyer flasks of the stomach model, 20
mini-tablets were packed into a gelatin capsule size 2. The capsule
dissolves upon contact with 0.1N HCl and releases the mini-
tablets into the assay medium. Drug release was monitored
continuously by UV-spectroscopy. In combination with visual
inspection and in silico modeling, tablet flotation could be
monitored. Dissolution profiles were thereby used to calibrate the
in silico dissolution model and to derive from these computer
models estimates of the forces acting on the immersed tablets as
described below.
In silico evaluation of dissolution and floating behavior
To assess in silico tablet dissolution and floating behavior, the
three-dimensional cellular automata-based dissolution model
from the software package F-CAD v.2.0 (CINCAP GmbH,
Switzerland) was used. The F-CAD component types, codes
and constants set for the computer simulations27 are detailed in
Table 3. The general cellular automata rules used in the present
study are the following: rules for active pharmaceutical ingredi-
ents, rules for polymer components, rules for hydrophobic
excipients and rules for porous FCC material. The primary
constant C1 of an automaton, independent of its component type,
controls the solvation of the solid; i.e. it defines the number of
iterations needed to change the ‘‘solid’’ state of a voxel into a
‘‘liquid’’ state. Each ‘‘liquid’’ voxel in the 3D Moore neighbor-
hood33 of a ‘‘solid’’ state voxel subtracts one unity at a time from
the C1 value of the ‘‘solid’’ state voxel. When reaching the C1
value of zero, the ‘‘solid’’ state voxel converts into a ‘‘liquid’’
voxel. The function of the C2 value depends on the component
type. In the case of polymer components, the C2 value defines the
degree of swelling of the hydrated polymer voxel. In order to
mimic a volume increase after contact with the dissolution liquid,
the ‘‘liquid’’ voxels in the three-dimensional Moore neighbor-
hood of the swelling material are converted into ‘‘hydrated’’
polymer voxels. The C1 value of these ‘‘hydrated’’ polymer
voxels is obtained by integer division of C1 by C2 value. The C2
constant of FCC controls the rate of liquid sorption into porous
FCC particle meshwork: division of the C2 value by the number
of liquid voxels in the three-dimensional Moore neighborhood
defines the number of iterations which are needed to change a
‘‘dry’’ into a ‘‘wet’’ state voxel27.
In addition to the FCC, a second FCC type – hydrophobized
FCC – was introduced for the computer simulations. The new
FCC type was generated to take into account the hydrophobiza-
tion of FCC due to melting of Lubritab! during the hot-melt
granulation process. Hydrophobized FCC was assumed to have a
C1 value of 100 000, which indicates a low solubility material, and
a C2 value of 3500
27. Hence, in silico dissolution of the
hydrophobized FCC was slowed down and penetration of
dissolution liquid into FCC particles was decelerated. Lubritab!
was assumed to have a C1 value of 7 000 000 to indicate
completely insoluble material.
Density of the virtual tablets was assessed as described in
Eberle et al27. The density value of hydrated polymer voxels was
assumed to be 1 g/cm3. Based on the results of liquid sorption
measurements (data not shown), the density of ‘‘wetted’’ FCC
was set to 0.45 g/cm3.
The resultant force ~Fr acting on an immersed dosage form was
calculated according to Equation (3)22
~Fr ¼ ~Fbuoyancy #~Fgravity
~F ¼ !f # !tð Þ $~g $ V
ð3Þ
where ~Fr is the total vertical force acting on an immersed object
(N), !f the fluid density (g/cm
3), !t the density of the tablet
(g/cm3), V the tablet volume (mm3) and ~g the acceleration of
gravity (m/s2). In order to evaluate the floating behavior of the
mini-tablet formulations, the resulting force ~Fr is plotted versus
the in silico caffeine release data.
Evaluation of the adequacy of the simulation model
In order to evaluate the adequacy of the simulation model, the
in silico dissolution profiles were compared to the experimentally
obtained drug release profiles. A model-independent approach
calculating a difference (f1) and similarity factor (f2) was used
34.
The difference factor f1 was calculated according to Equation (4)
f1 ¼
Pn
t¼1 Rt # Ttj jPn
t¼1 Rt
$ 100 ð4Þ
Table 3. Summary of the parameters used for in silico dissolution simulation.
Component
True density
(g/cm3) Type ID Component code C1 constant C2 constant
Caffeine 1.4489 1 API 700 Not applicable
Polyox! WSR-Coagulant 1.2372 41 Hydrophilic swelling matrix 1300 4
Lubritab! 0.9926 71 Hydrophobic ingredient 47 000 000 Not applicable
FCC 0.45* (2.7525y) 81 Porous material 500 15
Hydrophobized FCC 0.45 81 Porous material 100 000 3500
*Bulk density of FCC44.
yFor crystalline material (skeletal density).
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where n is the number of time points, Rt the dissolution value of
the experimental tablet at time t and Tt the dissolution value of the
simulated tablet at time t. A difference factor f1 in the range from
0 to 15 ensures equivalence of two dissolution curves34.
According to Equation (5) the similarity factor f2 is determined
as follows:
f2 ¼ 50 $ log 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 1n $
Pn
t¼1 Rt # Ttð Þ2
q $ 100
0B@
1CA ð5Þ
where, once again, n is the number of time points, Rt the
dissolution value of the experimental tablet at time t and Tt the
dissolution value of the simulated tablet at time t. A similarity
factor f2 in the range from 50 to 100 implies sameness of two drug
release profiles34.
In addition, Pearson correlation coefficients35 were calculated
to compare in vitro and in silico drug release profiles.
Results
Characterization of experimental mini-tablets
The properties of the experimentally prepared tablets are
summarized in Table 4. It was possible to compact mini-tablets
featuring a tablet density less than 1 g/cm3. In the case of
formulation F9, no mini-tablets were obtained due to sticking of
the tablets to the punches of the tablet press during the ejection
process. The contraction forces acting in the human stomach have
been reported to range between 0.2 and 1.89N depending on the
fasting or fed state and the used investigation method36. In the
case of formulations F1, F3, F8 and F13, the measured hardness
values were below 1.89N; however, all mini-tablet formulations
exhibited sufficient hardness for further processing. The other
tablet characteristics shown in Table 4 are within acceptable or
expected ranges.
In vitro evaluation of drug release and floating behavior, and
simulation model adequacy proof
The visual observation of the floating behavior (i.e. floating lag
time and floating duration) revealed that the mini-tablets were
floating immediately after being placed in the Erlenmeyer flasks
of the custom-built stomach model. All tablets stayed afloat
during the caffeine release measurement. In the case of formu-
lations F3, F6, F7 and F10, a lipophilic matrix remained after
complete drug release. In contrast, all other mini-tablet
formulations dissolved entirely. In Table 5, the coefficients of
first-order fitting of the in vitro drug release profiles are
summarized. Fastest caffeine release within 75min was obtained
for formulation F1. In the case of formulation F3, 100% caffeine
release was observed after about 27 h.
Flotation and drug release of a reference mini-tablet formu-
lation consisting of 17% (w/w) caffeine and 83% (w/w) Lubritab!
were analyzed only in vitro: within 66 h only 24% caffeine was
released from the dosage forms. Tablet density was 0.94 g/cm3
before immersion into the dissolution liquid; hence, the tablets
were floating immediately. Due to tablet density very close to
unity, floating behavior was unstable; most of the mini-tablets
sank down during the caffeine release measurement.
In Table 5, the results of the comparison of simulated and
experimental caffeine release curves are shown. The f1-factors
were found to be smaller than 15 and the f2-factors were higher
than 50, hence equivalence of the in silico and in vitro drug
release profiles was assumed. The calculated Pearson correlation
coefficients also confirmed this result.
Statistical analysis
Statistical analysis using the p value, expressing the probability of
obtaining the observed sample results when the null hypothesis is
actually true, showed that the excipients Lubritab! (p50.05) and
FCC (p50.05) significantly influenced the caffeine release speed.
The lipophilic excipient Lubritab! slowed down the drug release,
whereas FCC was found to increase the rate of caffeine release. In
addition, the interaction of Polyox! WSR-Coagulant and FCC
(p50.05) had an effect on the drug release from the mini-tablets.
Evaluation of mini-tablet formulation Foptimal
In Table 4, the properties of mini-tablet formulation Foptimal are
given. The tablet hardness calculated from response surface
methodology for Foptimal was 2.13N; a hardness of 2.62± 0.70N
was experimentally observed. In vitro and in silico caffeine
release profiles of the formulation are displayed in Figure 1. The
targeted drug release time of Foptimal was 12 h. Complete caffeine
release was experimentally observed after 13 h. In vitro evaluation
of the floating behavior showed that the mini-tablets had no
floating lag time and stayed afloat during the entire drug release
measurement. After complete caffeine release, lipophilic tablet
matrices remained in the dissolution vessels. The experimental
and simulated caffeine release curves of Foptimal showed good
correlation (Pearson correlation coefficient: 0.9875).
Table 4. Properties of the experimental mini-tablet formulations.
Formulation
True density
(g/cm3)
Weight
(mg)
Diameter
(mm)
Thickness
(mm)
Drug
content
(mg)
Porosity
(%)
Tablet
density
(g/cm3)
Calculated
inherent
resultant force
~Fr (10
#5 N)
Hardness
(N)
Tensile
strength (MPa)
F1 1.7004 5.98± 0.23 2.10± 0.02 2.85± 0.07 0.92± 0.06 58.58 0.7044 2.462 1.65± 0.26 0.1800±0.0284
F2 1.5706 5.50± 0.39 2.13± 0.01 2.59± 0.13 0.93± 0.10 54.40 0.7161 2.139 1.37± 0.47 0.1681±0.0582
F3 1.3987 6.31± 0.58 2.08± 0.03 2.57± 0.11 1.10± 0.13 41.79 0.8142 1.413 2.07± 0.96 0.2521±0.1171
F4 1.3267 6.66± 0.60 2.09± 0.01 2.46± 0.06 1.02± 0.02 31.70 0.9061 0.677 2.10± 0.93 0.2725±0.1200
F5 1.3691 6.39± 0.30 2.10± 0.01 2.55± 0.07 0.99± 0.02 38.51 0.8419 1.177 2.13± 0.62 0.2647±0.0772
F6 1.2862 6.70± 0.44 2.10± 0.02 2.75± 0.06 1.08± 0.04 36.63 0.8151 1.491 2.06± 0.50 0.2340±0.0567
F7 1.7570 5.91± 0.15 2.11± 0.01 2.62± 0.06 0.86± 0.01 57.20 0.7519 1.913 2.49± 0.41 0.3012±0.5010
F8 1.6427 5.83± 0.46 2.13± 0.01 2.76± 0.03 0.97± 0.05 58.20 0.7398 2.010 1.40± 0.38 0.1561±0.0422
F10 1.2284 6.21± 0.29 2.09± 0.01 2.44± 0.09 0.85± 0.11 27.78 0.8871 0.775 2.21± 0.67 0.2934±0.0890
F11 1.9089 5.82± 0.39 2.11± 0.01 2.76± 0.10 0.93± 0.06 63.66 0.6937 2.521 2.01± 0.75 0.2272±0.0847
F12 1.5387 5.90± 0.52 2.10± 0.01 2.45± 0.12 0.94± 0.17 48.11 0.7984 1.462 1.99± 1.09 0.2565±0.1409
F13 1.4975 5.93± 0.45 2.10± 0.01 2.74± 0.13 0.90± 0.05 51.17 0.7312 2.139 1.68± 0.49 0.1928±0.0561
Foptimal* 1.4341 5.95± 0.26 2.10± 0.02 2.45± 0.06 1.02± 0.03 44.08 0.8019 1.442 2.62± 0.70 0.3385±0.0901
*Preparation of the optimal mini-tablet formulation was done in cycle 2.
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The difference (f1) and similarity (f2) factors were 8.25 and 65.61,
respectively. As the values were within the factor limits (i.e. f1-
factor smaller than 15; f2-factor higher than 50) equivalence of the
in vitro and in silico drug release curves was concluded.
In silico evaluation of drug release and floating behavior
Figures 2(a) and 3 display the resulting force ~Fr of the mini-tablet
formulations as a function of the percentage of caffeine released.
The initial resulting force at time zero acting vertically on the
virtual tablets was positive for all formulations. This means that
all mini-tablet formulations had no floating lag time. The
magnitude of ~Fr at 0% caffeine release depended on the amount
of FCC in the mini-tablet formulations: the higher the amount of
FCC in the formulation, the higher the floating capability of the
mini-tablets (Figure 2b). According to Figure 2(b), a minimum
amount of 2.75% (w/w) FCC would be needed to reach a positive
resulting force acting on the tablet. Two different floating
behavior types were observed. The formulations in Figure 2(a)
exhibited an almost linear decrease in floating capability while
the drug substance was released. In the case of mini-tablet
formulation F7, an initial drop in floating force was observed.
Despite this observation for formulation F7, the calculated
floating forces did not reach negative values, i.e. the tablets did
not sink down. Due to positive floating forces, it was concluded
that the simulated mini-tablet was floating during the entire in
silico drug release measurements. Figure 2(c) illustrates the slope
of the floating force curves, obtained by linear regression, versus
the FCC content of the mini-tablet formulations. The higher the
amount of FCC in the formulations, the faster the resulting force
~Fr was decreased while releasing caffeine.
The floating behavior of formulations F3, F10 and Foptimal is
shown in Figure 3. The mini-tablets maintained their floating
forces up to 70% caffeine released from tablet formulations.
Afterwards, their floating capabilities were declining to zero
floating force (i.e. unit density) when 100% of the drug was
released from the simulated mini-tablets. The described floating
behavior was indeed observed for mini-tablet formulations with
Lubritab! contents of approximately 42% (w/w). It was
hypothesized that in the case of these formulations enough of
Lubritab! was available to result in a hydrophobization of the
FCC particles during hot-melt granulation process. This assump-
tion was supported by the fact that for the in silico dissolution
simulations of F3, F10 and Foptimal, the F-CAD component
‘‘hydrophobized FCC’’ with increased C1- and C2-values had to
be used. The decrease in floating forces of the simulated mini-
tablets was a result of the declining number of FCC voxels during
tablet dissolution simulations.
Discussion
Experimental mini-tablet formulations
As it was visually observed, the experimental mini-tablets
exhibited no floating lag times due to tablet densities less than
unity. The inherent calculated floating force of the tablets
depended on the amount of FCC in the formulations. High
amounts of FCC due to its inherently high porosity resulted in
high initial floating forces of the mini-tablets.
The resultant floating force values of the mini-tablets could not
be experimentally assessed by using the custom-built stomach
model approach. However, it was visually observed that the
floating tablets did not sink to the bottom during the in vitro
evaluation. This implies that the experimental tablets maintained
a positive resultant floating force while the drug substance was
released. In addition, it is assumed that the resultant force value of
the experimental mini-tablets was close to zero after complete
Table 5. Experimental and simulated data of the mini-tablet formulations and comparison of in silico to in vitro caffeine release profiles.
Experimental data Simulated data
Formulation
Coefficient of
first-order
dissolution
curve fitting
Quantification
of the fit
Coefficient of
first-order
dissolution
curve fitting
Quantification
of the fit
Difference factor
(f1)
Similarity factor
(f2)
Pearson
correlation
coefficient
F1 0.0384 0.9994 0.0413 0.9966 8.85 64.70 0.9963
F2 0.0252 0.9987 0.2565 0.9989 2.57 83.26 0.9986
F3 0.0019 1.0000 0.0028 0.9999 8.46 65.24 0.9950
F4 0.0152 0.9982 0.0175 0.9993 7.02 67.63 0.9973
F5 0.0142 0.9998 0.0175 0.9997 7.80 69.32 0.9976
F6 0.0221 0.9996 0.0217 0.9988 7.94 69.03 0.9996
F7 0.0346 0.9997 0.0431 0.9996 10.45 59.07 0.9939
F8 0.0391 0.9991 0.0319 0.9976 7.54 67.43 0.9999
F10 0.0158 0.9999 0.0244 0.9999 4.56 62.44 0.9899
F11 0.0476 1.0000 0.0410 0.9984 11.76 56.34 0.9908
F12 0.0344 0.9995 0.0327 0.9989 3.46 81.55 0.9985
F13 0.0256 0.9984 0.0268 0.9990 7.21 68.66 0.9997
Difference factors (f1) from 0 to 15 and similarity factors (f2) greater than 50 ensure equivalence of two dissolution curves
35.
Figure 1. (a) Experimental (œ) and simulated (g) caffeine release
profiles of mini-tablet formulation Foptimal. (b) Cross-section of the in
silico mini-tablet matrix of Foptimal, where caffeine, FCC, and Lubritab
!
are displayed in light grey, white and dark grey, respectively.
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caffeine release, as flotation-promoting FCC reacts in acidic
dissolution medium and the only formulation component which
remained in the dissolution test set-up was Lubritab! featuring a
density of 0.99 g/cm3. Taking into account these considerations
and the visual observation of flotation behavior, it was concluded
that the floating capability of the experimental mini-tablets
decreased, compared to their inherent floating potential, while
caffeine was released.
In silico mini-tablet formulations and simulation model
adequacy proof
The data suggest that floating forces of dosage forms should be
analyzed as a function of drug release instead of a function of
time. For example, it was then possible to evaluate if a dosage
form stayed afloat while releasing the drug and if it was still
floating after complete drug release. Plotting the resulting force
versus the amount of drug released offers the possibility to
compare the floating capabilities of different formulations against
each other. The proposed method is advantageous for formulation
development of FDDS, as formulations with unstable floating
properties (i.e. floating lag time or the risk of sinking) can be
identified. Good correlation (f2456) between simulated and
experimental caffeine release profiles was obtained, hence,
providing a proof for the correct design of the virtual mini-
tablet matrices and the simulation parameters set for the computer
calculations of floating forces. Consequently, it can be assumed
that the floating force curves were in accordance with the real
floating capabilities of the tablets.
For formulations with a linear decrease in floating capability, it
was observed that the higher the amount of FCC in the
formulation the faster the decrease in floating force during in
silico caffeine release simulation. This observation might be
explained by the fact that FCC, which promotes flotation of the
dosage form, reacted with the acidic dissolution medium and,
hence, the resultant floating force was reduced. At 100% caffeine
released, the calculated resultant floating force value was approx.
0N for all mini-tablets. In addition, tablet formulations containing
high amounts of FCC were found to be prone to have unstable
flotation properties (e.g. in the case of formulation F7 an abrupt
decrease in resulting force occurred).
Figure 2. (a) Resulting force curves of simulated mini-tablet formulations. (b) Initial floating forces of the mini-tablets plotted against the amount of
FCC in the formulations. (c) Slope of the resulting force curves plotted versus the amount of FCC in the formulations. The slope of formulation F7 was
almost zero, implying that the mini-tablets were prone to sink while releasing the drug substance.
Figure 3. Resulting force curves of simulated mini-tablet formulations.
Formulations F3 (œ), F10 (g) and Foptimal (x) exhibited no floating lag
time as the initial values were positive. Mini-tablets maintained their
floating capabilities while releasing caffeine followed by a decrease in
floating force.
814 V. A. Eberle et al. Drug Dev Ind Pharm, 2016; 42(5): 808–817
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The experimental and simulation data indicate that the
preparation of FCC-based lipophilic mini-tablet formulations
with targeted floating and drug release kinetics was possible.
Mini-tablets with immediate flotation, which retained their
floating capability while releasing the drug substance, were
produced. After complete drug release, the mini-tablets had lost
their floating capability. However, porous FCC or similar porous
materials were necessary as matrix-forming excipients to achieve
stable floating behavior (i.e. no risk of the tablets sinking) and
desired drug release.
Classification system for types of floating behavior
Figure 4 shows five different model behavior types for FDDS.
Each model floating behavior is for illustrative purpose and
obtained by summing up experimental, simulation and literature
data. The FDDS are floating immediately, except for the system
of type IV. Type I shows the floating characteristics of hydrophilic
eroding systems, where the floating force is decreasing due to
predominant dissolution of the tablet components. Type I floating
kinetics were experimentally obtained for matrix capsules filled
with a hydrophilic formulation22. Floating behavior type II
illustrates the idealized in vitro floating characteristics of
dosage forms whose floating capabilities do not change while
releasing the drug. Type II is a model for systems where the drug
density is equal to the density of the surrounding liquid. Mass
exchange between the drug and liquid is steady and monotonic;
hence, the floating capability of the dosage form is maintained.
As displayed in Figure 4, FDDS can gain in floating force during
drug release. This kind of floating model behavior (type III) can
be obtained in the case of constantly buoyant inert fillers, such as
hollow cores37. The release of the drug substance results in a
decrease in gravity force due to decreasing mass. A type III
floating behavior was measured for bilayer floating tablets
composed of drug-loaded and floating granules38. However,
types II and III floating systems might possess a risk of being
accumulated in the human stomach after multiple administering.
The problem of permanent retention in the human stomach
is especially associated with large single-unit floating gastro-
retentive dosage forms in particular for patients with bowel
obstruction, gastropathy or a constricted pyloric opening. It
may lead to local irritations in the stomach39,40. For multiple-
unit dosage forms, such as mini-tablets, this risk is negligible
following a single administration; however, the potential risk
for aggregation and accumulation of drug-depleted mini-tablets
in the human stomach increases after multiple, sequential
administrations.
Figure 4. Model floating behavior of FDDS, where ~Fr is the resulting force, D is the drug release, kb is the buoyancy constant and ks is the constant of
dosage form sinking. The proposed model behavior is for illustrative purpose and more complex behavior may be observed.
Table 6. Categories of model floating behavior of FDDS.
Characteristics
Category
Floating
lag time
Behavior while drug substance
is released
Potential danger
of permanent
retention Example floating formulation
Type I No Resultant floating force decreases No Eroding, hydrophilic drug delivery system
Type II No Resultant floating force is maintained Yes Constantly buoyant inert fillers
Type III No Resultant floating force increases Yes Constantly buoyant inert fillers
Type IV Yes Resultant floating force first increases
and is followed by a decrease
No Drug delivery system with flotation due to effervescence
Type V No Resultant floating force is maintained
with subsequent decrease
No Hydrodynamically balanced system;
lipophilic FCC-based drug delivery system
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Floating behavior type IV shows the in vitro floating behavior
of a FDDS exhibiting a floating mechanism which needs to be
activated first41,42. The initial density of the system is higher than
unity, implying that the delivery device is not floating. Upon
contact with an acidic medium, carbon-dioxide is being generated
and entrapped in a hydrated polymer layer forcing the dosage
form to float43. The buoyancy capability of the system decreases
during drug release as carbon-dioxide is escaping from the gel
layer. A floating behavior considered to be ideal for floating
gastroretentive drug delivery systems is type V. This system, due
to its inherent low density, is immediately floating and maintains
its floating force while releasing the drug substance. The tablet
matrix sinks down after complete drug release followed by gastric
emptying. Type V floating behavior was experimentally
obtained in the case of hydrodynamically balanced systems like
Valrelease! and Valium! CR22. A summary of the defined flo-
tation behavior types and their characteristics is given in Table 6.
Conclusions
The proposed strategy of combining the analysis of drug release
and flotation behavior offers the possibility to design FDDS with
desired drug release and floating kinetics, and, hence, safer
gastroretentive floating dosage forms. A classification system to
characterize the performance of FDDS was introduced in the
present study and applied to describe floating behavior of FCC-
based lipophilic mini-tablet formulations.
Mini-tablets exhibiting a type V floating behavior were
prepared and are considered desirable for gastroretentive FDDS.
Pharmaceutical dosage forms with a type V behavior start floating
in the stomach immediately after administration. The risk for
uncontrolled and premature stomach emptying of the FDDS is
therefore reduced as no floating mechanism needs to be activated
first. The floating force curve of model behavior type V looks
simplistic: the drug delivery system is supposed to have no
floating lag time and it should maintain its floating capability
while releasing the drug substance. The floating force should
decrease after complete drug release to allow gastric emptying of
the dosage form in order to prevent accumulation in the stomach.
But, in fact, the floating behavior is a result of complex
interactions of different formulation components.
The present study shows that porous materials with an inherent
porosity-driven low density, like FCC, are ideal candidates for the
preparation of gastroretentive floating dosage forms. However, in
order to activate the flotation promoting role of FCC, additional
excipients (e.g. lipophilic components) are needed. Proper
combination of the components is required to design FDDS
exhibiting controlled floating dynamics. The proposed classifica-
tion system and measurement approach (i.e. combination of
in vitro and in silico methods) help to identify ideal flotation
characteristics of solid dosage forms and assist thereby in the
development of such advanced drug delivery strategies.
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Abstract
Hydrophobic matrix systems are used to design delivery platforms with sustained release kinetics; but, 
they are associated with the shortcoming of incomplete drug release.
The aim of the present study was to identify the key factors influencing the desired drug release and 
the statistics of the design space for hydrophobic matrix formulations. A floating drug delivery system 
(FDDS) was used as a model system.
Hydrophobic matrix formulations, containing paraffin wax and functionalized calcium carbonate (FCC) 
as release-modulating agents, were produced my melt granulation in a twin-screw hot-melt extruder.  
Release  of  the  model  drug  caffeine  was  assessed  in  vitro using  a  custom-built  stomach  model. 
Additionally, a three-dimensional cellular automata-based model was applied for the design of in silico 
tablet matrices and for dissolution simulation. 
In silico dissolution simulation and scanning electron microscopy suggested a hydrophobization of 
FCC  due  to  molten  paraffin  wax  at  elevated  temperatures  influencing  the  arrangement  of  the 
formulation components within the tablet matrix. The combination of in vitro measurements, statistical 
analysis, and computer simulations provided a tool to understand the influence of the excipients on the 
characteristics of multicomponent formulations, taking into an account the effects induced by the unit  
operation. The simulated thickness of the lipophilic layer ranged from 0.15 up to 3.00 µm resulting in a  
different degree of FCC hydrophobization; depending on the formulation, the amount of paraffinized 
FCC was found to range from 5.93 up to 66.31% (w/w). 
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Abbreviations
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1. Introduction
Hydrophobic  matrix systems are widely used for the preparation of oral  controlled-release drug delivery 
platforms [1]. A hydrophobic matrix system describes a dosage form composed of drug substances being 
embedded in a water-insoluble, non-swelling matrix material (e.g. fatty acids, fatty alcohols, fatty acid esters,  
or waxes of natural and synthetic origin) in order to achieve sustained drug release [2]. Several excipients 
are used as drug release-retarding  agents  for  the  preparation  of  sustained-release,  hydrophobic  matrix 
formulations,  including  materials  such  as  glycerides  (e.g.  Compritol® 888 ATO  (glyceryl  behenate)  [3], 
Precirol® ATO5 (glyceryl palmitostearate) [4]), polymeric materials [5] (e.g. ethyl cellulose, methyl cellulose, 
acrylate copolymers [6]), and waxes (e.g. beeswax [7], carnauba wax [8], candelilla wax [2], microcrystalline 
wax  [2],  paraffin  wax  [9]).  The  drug  release  kinetics  can  be  mathematically  described  by  the Higuchi 
equation; i.e. a direct proportionality between the cumulative amount of drug released and the square root of  
time is  observed [10,11].  The drug release rate-controlling step for  this matrix  system type is the liquid 
penetration into the hydrophobic matrix [1]. Upon contact of the delivery device with the dissolution liquid,  
channels, cracks, and pores appear on the tablet matrix surface due to dissolution of the drug [3]. Depending 
on the composition of the formulation as well as on the preparation method, the drug release mechanism of  
hydrophobic matrix tablets is either diffusion-controlled or erosion-by-disintegration-controlled [1,12]. 
Various processing techniques, including dry blending and direct compression [3], wet granulation [13], melt  
granulation [14], or extrusion spheronization [15], were applied for the manufacture of hydrophobic matrix 
systems. Usually, melt granulation and melt pelletization are done using high-shear mixers; thereby, granules 
and pellets are produced batch-wise [16]. However, in contemporary industrial pharmacy, of special interest 
are  the  areas  of  continuous  manufacturing  and  in  technologies  and  materials  enabling  a  continuous 
production [17,18]. Despite the fact that the hot-melt extrusion process is normally used to obtain extrudates; 
its ability to mix components can be used as a continuous granulation technique [19]. The melt granulation 
process features the advantage that the molten excipient functions as a binding liquid and drug release 
retardant; thus, an addition of solvents to serve as granulation liquid is not required [20]. In other words, 
combining the twin-screw granulation at elevated temperatures provide a possibility for processing moisture-
sensitive active pharmaceutical excipients (APIs) and enables the use of hydrophobic materials as agents to 
control  drug  release  [21].  However,  the  thermal  sensitivity  of  drug  substances  needs  to  be  taken  into 
consideration. An alternative continuous manufacturing technology for the granulation of hydrophobic matrix 
formulations is by processing using a roller compactor; hydrophobic excipients may function as plastically  
deforming binder during roller compaction [22].
Hydrophobic matrix systems are frequently used in order to obtain controlled release of APIs due to the 
following reasons: high flexibility to generate the desired drug release profiles, easy manufacturability, cost 
effectiveness, and good drug stability due to the chemical inertness of waxes [3,20]. On the other hand, 
despite numerous advantages, the type of matrix system has the potential risk of an incomplete drug release 
due to the immersion of the API crystals in an impermeable hydrophobic layer [23]. Another important point 
to be considered is  the non-homogeneity  of  the API  in the matrix  system delivery platform [24].  These 
shortcomings  need  to  be  taken  into  an  account  and  controlled  during  the  formulation  design  and 
development. The co-formulation of soluble ingredients/  channeling agents/release enhancers allows the 
drug release profiles to be modulated and might help to overcome the drawback of incomplete drug release  
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[3,20,23]. 
Several  hydrophobic  matrix-based sustained release  drug delivery platforms have  been reported in  the 
literature,  in which evidence was provided that, for  example floating drug delivery systems (FDDS) may 
significantly profit from using hydrophobic carrier materials [25–27].
In the present study, we used a twin-screw hot-melt extruder for the granulation of paraffin wax functionalized 
calcium carbonate (FCC) matrix  formulations.  The design space for  wax-based matrix  formulations was 
examined by applying in vitro and in silico evaluation methods to the example of hydrophobic tablets using 
caffeine  as  a  model  drug  substance.  The  study  was  aimed  to  understand  the  influence  of  FCC 
hydrophobization and formulation component arrangements on the breaking strength and the drug release 
behavior  of  tablets.  Additionally,  it  was  attempted  to  propose  formulation  design  guidelines  for  the 
preparation of stable paraffin wax FCC matrix systems to overcome the problems of hydrophobic matrix drug 
delivery  platforms,  i.e.  inhomogeneous  distribution  of  the  components  within  the  tablet  matrices  and 
incomplete drug release behavior. As a proof-of-concept, the studied principles were applied to design and 
optimize a floating gastroretentive drug delivery system.
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2. Materials and methods
2.1 Materials
FCC (VP-220976 S02, Omya International AG, Oftringen, Switzerland) was used as the porous, flotation-
promoting and release-modulating material for the preparation of floating tablets. Paraffin wax (Merck KGaA, 
Darmstadt,  Germany)  was  selected  as  meltable  binder  for  granulation  and  as  lipophilic  matrix-forming 
excipient. As gelation-layer forming polymer, water-soluble polyethylene oxide Polyox™ WSR 301 (The Dow 
Chemical Company, Midland, Michigan, USA) was used. Caffeine (BASF, Ludwigshafen, Germany) served 
as the model drug substance.
2.2 In vitro methods
2.2.1 Preparation of hydrophobic matrix formulations
The design of the hydrophobic matrix formulations was made using the factorial design program Stavex  5.0 
(Aicos, Switzerland). An external design, quadratic (D-optimally supplemented), was generated (Table 1). We 
specified four  factors  as well  as their  lower  and upper  limits,  as follows:  concentration of  caffeine (15-
70% (w/w)), concentration of FCC (20-60% (w/w)), concentration of PolyoxTM  WSR-301 (5-20% (w/w)), and 
concentration of paraffin wax (5-40% (w/w)). The defined response variables were: tablet breaking strength 
and coefficient of first order drug release kinetics. 
The required amounts of caffeine, FCC, PolyoxTM WSR-301, and paraffin wax were weighed and mixed in a 
tumbling mixer (Turbula type T2C, Willy A. Bachofen, Switzerland) for 10 minutes. 
A twin-screw hot-melt extruder (ZE 9, Three- Tec GmbH, Switzerland) was used for melt granulation. The 
screws had a diameter of 9 mm and an L/D ratio of 40 D. The screw rotation speed was 200 rpm. In order to 
obtain  granules  directly,  the  die-plate  of  the  hot-melt  extruder  was  removed  to  reduce  the  degree  of 
densification of the material in the extruder barrel during the granulation process. The temperatures of the 
eight heating zones were set to 30, 40, 60, 80, 80, 30, 30, and 30 °C.
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Table 1 Composition of the tablet formulations.
Formulation
True 
density 
(g/cm3)
Caffeine
(%, w/w)
PolyoxTM WSR 301
(%, w/w)
FCC
(%, w/w)
Paraffin wax
(%, w/w) 
pFCCa
(%, w/w) 
Paraffin wax 
layer thickness 
(μm)
Experimental In silico Experimental In silico Experimental In silico Experimental In silico In silico
F1 1.8632 15.00 16.54 20.00 21.95 60.00 26.24 5.00 35.27 0.15
F2 1.4225 15.00 15.70 5.00 5.06 40.00 14.13 40.00 65.10 1.10
F3 1.2202 35.00 32.68 5.00 4.67 20.00 2.59 40.00 60.07 1.10
F4 1.2516 15.00 14.57 20.00 18.69 25.00 3.92 40.00 62.82 1.10
F5 1.2546 20.00 18.89 20.00 18.99 20.00 1.37 40.00 60.76 1.10
F6 1.6806 15.00 16.27 5.00 5.45 60.00 53.33 20.00 24.95 3.00
F7 1.8690 35.00 35.02 5.00 5.32 55.00 53.73 5.00 5.93 3.00
F8 1.5328 15.00 15.64 13.00 13.41 46.00 16.30 26.00 54.65 0.70
F9 1.3143 25.00 24.19 5.00 4.93 30.00 4.58 40.00 66.31 1.00
F10 1.2445 28.00 26.18 13.00 12.15 20.00 1.43 40.00 60.24 1.10
F11 1.5149 35.00 33.83 5.00 5.13 38.00 35.52 23.00 25.52 3.00
F12 1.5005 20.00 19.24 20.00 20.05 38.00 12.60 23.00 48.11 0.65
F13 1.8180 23.00 23.77 5.00 5.91 60.00 56.33 13.00 13.99 3.00
F14 1.8777 28.00 28.31 13.00 13.15 55.00 39.50 5.00 19.04 0.30
F15 1.4337 17.00 17.38 5.00 5.34 38.00 11.22 40.00 66.06 1.10
a pFCC: FCC particles coated with molten paraffin. 
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2.2.2 Preparation of floating hydrophobic matrix tablets
A single-punch tablet press simulator (STYL’One, MedelPharm, France) equipped with a Kilian D 11.28 mm 
round  flat-faced tooling  was used  for  the  compaction of  the  low-density  hydrophobic  matrix  tablets.  In  
Table 2, the properties of the experimental tablet formulations are summarized.
Table 2 Characteristics of the experimental prepared floating hydrophobic matrix tablets. The in silico tablet matrices designed for the 
computer simulation had a diameter of 11.36 mm and height of 3.31 mm. The absolute average errors for the in silico tablet weight and 
tablet density were 11.70 mg and 0.0805 g/cm3, respectively. The discrepancies in tablet weight, diameter, and thickness between the 
experimental and the simulated parameters were enumerated via the discretization error. It was not possible to simulate  in silico the 
mechanical stability of the compacts using the current version of the F-CAD software.
Formulation
Weight 
(mg)
Diameter 
(mm)
Thickness 
(mm)
Tablet density 
(g/cm3)
Tensile strength 
(N/mm2)
Porosity 
(%)
F1 300.1±0.7 11.32±0.01 3.37±0.06 0.8846 0.4616±0.0171 52.25±0.68
F2 300.3±0.7 11.30±0.02 3.32±0.03 0.9005 0.5423±0.0040 36.69±0.25
F3 299.9±0.2 11.27±0.01 3.32±0.04 0.9051 0.4306±0.0427 25.86±0.92
F4 300.2±0.2 11.28±0.01 3.34±0.01 0.8991 0.3884±0.0297 28.16±0.13
F5 300.0±0.3 11.29±0.00 3.33±0.02 0.8999 0.3500±0.0262 28.27±0.34
F6 300.0±0.5 11.30±0.01 3.33±0.02 0.8982 0.4680±0.0240 46.55±0.12
F7 300.4±0.3 11.32±0.01 3.34±0.01 0.8929 0.5719±0.0171 52.23±0.03
F8 300.0±0.1 11.30±0.01 3.36±0.03 0.8908 0.4026±0.0179 41.89±0.48
F9 300.3±0.0 11.29±0.00 3.34±0.03 0.8991 0.4955±0.0651 31.60±0.52
F10 300.5±0.4 11.30±0.01 3.31±0.03 0.9049 0.4198±0.0394 27.29±0.78
F11 300.0±0.2 11.31±0.01 3.33±0.02 0.8972 0.3665±0.0201 40.77±0.33
F12 299.6±0.3 11.31±0.00 3.35±0.02 0.8894 0.2798±0.0109 40.73±0.31
F13 300.3±0.4 11.33±0.01 3.36±0.04 0.8862 0.5515±0.0184 51.25±0.63
F14 300.5±0.1 11.33±0.00 3.36±0.03 0.8879 0.4968±0.0295 52.71±0.41
F15 300.1±0.3 11.29±0.00 3.33±0.02 0.9010 0.4746±0.0172 37.15±0.39
2.2.3 Characterization of hydrophobic matrix formulations
The mean tablet weight (n=5, where n is the sampling number of measurements) was determined with an 
electronic balance (AX204 Delta Range, Mettler Toledo, Switzerland). A slide caliper gauge (CD-15CPX, 
Mitutoyo, Japan) was used for the determination of the tablet diameter (n=5) and thickness (n = 5). Helium 
pycnometry (AccuPyc 1330, Micromeritics, USA) was performed in order to measure the true density of the 
hydrophobic matrix formulations. 
Porosity ε of the flat-faced tablets was calculated according to Equation (1): 
ε=1−(
m
ρ )⋅(
1
V
) (1)
where  m is  tablet  weight  (g),  ρ is  true  density  of  the  powder  mixture  (g/cm3),  and  volume  is 
V (mm3)=π⋅(d /2)2⋅h , where d is the tablet diameter (mm), and h the tablet height (mm).
Tablet  breaking strength (n=3) was determined by a hardness tester  (Tablet  Tester 8M, Dr.  Schleuniger 
Pharmatron, Switzerland). The tablet tensile strength σt (Pa) was calculated according to Equation (2):   
σ t=
2⋅F
π⋅d⋅h (2)
where F is the diametrical crushing force (N).
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2.2.4 Scanning electron microscopy
Prior to the analysis, the tablet samples were placed on a carbon layer and sputtered with a 40 nm gold layer 
in a sputter coating device (MED 020, BalTec, Lichtenstein). Scanning electron microscopy (SEM) images of 
the tablet surface were taken using an ESEM XL30 FEG (Philips, Netherlands).
2.2.5 In vitro evaluation of floating behavior and drug release
A custom-built  stomach model  [28]  was used in order  to assess  in  vitro the floating behavior  and drug 
release of the hydrophobic matrix tablets (n=2). The measurements were performed in 400 ml 0.1 N HCl as 
dissolution medium at a temperature of 37 °C. At predetermined time points, the caffeine content in the 
Erlenmeyer flasks was analyzed online using UV/Vis spectroscopy (Perkin Elmer Lambda 25, Perkin Elmer, 
Switzerland) at 272 nm. Additionally, floating lag time and floating duration of the tablets were studied by 
visual observation. 
2.3 In silico methods
The  software  package  F-CAD v 2.0  (CINCAP  GmbH,  Switzerland)  [29]  was  applied  for  the  in  silico 
preparation and evaluation of the hydrophobic matrix tablet formulations. Table 3 summarizes the F-CAD 
component types, codes, and constants used for the tablet dissolution simulation. 
Table 3 F-CAD component types, codes, and constants used for the  in silico tablet dissolution.
Component
Apparent true density
(g/cm3)
Type ID Component code
Dissolution simulation
C1-value C2-value
Caffeine 1.4489 1 API 1 300 (1 054a) ---
FCC 0.7000 81 Porous material 900 15
pFCC 0.7244-0.8743b 82 Porous material 50 000 50 000
PolyoxTM WSR 301 1.2332 41 Hydrophilic swelling matrix 2 500 4
a C1-value calculated according to Equation 5.
b The apparent true density of pFCC was calculated for every formulation depending on the thickness of the paraffin wax layer around  
the individual FCC particle. 
The rate of dissolution dm/dt of a solid in a solvent under sink conditions can be mathematically described by 
the Noyes-Whitney equation:
dm
dt
=
A⋅D
h '
⋅C s (3)
where,  m is  mass of  dissolved material,  t is  time,  A is  solid-liquid interface surface area, D is  diffusion 
coefficient,  Cs is solubility at equilibrium for the given experimental temperature, and h´ is thickness of the 
diffusion layer [30].  
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The Noyes-Whitney equation in spatial form has the form of Fick’s second law [31] and can be shown in 
three dimensions, as follows:
φ
 t
=D∇ 2φ with ∇ 2=( 
2
 x2
+ 
2
 y2
+ 
2
 z2) (4)
where, φ is concentration and D is the diffusion coefficient.  
By applying the finite difference method for computing the numerical solutions of the systems of differential 
equations, the translation of Equation 4 into cellular automata rules for dissolution simulation is made [29]. 
The primary constant (C1-value) can be calculated by Equation 5: 
C1=
m
dm
⋅26 (5)
where, the discretized interval dm is from Equation 3 in the case of the equivalent dt=1, mass of the voxel is 
m (g)=V∙ρ, volume of the voxel is V (cm3)=l3, where l (cm) is the voxel side length, ρ (g/cm3) is density of the 
given  component,  and  26  is  the  number  of  surrounding  “liquid”  voxels  in  the  three-dimensional  Moore 
neighborhood [29].  
In the F-CAD dissolution simulation, the digitized time resolution dt is 1 s. According to Equation 3, it follows:
dm=
A⋅D
h
⋅Cs (6)
where,  the  diffusion  coefficient  D (cm²/s) is  defined  according  to  the  Stokes-Einstein  relation 
D=
1
f
⋅κ⋅(T+273.15) [32],  where  the  frictional  coefficient  f for  a  sphere,  given  by  the  Stokes’  law,  is 
f =6π⋅η⋅R [33], with the viscosity of  water  η  (Pa·s)= 2.414⋅10−5⋅10(247.8 /((T+273.15)−140)) [34], and the voxel 
surface  area  is  A  (cm²/s)=6∙h²,  κB=1.3806488·10-16 cm2·kg·s-2·K-1 is  the  Boltzmann  constant,  T (°C)  is 
temperature, and R (Å) is the molecular radius of gyration. 
2.3.1 Hydrophobization of functionalized calcium carbonate particles: estimation of 
paraffin wax layer thickness
It was hypothesized that paraffin wax melted during the granulation process at elevated temperatures and 
formed  a  hydrophobic  layer  around  FCC  particles.  For  the  computer  simulation,  the  percentage  of  
paraffinized FCC (pFCC), which could be generated, was calculated for each tablet formulation. Based on 
the composition of the starter powder mixtures, it was tried to predict by simulation the thickness of the  
hydrophobic coating layer. 
FCC particles were reported to have a diameter of about 7 μm [35]. For the determination of the extent of 
FCC  hydrophobization,  it  was  assumed  that  FCC  particles  are  inscribed  by  smooth  spheres.  For 
simplification of the hypothesis, it was taken into consideration that molten paraffin wax does not penetrate  
into the porous internal structures of the FCC particles.  
The volume of paraffin wax needed in order to create a layer of defined thickness (0.15-3.00 μm) around an 
individual FCC particle was calculated. It was assumed that the entire amount of paraffin wax contributed to 
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the coating of the FCC particles. Based on the volume of paraffin wax per tablet formulation, the possible 
amount of pFCC, which could be created, was determined.
For the in silico simulations, pFCC was also classified as porous excipient [28]. In comparison to “standard” 
FCC (sFCC),  the  C1,pFCC-constant  was  set  to  50  000  in  order  to  generate  a  material  with  hydrophobic 
properties. The C2,pFCC-value (i.e. constant responsible for the rate for liquid sorption into porous particle 
meshwork),  was also 50 000 as molten paraffin wax was supposed to  form a  hydrophobic layer which 
blocked the pores and channels of the FCC particles and, hence, retarded the penetration of dissolution  
liquid  into  the compacts.  For  all  hydrophobic  matrix  formulations,  only  one pFCC component  type was 
generated keeping the C1,pFCC-constant and the C2,pFCC-constant constant; i.e. the composite material pFCC 
was assigned to have the same F-CAD C1,pFCC-value and C2,pFCC-value independent of the thickness of the 
simulated paraffin wax layer.
2.3.2 Simulation of hydrophobic matrices
Flat-faced tablet geometry with a diameter  of 11.28 mm and a height  of 3.34 mm was designed for the 
computer simulation. The virtual tablet matrix was transformed into a discrete cubic grid with an individual  
voxel side length of 75.2 µm. The different components of the hydrophobic matrix formulations were filled in 
the created grid using the particle arrangement and compaction (PAC) module according to the composition 
summarized in Table 1. The three-dimensional matrices were simulated assuming 0% interparticle tablet  
porosity, while the porous sFCC material is considered to account for the experimentally determined tablet 
porosities, and thus not contributing to tablet bulk permeability.
2.4 Comparison of in vitro and in silico dissolution profiles
The experimental and simulated dissolution profiles were compared by a model-independent approach using 
a difference factor and a similarity factor [36]. 
The difference factor f1 was calculated according to equation (7), as follows: 
f 1=
∑
t=1
N
∣Rt−T t∣
∑
t=1
N
Rt
⋅100 (7)
where  N is number of time points, Rt is  the dissolution value of the simulated tablet at time  t,  and  Tt is 
dissolution value of the experimental tablet at time  t. A difference factor f1 ranging from 0 to 15 indicates 
equivalence of dissolution profiles.     
For the determination of the similarity factor f2, equation (8) was used:  
f 2=50⋅log(
1
√1+ 1N⋅∑t=1
N
(Rt−T t)
2 )⋅100 (8)
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where, again, the variables are those defined in Equation 7. A similarity factor f2 in the range from 50 to 100 
implies equivalence of drug release profiles. 
Additionally,  the degree of  linear  dependence between the  in  vitro  and  in  silico drug release data was 
assessed by the Pearson correlation coefficient [37].
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3. Results
3.1 Characterization of hydrophobic matrix tablets
Fifteen hydrophobic matrix formulations were prepared by factorial  design (Table 1) and analyzed. As a  
representative example, SEM images of formulation F12 are shown in Figure 1 (a, b). The compact surface  
suggests an inhomogeneous distribution of the components in the tablets. Clusters of needle-like caffeine 
crystals with a size of about 30 μm surrounded by the tablet matrix were observed (Figure 1b). 
The granulation process in the twin-screw hot-melt extruder seemed to generate different degrees of FCC 
hydrophobization including sFCC which exhibits the characteristic lamellar surface structures. On the other 
hand, SEM pictures of the tablet surface showed large agglomerates (>60 μm) with a smooth covering. Most 
likely,  these agglomerates were  formed out  of  FCC, PolyoxTM,  and molten paraffin  wax during the melt 
granulation. For all other formulations, the distinction approach was identical.
The virtual compacts of the hydrophobic matrix tablets were constructed based on the structural information 
gained by SEM. Figure 1(c) displays, as an example, the cross-section of the virtual tablet matrix of F12.
Figure 1 (a) SEM image of the surface of a floating tablet (F12), (b) images magnified further, and (c) cross-section of the F-CAD tablet 
matrix. Caffeine is displayed in red, sFCC in light gray, pFCC in blue, and the swelling excipient in yellow. A representative example is  
shown.
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3.2 In vitro and in silico evaluation of tablet dissolution
Figure  2  (a-d)  displays  the  experimental  and  simulated  caffeine  release  profiles  of  several  selected 
formulations. In addition, the cross-sections of the simulation matrices are shown. It was observed that for 
the preparation of the in silico tablet matrices, simple virtual mixtures of the formulation components were not 
sufficient.  Taking  into  account  the  arrangement  of  the  components  within  the  three-dimensional  tablet  
matrices resulted in a good correlation between in vitro and in silico dissolution profiles.
A  fast  caffeine  release  within  40 to 60 min  was  obtained  for  tablet  formulations  F6  (Figure  2c),  F7 
(Figure 2d), F11, and F13. The experimental data of these formulations showed high standard deviations; 
this observation might be explained by erosion by disintegration during in vitro dissolution experiments. The 
simulated tablets of formulation F6 were constructed with variable sizes of pFCC clusters to account for 
significantly high caffeine release variability. 
In the case of formulations F3, F4, F5 (Figure 2b), and F10, an initially fast caffeine release followed by a 
slowdown in release speed was observed. For F10 the drug release was incomplete; only about 80% of the 
API was released during the in vitro dissolution measurement.
For  formulations  F1  (Figure  2a),  F8,  and  F14,  the  tablets  eroded  completely  during  the  dissolution 
experiments; in contrast, tablet matrices of formulations F2, F3, F F4, F5, F9, F10, F12, and F15 remained in  
the Erlenmeyer flasks. 
The results of in vitro and in silico dissolution measurements suggest the dependency of drug release rate 
on the agglomeration of FCC and paraffin wax.
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Figure 2 (a) Experimental and simulated caffeine release profile of tablet formulation F1, (b) experimental and simulated caffeine release  
profiles of F5, (c) experimental and simulated caffeine release profiles of tablet formulation F6. Variations in in silico drug release profiles 
were obtained by different arrangement of the components in the F-CAD tablet matrix to illustrate the effect of formulation-induced 
deviations. (d) Experimental and simulated caffeine release profiles of tablet formulation F7. 
3.2.1 Comparison of in vitro and in silico dissolution profiles
Good  correlation  between  the  experimental  and  simulated  dissolution  data  was  obtained  (Table 4).  In 
addition, a model-independent approach by calculating the difference (f1) and similarity (f2) factors was used 
for comparison of the data sets (Table 4). The obtained f1 values were in the range from 0 up to 15 and the f2 
values greater than 50, ensuring equivalence of the in vitro and in silico release profiles [36].
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Table 4 Comparison of experimental and simulated dissolution profiles of different tablet formulations.  
Formulation
Coefficient of 
first order fitting
R2 f1 factor f2 factor Pearson’s correlation coefficient, p
F1 0.007 0.9977 10.92 68.72 0.9985
F2 0.007 0.9882 7.33 74.08 0.9969
F3 0.001 0.9728 9.51 62.99 0.9728
F4 0.002 0.9877 5.12 72.88 0.9831
F5 0.002 0.9866 9.72 63.71 0.9987
F6 0.017 0.9795 4.75 78.56 0.9983
F7 0.030 0.9964 6.95 69.42 0.9957
F8 0.005 0.9890 8.93 63.89 0.9942
F9 0.002 0.9403 9.34 58.30 0.9874
F10 0.001 0.9980 5.86 71.91 0.9873
F11 0.070 0.9985 6.48 60.78 0.9921
F12 0.004 0.9863 4.14 82.05 0.9984
F13 0.024 0.9847 7.89 64.65 0.9811
F14 0.009 0.9979 15.55 59.23 0.9965
F15 0.005 0.9754 10.36 64.31 0.9979
3.2.2 Statistical analysis of experimental data: influence of the factors on the response 
variables
Statistical evaluation revealed that the factors FCC (p=0.0093) and PolyoxTM (p=0.0068) had a significant 
influence on the breaking strength (goodness of  fit  R2=0.9553).  In  contrast,  the interaction of  FCC and 
paraffin wax (p=0.0314) influenced negatively the breaking strength; higher concentrations of Polyox TM were 
also found to reduce the tablet hardness.
For the statistical analysis of the in vitro dissolution profiles, the coefficient of first order drug release kinetics 
was determined (Table 4). The logarithmic transformation of the response variable resulted in a very good fit  
of the model (R2=0.9903). The concentrations of the components FCC (p=0.0027), paraffin wax (p=0.0053), 
and PolyoxTM (p=0.0083) were found to influence significantly the speed of drug release from the tablet  
formulations. The swelling polymeric excipient PolyoxTM and the paraffin wax prolonged the drug release; 
whereas,  the  highly  porous  material  FCC increased the  caffeine  release  speed.  The  interaction  of  the 
excipients FCC and PolyoxTM (p=0.0295) had a significant influence; it  decreased the speed of  caffeine 
release from the tablet matrices, indicating a synergistic effect. 
Figure  3  displays  the  ternary  contour  plot  of  the  response  variables  tablet  breaking  strength  and  the 
coefficient of first order drug release kinetics of the hydrophobic matrix floating formulations at a caffeine 
content of 35% (w/w).
For the statistical analysis, F11 was excluded from the data set as the floating tablets disintegrated within 
approx. 4 min during the in vitro dissolution experiments. 
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Figure 3 Ternary contour plot of the hydrophobic matrix formulations at a caffeine content of 35% (w/w), where the response variables 
of tablet breaking strength and coefficient of first order drug release kinetics are displayed in black and light gray, respectively. Dark gray 
dotted line represents recommended rate of drug release to yield 100% drug release at 12 h time.
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4. Discussion
It was hypothesized that the manufacturing process (i.e. melt granulation in a twin-screw extruder) induced a  
hydrophobization of FCC due to molten paraffin wax. In order to evaluate the extent of hydrophobization, it  
was assumed for  the in  silico simulations that  FCC particles are smooth spheres.  The thickness of the 
simulated  paraffin  layer  around  an  individual  FCC particle  was  adapted  for  each  formulation  to  mimic 
different degrees of hydrophobization. It was hypothesized that up to an equal ratio of paraffin wax to FCC,  
increasing the amount of paraffin wax in the formulation created a thicker layer around the FCC particles. 
Further increase of the amount of paraffin wax in the mixtures did not increase the thickness of the simulated 
paraffin wax layer. Simulated paraffin wax layers around individual FCC particles with a maximum thickness 
of  approx.  1 μm were obtained.  The FCC hydrophobization  hypothesis  was simulated  in  silico and  the 
assumption resulted in a good correlation of in vitro and in silico tablet dissolution profiles. 
A simplified FCC hydrophobization approach was applied for the in silico simulations; it did not account for 
the porous internal structures of the FCC particles and filling of molten paraffin wax into FCC particles was 
neglected. The simulated paraffin wax layers with a maximum thickness of approx. 1 μm correspond to the  
thickness of the FCC particle stratum layer [35]. Based on the results of the in silico calculations and the in  
vitro data, it was concluded that molten paraffin wax was filled into the pores and channels of the stratum 
layer of FCC particles during melt granulation; but did not penetrate into the inner pores of the FCC particles.  
The tablet formulations F6, F7, F11, and F13 showed the fastest caffeine release; despite the fact that they 
had a simulated paraffin wax layer of about 3 μm around an individual FCC particle. It was hypothesized that 
the outer porous meshwork of the particles was completely filled with molten paraffin and large agglomerates  
of  FCC, paraffin  wax, and PolyoxTM  were generated during the melt  granulation process.  These results 
suggest the dependency of drug release rate on agglomeration of FCC and paraffin wax.  
The results of factorial design revealed a significant influence of the excipients FCC, PolyoxTM and paraffin 
wax on tablet breaking strength and caffeine release speed. However, it  did not provide any information 
regarding the impact of the applied continuous melt granulation technique on the formulation components –  
in particular FCC and paraffin wax – and on their arrangement within the tablet matrices. FCC increased the  
hardness of the compacts due to its lamellar surface structures that promote a tight interlocking of the FCC 
particles during compaction;  whereas, the interaction of FCC and paraffin wax influenced negatively the 
breaking strength. This observation provided evidence for the hypothesis of FCC hydrophobization; it can be 
explained by coating of the FCC particles with a layer of paraffin wax and PolyoxTM during melt granulation; 
hence, rendering ineffective the tight surface-driven interlocking of FCC.
The influence of the factors, identified by factorial design, was well correlated with the experimental data and 
supports  the  initial  hypothesis.  However,  the  results  do  not  represent  sufficiently  the  complexity  of  the 
developed  paraffin  wax  FCC  matrix  formulations,  namely  hydrophobization  of  FCC  particles  and  the 
influence of pFCC on tablet properties. pFCC was found to feature heterogeneous effects in respect to the 
formulation release performance. 
A combination of  in  vitro measurements,  statistical  analysis,  and a computer  simulation approach were 
applied to gain a deeper understanding of paraffin wax FCC matrix formulations and to explore their design 
space.
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The understanding of the melt granulation process was considered to be of importance due to the formation 
of  agglomerates.  The inhomogeneous distribution  of  the  excipients  and  the API  within  the hydrophobic 
matrices may lead to a highly variable drug release behavior (e.g. tablet erosion by disintegration). 
In the case of formulations with high paraffin and low FCC contents, an observable change in drug release 
speed might be due to re-arrangement of the components in the compacts; additionally, softening of paraffin 
wax might have occurred. Consequently, the permeation of dissolution liquid into the floating compacts would 
be delayed and the caffeine release would be retarded, or the release of the entire amount of caffeine would 
be rendered impossible.
The combined factorial design and in silico analysis suggest that depending on the composition of the tablet 
the hydrophobization of the FCC particles has crucial effects on the release and mechanical stability of the  
compacts. The degree of hydrophobization is a main parameter to keep under control for such formulations; 
this factor is heavily influenced by a chosen process i.e. melt granulation. In order to achieve a drug release 
time of about 12 h for FCC-based floating formulations, a degree of hydrophobization of 48 to 55% (w/w) 
pFCC and a simulated paraffin layer thickness of 0.65 to 0.7 µm are recommended.
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5. Conclusions
For the future formulation design and optimization of porous hydrophobic matrix formulations composed of 
FCC and a lipophilic excipient, not only the formulation composition but also the component arrangement 
within the tablets which is induced by the manufacturing process, i.e. melt granulation, needs to be taken into 
consideration.
The combined application of in vitro measurements, statistical evaluation of experimental data, and in silico 
simulations  has  led to  a  deeper understanding  of  the  interaction of  the hydrophobic  matrix  formulation 
components and the unit operation, such as granulation in a twin-screw hot-melt extruder. 
It was possible to come with recommendations for formulation development strategies in case of porous 
components such as FCC and hydrophobized material.
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3.4. IN VIVO EVALUATION OF FLOATING SYSTEMS
3.4 In vivo evaluation of floating systems
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Abstract
Floating dosage forms are supposed to exhibit an enhanced gastric residence time. Their development is challenging as the prediction of the 
retention potential in humans based on in vitroVWXGLHVDQGDQLPDOPRGHOVLVGLI¿FXOW
$VWUDWHJ\WRGHWHUPLQHWKHVWRPDFKUHVLGHQFHWLPHRIDÀRDWLQJGRVDJHIRUPZLWKDQLQKHUHQWO\ORZGHQVLW\LQKXPDQZLWKRXWXVLQJLPDJLQJ
techniques was explored in a self-experiment.
)ORDWLQJWDEOHWVDQGQRQÀRDWLQJFRQWUROVZHUHSUHSDUHGFRQWDLQLQJFDIIHLQHDVDPRGHOGUXJ7KHFRPSDFWVKDGDS+GHSHQGHQWHQWHULF
coating to assess their stomach residence time. Since caffeine is rapidly absorbed in the gastrointestinal tract, the prolonged gastric retention 
of tablets can be demonstrated by a delayed systemic exposure. Caffeine and paraxanthine were determined in capillary blood by liquid 
chromatography coupled to tandem mass spectrometry.
$QLQFUHDVHLQFDIIHLQHDQGSDUD[DQWKLQHEORRGOHYHOVZDVREVHUYHGLQKXPDQYROXQWHHUVDIWHUWRPLQIRUWKHQRQÀRDWLQJFRQWUROV)RU
WKHÀRDWLQJWDEOHWVQRHOHYDWHGEORRGFRQFHQWUDWLRQVZHUHIRXQGLQWZRRXWRIWKUHHSDUWLFLSDQWVGXULQJKRIVDPSOHFROOHFWLRQ
7KHUHVXOWVGHPRQVWUDWHWKHWHFKQLFDOIHDVLELOLW\RIWKHSURSRVHGFOLQLFDOVWXG\SURWRFRO)ROORZXSFOLQLFDOWULDOVZLOOEHQHHGHGWRFRQ¿UPWKH
SUHOLPLQDU\GDWDRQVWRPDFKUHVLGHQFHWLPHRIRXUÀRDWLQJGRVDJHIRUP
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Introduction
Gastroretentive drug delivery systems (GRDDS) offer the possibility 
to prolong and control the residence time of drugs in the stomach and 
the upper part of the small intestine [1]. The reason and need for a 
gastroretentive delivery approach is in most cases dictated by physiological 
necessity [2]. The passage time of conventional oral pharmaceutical 
dosage forms through the stomach is relatively short; thus, GRDDS 
provide a technology to overcome this limitation. Several drug substances, 
e.g. drugs acting locally or being absorbed in the stomach region might 
benefit from enhanced gastric retention times [3]. Floatation has been 
proposed as a mechanism to avoid unpredictable and premature gastric 
emptying of pharmaceutical dosage forms [4]. Due to the low density of 
the drug delivery systems, they float on stomach contents and are retained 
while releasing the drug substance.
During the last years, the development of floating drug delivery systems 
(FDDS) has gained importance. However, there are only few examples of 
clinical trials or marketed GRDDS. One explanation of this shortcoming 
is the fact that it is very difficult to extrapolate from in vitro studies or 
from animal experiments to human. Thus, the phenomenon of flotation 
has to be explored in human to account for the unique anatomical and 
physiological situation in humans. Nevertheless, even complex clinical 
trial protocols often fail to show significantly enhanced gastric residence 
times of FDDS in comparison to non-floating references. A number 
of shortcomings are associated with the clinical evaluation of floating 
dosage forms: the gastric retention time is often determined in the fed 
state; although, high-caloric food is known to delay the gastric emptying 
rate [5]. Additionally, numerous researchers select non-appropriate non-
floating control dosage forms, e.g. immediate release formulations, in 
order to prove prolonged gastric residence times. In some clinical studies, 
only pharmacokinetic data are recorded to provide an indirect estimate of 
the retention time of a dosage form in the stomach. 
A FDDS, which is based on the use of the porous carrier functionalized 
calcium carbonate (FCC), was developed and in vitro flotation in a custom-
built stomach model was demonstrated. Tablet dissolution and buoyancy 
behavior were simulated in silico and provided insight into drug release and 
floating mechanism [6]. But, the extrapolation from these model systems 
to the in vivo situation proofed to be a challenge. Therefore, it was decided 
to evaluate a strategy to test the gastric retention potential in human of 
FCC-based tablets featuring an inherently low density. The aim of the 
present project was to design and evaluate a method in human, which can 
be used to assess and compare the in vivo gastric residence time of floating 
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and non-floating tablets. The compacts contained caffeine as a model 
drug substance and were coated with a pH-dependent enteric-coating. 
Upon retention of a tablet in the acidic environment of the stomach, the 
marker caffeine is thus retained within the tablet. Using minimal amounts 
of capillary blood, the systemic exposure of caffeine and its metabolite 
paraxanthine were determined using liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS).
Materials and Methods
Materials
Highly porous functionalized calcium carbonate (FCC VP-DP141 S04, 
Omya, Oftringen, Switzerland) [7] was used as matrix for the preparation 
of tablets with an inherently low density. Two gelation-layer forming 
polymers, water-soluble polyethylene oxide (Polyox™  WSR  301, The 
Dow Chemical Company, Midland, Michigan) and hydroxypropyl 
methylcellulose (Methocel®  K100  Premium  LV, Sandoz Pharma AG, 
Basel, Switzerland) were selected to slow down penetration of liquid 
into the tablet and retard release of the model drug substance caffeine 
(Coffeinum WSF, Böhringer-Ingelheim, Ingelheim, Germany). Citric acid 
(Acid citricummonohydr. pulvis, Hänseler AG, Herisau, Switzerland) 
was chosen as effervescent excipient. The floating formulation was 
prepared by wet-granulation with ethanol 96% (SchweizerhallChemie 
AG, Flawil, Switzerland). The enteric-coating suspension consisted of the 
following materials: Kollicoat MAE 30 DP (BASF, Germany), propylene 
glycol (Hänseler AG, Switzerland), talc (Hänseler AG, Switzerland), and 
titanium dioxide (Hänseler AG, Switzerland).
Methods
Preparation of floating and non-floating tablets: Floating tablet 
formulation was prepared as described 
previously [6]. For in vivo investigation of gastric retention times, 
floating and non-floating tablets using a single punch eccentric press 
(Styl’One, Medelpharm, France) were manufactured. The convex-shaped 
tablets had a curvature radius of 12 mm and a tablet radius of 5mm. The 
cap height was 1.1 mm. The caffeine containing formulation had the same 
composition for both the floating and the non-floating tablets. Tablet 
density was adjusted by using different compaction forces. Since non-
floating tablets had a reduced tablet height, an additional layer of 
130 mg pure FCC was added to obtain identically sized floating and 
non-floating control tablets. Thus, an impact of tablet size on gastric 
retention could be excluded. The characteristics of the prepared 
compacts are summarized in Table 1.
After compaction, the floating and non-floating tablets were coated 
with an enteric-coating in a drum coater (Lab-Coater GC-300, Glatt, 
Switzerland).
Evaluation of in vivo gastric retention in humans: Prior to the in 
vivo evaluation, drug release and flotation behavior of the enteric-coated 
tablets were studied in vitro using a custom-built stomach model [6]. Non-
floating tablets were expected to remain in the gastric region for about 
2 to 3 h [8]. Within this time, the enteric-coating was supposed to remain 
intact; thus, no caffeine and paraxanthine should be observable in the 
blood samples of the volunteers. After being emptied from the stomach, 
the enteric-coating of the compacts should dissolve due to a pH change in 
the intestine, and caffeine as well as paraxanthine plasma concentrations 
increase. In the case of the gastric-coated floating dosage forms, no 
caffeine and paraxanthine should be present in the blood samples of the 
volunteers during 8 h of sample collection.
Study design: The exploratory experiment in human volunteers (n=3) 
using the marker caffeine was brought to the attention of the local ethics 
committee (EKNZ; reference number UBE-15/17) and was considered by 
the committee to be compliant with Swiss legislation. All participants gave 
informed consent prior to the study. 
The study started with a caffeine washout period of 3  days; the 
participants were not allowed to consume any caffeine-containing food. 
In order to evaluate the in vivo gastric retention times, tablets were 
administered at 08:00 a.m. with 300 ml of water after an overnight fasting. 
Every half hour, 300 ml of liquid was provided. A standardized, low-
caloric liquid meal was given 4 h post-administration. Blood samples of 
10 µl were collected via capillary puncture of the fingertip at the indicated 
times. Collected blood samples were diluted with 200  µl methanol 
containing 50 ng/ml of caffeine-d9 as the internal standard and stored at 
-20 °C for further analysis.
Determination of caffeine and its metabolite paraxanthine in 
human plasma: Blood concentrations of caffeine and paraxanthine 
were determined in collected blood samples using LC-MS/MS. The 
analytes were extracted by protein precipitation using methanol (see 
above). Chromatographic separation of sample supernatants was done 
on a Shimadzu HPLC system consisting of an HTS PAL autosampler 
(CTC Analytics AG, Switzerland), two Shimadzu LC-20 AD pumps 
(Shimadzu AG, Switzerland) controlled by a Shimadzu CBM-20A unit, 
and a Shimadzu CTO-20AD column oven. An Atlantis T3 column (2.1 
x 50 mm, Waters AG, Switzerland) was used to separate the analytes. 
Eluent A (0.1% formic acid in water) and eluent B (0.1% formic acid in 
methanol) were delivered at a constant flow of 0.8 ml/min. The following 
gradient was applied: 100% A from 0 to 0.5 min, 50 – 98% B from 0.5 
to 2 min, 98% B from 2 to 2.5 min, 100% A from 2.5 to 2.8 min. Total 
run time was 2.8 min. A thermo stated column oven was set to 60 °C. 
The injection volume was 10 μl. The flow was directed to waste for the 
first and last 0.6 min, to minimize contamination of the MS source. Mass 
spectrometric detection was performed using a triple quadrupole mass 
spectrometer (API4000, Applied Biosystems, Switzerland) operating in 
electrospray-ionization positive-ion mode. Samples were quantified using 
peak area ratios and caffeine-d9 as the internal standard. The assays were linear 
in the concentration ranges of 25 – 1000 ng/ml for caffeine and paraxanthine.
Statistical analysis: A one-sided Grubb’s test for outliers with a 90% 
confidence interval was used in order to detect outliers in the in vivo 
caffeine plasma concentration profiles of floating tablets [9].
Results and Discussion
Figures  1a-1c displays the caffeine and paraxanthine blood 
concentrations measured in human volunteers (n=3) after administration 
of the prepared non-floating enteric-coated tablets. Participants 1, 2, and 3 
showed no elevated caffeine and paraxanthine plasma concentrations up 
to 90, 126, and 175 min, respectively. Thus, the enteric-coating of the 
compacts remained intact within this time period and no caffeine was 
released from the tablets. We assume that the control tablets were located 
in the stomach of the participants during this time.Afterwards,a caffeine 
Formulation Weight (mg)
Diameter 
(mm)
Height 
(mm)
Tablet 
density (g/
cm3)
Floating tablet 399.17 10.02 7.06 0.85
Enteric-coated 
ÀRDWLQJDWDEOHW 439.77 10.20 7.19 ---
1RQÀRDWLQJWDEOHW 530.10 10.03 7.04 1.13
Enteric-coated non-
ÀRDWLQJWDEOHW 564.80 10.21 7.16 ---
Table 1: Properties of the convex-shaped round tablets
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release from the tablets was observed, resulting in an increase in caffeine 
and paraxanthine levels. It can be concluded that the tablets passed 
through the pylorus into the small intestine. Due to a change in pH in the 
intestinal environment, the enteric-coating started dissolving and caffeine 
was released. Consequently, blood concentrations of caffeine and its 
metabolite paraxanthine increased. For the non-floating tablets, the time 
points at which caffeine and paraxanthine blood concentrations increased 
after administration were comparable for all three study participants. 
The results were in good agreement with another study performed by 
Podczeck et al., where the mean gastric residence time was determined 
to be 91 min for 10 mm tablets administered with a dextrose drink. 
The gastric emptying of food and its influence on the gastric emptying 
of tablets of different dimensions was measured by γ-scintigraphy and 
electrical impedance tomography [10]. 
In contrast, in two out of three participants no increase in caffeine 
and paraxanthine concentrations was measured during 8 h blood sample 
collection for the floating tablets (Figures 2a and 2b). Elevated caffeine 
plasma concentrations were observed at isolated time points. However, 
high caffeine levels were not accompanied by high paraxanthine levels. 
No systemic exposure of caffeine and its metabolite paraxanthine could 
be detected; hence, indicating that the floating dosage forms remained in 
the human stomach.
In the case of one study participant, plasma profiles after administration 
of the floating enteric-coated tablet were similar to the ones of the non-
floating tablet; an increase in caffeine and paraxanthine concentrations 
was seen after approximately 90 min. In this situation, it was not possible 
to determine the reason for failure of the experiment. It might be that 
either the enteric coating of the tablet was defective or that the tablet was 
emptied prematurely from the stomach. 
The pilot experiment did reveal shortcomings of the chosen study 
design. Blood sample collection during 8 h was found to be not sufficient 
in order to detect the increase in caffeine and paraxanthine plasma 
concentrations caused by gastric emptying of the FDDS. First, blood 
sampling time should be extended to at least 24 h to cover longer than 
expected gastric retention times of the tablets. Second, increased caffeine 
levels at isolated time points were obtained in two volunteers. They were 
identified as outliers based on statistical analysis and the absence of a 
concomitant occurrence of the caffeine metabolite paraxanthine. We 
concluded that these outliers were due to a contamination of samples 
by caffeine. In addition, analytical methods have to be used which cover 
both caffeine and its metabolite paraxanthine to exclude blood sample 
contaminations. It might be advisable to validate in a second step the 
position of the tablets in the stomach by e.g. γ-scintigraphy and not to rely 
exclusively on pharmacokinetic analysis of plasma profiles of a marker 
substance.  
The volunteers in this study were provided with low-caloric and liquid 
food in order to exclude the effects of high-caloric meals, which delay 
the gastric emptying process and thus influence the gastric retention of 
pharmaceutical dosage forms. The amount of liquid and food consumed 
during the experiment should therefore be strictly controlled. The 
a) b)
 
C)
 
Figures 1: In vivoFDIIHLQHƑDQGSDUD[DQWKLQHŶFRQFHQWUDWLRQVLQWKHSODVPDRIWKUHHKXPDQYROXQWHHUVDIWHUDGPLQLVWUDWLRQRIWKHQRQÀRDWLQJ
enteric-coated control tablet. Each data point represents one blood sample.
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volunteers had to maintain an upright position during the duration of the 
experiment; however, they were allowed to move and to do light exercise. 
Our preliminary results seem to suggest that body motion was not a 
critical factor.
Conclusions
Coating of tablets with a pH-dependent enteric-coating seems to be an 
interesting strategy to compare the retention times in the human stomach 
of floating tablets with non-floating reference systems. Non-floating 
controls can be designed to differ only by their density from the test 
tablets. They are superior to immediate-release formulations, which are 
often used as controls. The use of the marker component caffeine seems to 
be an alternative to more expensive imaging techniques.
It was the aim of the present pilot study to demonstrate the technical 
feasibility of a clinical study protocol. Obtained preliminary results 
demonstrate that in vivo characterization in human of a floating dosage 
form is possible. Floating and non-floating control tablets can be compared 
without applying complex imaging technologies.
The performed exploratory study is encouraging and will therefore 
serve as a basis for the preparation of clinical phase I studies to evaluate 
the properties of FCC-based floating dosage forms. In addition, the pilot 
experiment will help to define study conditions and parameters. The 
experience gained from this exploratory study might convince other 
researchers that in vivo performance of FDDS can potentially be explored 
using a relatively simple clinical study design. We hope that our preliminary 
findings might therefore promote the use of this innovative drug delivery 
strategy. Follow-up clinical trials using larger cohorts of volunteers will be 
needed to obtain statistically significant data on stomach residence time 
of our floating dosage form.
Acknowledgements
Rainer Alles, Dr. Maxim Puchkov, and Prof. Dr. Jörg Huwyler have 
contributed equally to the present work. Financial support for the Ph.D. 
thesis of Veronika Eberle was kindly provided by OmyaInternational AG 
(Oftringen, Switzerland).Many thanks to Dr. TanjaStirnimann for her 
support during the study.
References
1. Streubel A, Siepmann J, Bodmeier R (2006) Gastroretentive drug 
delivery systems. Expert Opin Drug Deliv 3: 217–233. 
2. Coupe AJ, Davis SS, Evans DF, Wilding IR (1992) Nocturnal 
scintigraphic imaging to investigate the gastrointestinal transit of 
dosage forms. J Control Release 20: 155–162.
3. Prinderre P, Sauzet C, Fuxen C (2011) Advances in gastro retentive 
drug-delivery systems. Expert Opin Drug Deliv 8: 1189–1203. 
4. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, et al. (2011) 
Gastroretentive dosage forms: A review with special emphasis on 
ÀRDWLQJGUXJGHOLYHU\V\VWHPV'UXJ'HOLY± 
5. Waterman KC (2007) A critical review of gastric retentive controlled 
drug delivery. Pharm Dev Technol 12: 1–10.
6. Eberle VA, Schoelkopf J, Gane PA, Alles R, Huwyler J, et al. (2014) 
Floating gastroretentive drug delivery systems: Comparison of 
H[SHULPHQWDO DQG VLPXODWHG GLVVROXWLRQ SUR¿OHV DQG ÀRDWDWLRQ
behavior. Eur J Pharm Sci 58: 34–43. 
7. Stirnimann T, Maiuta N, Gerard D, Alles R, Huwyler J, et al. (2013) 
Functionalized Calcium Carbonate as a Novel Pharmaceutical 
Excipient for the Preparation of Orally Dispersible Tablets. Pharm Res 
30: 1915–1925. 
8. Washington N, Washington C, Wilson CG (2001) The Stomach. In: 
Physiological Pharmaceutics Barriers to Drug Absorption, 2nd edition, 
CRC Press 75–108.
9. Grubbs FE (1969) Procedures for Detecting Outlying Observations in 
Samples. Technometrics 11: 1-21. 
10. Podczeck F, Mitchell CL, Newton JM, Evans D, Short MB (2007) The 
gastric emptying of food as measured by gamma-scintigraphy and 
HOHFWULFDOLPSHGDQFHWRPRJUDSK\(,7DQGLWVLQÀXHQFHRQWKHJDVWULF
emptying of tablets of different dimensions. J Pharm Pharmacol 59: 
1527–1536.
a)
b)
Figures 2: In vivoFDIIHLQHƑDQGSDUD[DQWKLQHŶFRQFHQWUDWLRQVLQ
WKHSODVPDRIWZRKXPDQYROXQWHHUVDIWHUDGPLQLVWUDWLRQRIWKHÀRDWLQJ
enteric-coated tablet. Each data point represents one blood sample. 
&DIIHLQHRXWOLHUVLGHQWL¿HGE\DRQHVLGHG*UXEE¶VWHVWIRURXWOLHUVZLWKD
FRQ¿GHQFHLQWHUYDODUHQRWVKRZQRQWKHJUDSK
3.4. IN VIVO EVALUATION OF FLOATING SYSTEMS
85

4
Discussion
In the following chapter, the suitability of FCC for the manufacture of instantly floatingdrug delivery platforms is discussed on the example of FCC-based floating tablets and
mini-tablets. In addition, the advantages of the proposed formulation strategy for the e cient
and successful development of FDDS are illustrated.
4.1 Applicability of functionalized calcium carbonate
In the introduction, various mechanisms to achieve flotation of dosage forms are summarized
(1.3.1.6 Floating systems). Some of the described approaches feature the disadvantages
of being expensive and complex from the manufacturing point of view. The development of
FDDS, which float in the stomach due to an inherently low density, is favored; because, the
floating mechanism does not need to be activated first. But, immediately floating tablets have
to combine two, often self-excluding, properties. They must feature an inherent density less
than unity and a su cient hardness to be further processable and to withstand the destruction
by gastric peristalsis. Up to now, there is no pharmaceutical excipient available on the market
which seems to render possible the compaction of tablets that fulfill both requirements.
FCC was identified as a material that is suitable for the manufacture of tablets featur-
ing the above-mentioned characteristics. It exhibits unique properties: a high porosity of
approx. 70% (v/v) and a high specific surface area of 40-60 m2/g due to the lamellar structure
of the particles (Figure 4.1). During the compaction process, an interlocking of the FCC
paddle-like surface structures occurs. Even at low compression pressures, tablets with a high
tensile strength are obtained and a high tablet porosity is retained [215]. The key element of
87
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Figure 4.1. Scanning electron microscopy images of FCC. (a.) magnification: x3’000.
(b.) magnification: x10’000 [216]. FCC particle sizes range from 5-15 µm [215].
FCC - its lamellar structural organization - makes FCC a promising material for the manufacture
of floating tablets featuring no floating lag time.
The intermixing of API and FCC exclusively was not su cient for the preparation of floating
tablets with targeted flotation behavior and drug release profiles. Due to the porous structural
organization of FCC particles, the liquid sorption into the compact was triggered. As a result,
the tablet density increased quickly and, finally, the floating device sank down. Additionally,
it had to be taken into account that a reaction-based erosion of FCC took place under acidic
conditions. For the successful development of FCC-based floating drug delivery platforms, the
porous component FCC had to be combined with appropriate excipients.
4.1.1 Hydrophilic floating systems
For the hydrophilic floating systems, FCC was co-formulated with gelation-layer-generating
components (e.g. Methocel®, PolyoxTM). The formulation was prepared by wet granulation.
It had to be kept in mind that during the granulation process, in particular at high shear
forces, the lamellar organization of the FCC particles might be partially destroyed or completely
covered with a layer of granulation binder. The lamellae of the particle’s stratum layer [215]
provided a large contact area which allowed a tight interlocking of the FCC particles during
compaction. This was essential for the manufacture of tablets featuring a su ciently high
tensile strength. Thus, the paddle-like structures of FCC needed to be preserved during the
granulation step.
Upon contact of the delivery device with the gastric fluids, hydration and swelling of the
polymeric excipients occurred at the surface of the tablet. The swollen polymer layer around the
compact played an essential role regarding the flotation mechanism of the hydrophilic systems.
On the one hand, it retarded the penetration of gastric fluids into the porous FCC-based tablet
matrix. The liquid sorption would result in an increase of the tablet density higher than unity
and, consequently, would force the compact to sink down. On the other hand, the surface
88
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Figure 4.2. Schematic representation of “gas plug” formation.
gelation layer can entrapp air and carbon dioxide, that was formed by the reaction of FCC
with the acidic dissolution medium, within the internal porous structures of the FCC-based
matrix (Figure 4.2). As the gas bubbles needed to di use through the gel layer, they were
enclosed in the matrix and buoyancy of the dosage form was maintained for a prolonged period
of time. This mechanism was referred to as “gas plug” formation.
The analysis of the hydrophilic formulations by displaying the floating force of the tablets
as a function of drug release revealed that the flotation performance belonged to the type I
model behavior of our classification system. While the API was released, the floating capability
of the compacts decreased linearly and a floating force value of zero was obtained after almost
entire ca eine release. This observation was explainable by the reaction-based erosion process
of the flotation-promoting FCC in HCl.
4.1.2 Lipophilic floating systems
For preparation of the lipophilic floating formulation type, FCC was combined with a lipophilic
component (e.g. Lubritab®, para n wax). Though, the co-formulation of FCC and lipophilic
material by intermixing did not result in the targeted drug release and flotation times. The
FCC pores were not blocked and, consequently, the immediate wetting of the porous matrix
was not prevented. The hydrophobization of FCC due to melting of the lipophilic excipient was
of relevance for this formulation type; di erent degrees of FCC hydrophobization (i.e. thickness
of the lipophilic layer) were assumed.
A critical role played the selection of the pharmaceutical manufacturing process, as the
lipophilic component had to be melted and distributed homogeneously within the porous
FCC matrix. Despite the twin-screw hot-melt extruder, which was used in the context of this
thesis, the melt granulation process may be performed in a high-shear mixer or fluidized melt
granulation is applicable.
The lipophilic coating layer of FCC particles (Figure 4.3) delayed or prevented the erosion
of FCC under acidic conditions. In addition, it slowed down the penetration of dissolution
liquid into the tablet. Consequently, air and/or carbon dioxide can be entrapped within the
89
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Figure 4.3. Hydrophobization of FCC: the particles are covered with a lipophilic layer
and/or the lipophilic excipient is filled into the stratum voids of the particles.
porous matrix system in form of a “gas plug”.
A floating system consisting of an inert, lipophilic drug-releasing matrix is supposed to show
a type III floating behavior: the floating force of the FDDS increases as the API is released
and is replaced by the dissolution medium. For the lipophilic FCC-based mini-tablets, two
types of floating kinetics - type I and type V - were identified depending on the formulation
composition. We hypothesized that in the case of the mini-tablet formulations with a type
I floating behavior, the amount of lipophilic excipient was not su cient to ensure complete
hydrophobization of the FCC matrix. Therefore, an erosion reaction of non-hydrophobized
FCC under acidic conditions occurred. The floating force increase, induced by drug release
from the floating tablet, was compensated and predominated by the floating force decline
due to mini-tablet erosion. As a result, the floating potential of the FDDS decreased linearly.
In the case of the lipophilic mini-tablet formulations featuring a type V floating behavior, a
mass exchange between dissolved API and dissolution liquid took place. The resulting increase
of floating capacity was compensated by erosion of the tablet matrix. In consequence, the
mini-tablets maintained their resultant floating force while the drug substance was released. The
erosion of the lipophilic tablet matrix was possible due to the dissolution of ca eine and non-
hydrophobized FCC which resulted in the detachment of buoyancy-promoting, hydrophobized
FCC particles from the tablet core. After almost complete release of the API, the flotation
capability of the mini-tablets decreased; it implied that the erosion by disintegration process
exceeded.
Floating systems with an inherently low density due to the incorporation of porous ex-
cipients, such as FCC, have the advantage that higher drug loads are feasible. In particular
in the case of e ervescent FDDS, the drug load of the delivery platforms is limited by the
need of co-formulated e ervescent excipients. Our FCC-based approach describes industrially-
manufacturable floating devices with drug loads of up to 35% (w/w).
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4.2 In vitro evaluation of flotation and drug release
As mentioned in the introduction, several parameters exist to characterize FDDS (1.3.3
Methods for the evaluation of floating systems). However, there are no generally-
accepted considerations which of the factors are fundamental. The relevance of the individual
parameters is discussed in the following section.
First, the density of the dosage form, before its immersion into liquid, is an important
property of FDDS. An inherent density below unity implies immediate flotation of the device
in the dissolution medium. However, we consider the exclusive assessment of the density before
immersion of the dosage form into liquid as insu cient for the appropriate characterization
of FDDS. The parameter, initial density, does not provide any information about the floating
behavior of the device over time while the drug substance is released.
Further relevant factors for the in vitro investigation of FDDS are floating performance and
drug release behavior. For the design of floating formulations, most researchers characterize
FDDS based on visually-assessed floating behavior (i.e. floating lag time and total floating time)
and do not take into account floating kinetics.
Figure 4.4. Limitations of the United States Pharmacopeia methods. (a.) USP I dissolu-
tion apparatus: the dosage form is forced to stay immersed in the medium (A);
the floating system sticks to the basket or the swelling of the device is in-
hibited (B). (b.) USP II dissolution apparatus: the floating system is not
completely submerged into the liquid (C); the device sticks to the paddle
shaft (D); the floating tablet surface dries, a crater is formed, and the floating
time is artificially prolonged (E).
A reason may be the fact that there is currently no evaluation system available to investigate
simultaneously in vitro drug release and in vitro floating force. From our point of view, the
visual observation of floating characteristics seems not su cient for the successful development,
comparison, and optimization of floating formulations. The approach does not quantify the
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floating capability of FDDS; i.e. it does not allow to determine the resultant floating force of
dosage forms.
Additionally, there does not exist a generally-accepted method for the in vitro evaluation
of drug release behavior of FDDS and di erent approaches are described in literature. The
conventional USP I and II dissolution methods show limitations regarding the analysis of FDDS
which are highlighted in Figure 4.4. In order to overcome these shortcomings, we proposed a
custom-built stomach model. The features of the custom-built stomach model were evaluated
in comparison to the available models for simulation of the human GI tract (3.1 Preparation
and in vitro evaluation of floating gastroretentive drug delivery systems). Our
method allowed for a combined analysis of drug release by UV/Vis spectroscopy and floating
behavior by visual observation. But, it was not possible to perform the combined in vitro
assessment of drug release and resultant floating force. In order to compensate this drawback,
the in vitro evaluation method was combined with in silico computer simulations.
To sum up, the determination of the density, the in vitro evaluation of floating behavior, the
in vitro and in silico analysis of drug release, and the in silico assessment of floating kinetics
were found to be essential for the successful development of FDDS.
4.3 In silico simulation of tablet dissolution
In general, computer simulations o er the possibility to assess parameters which cannot
be experimentally determined or which require a complex experimental setup. The F-CAD
software (CINCAP GmbH, Switzerland) is an approach to drug release simulation based on the
mathematical concept of cellular automata [177]. Cellular automata present an idealization of
a physical system in which time and space (i.e. equal-sized voxels arranged in a regular grid)
are discrete, and physical quantities take a finite set of values (i.e. each voxel owns a finite
number of states). After every time step/iteration step, the state of each individual voxel in a
new generation of voxels is defined by its previous state and by the state of the voxels in its
neighborhood [34, 177].
The Noyes-Whitney equation mathematically expresses the rate of dissolution dm/dt of a
solid in a solvent, as follows:
(4.1) dm
dt
= A ·D
h
· (Cs≠Ct) [155]
where, m is mass of dissolved material, t is time, A is solid-liquid interface surface area, D is
di usion coe cient, Cs is solubility on the equilibrium at experimental temperature, Ct is
concentration of the solid in the bulk of the dissolution medium at time t, and h is thickness of
the di usion layer.
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By maintaining sink conditions during the dissolution, the resulting equation is:
(4.2) dm
dt
= A ·D
h
·Cs for Ctæ 0 [180]
The Noyes-Whitney equation in spatial di erential form has a form of the Fick’s second law
and can be shown in three dimensions, as follows:
(4.3) ˆ„
ˆt
= DÒ2„ with Ò2 = ( ˆ
2
ˆx2
+ ˆ
2
ˆy2
+ ˆ
2
ˆz2
) [66]
where, „ is concentration, t is time, and D is di usion coe cient.
By applying the finite di erence method for computing the numerical solutions of the
systems of di erential equations, the translation of Eq. 4.3 into cellular automata rules for
dissolution simulation is done. The voxels are classified in di erent types and a finite number of
rules are applied on every voxel type. For the dissolution simulation, every cellular automaton
has a primary constant (C1) and a secondary constant (C2).
The C1-value indicates the number of iterations which are needed to change the state of a
voxel from “solid” to “liquid” [177]; it can be calculated as shown below:
(4.4) C1 =
m
dm
·26
where, dm is from Eq. 4.2 in case of dt = 1, mass of the voxel m (g) is m=V · ﬂ, volume of the
voxel V (cm3) is V = h3 , h (cm) is voxel side length, ﬂ (g/cm3) is density of the component, and
26 is number of surrounding “liquid” voxels in the three-dimensional Moore neighborhood [177].
In the F-CAD dissolution simulation, the time resolution is 1 sec; according to Eq. 4.2, it
follows:
(4.5) dm = A ·D
h
·Cs for dt = 1
(4.6) with the Stokes-Einstein relation: D = 1
f
·ŸB · (T + 273.15) [116]
(4.7) with f for a sphere given by the Stokes’ law: f = 6ﬁ ·÷ ·R [92]
(4.8) with viscosity of water: ÷ = 2.414 ·10-5 ·10(247.8/((T + 273.15)-140)) [2]
where, voxel surface area A (cm2) is A=6 · h2 , D (cm2/s) is di usion coe cient, f is frictional
coe cient, ŸB = 1.3806488 · 10 -16 cm2·kg·s-2·K-1 is Boltzmann constant, T (¶C) is temper-
ature, 6ﬁ is dimensional factor [58], ÷ (Pa·s) is viscosity of the dissolution medium at given
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temperature, and R (Å) is molecular radius of gyration.
Table 4.1 provides an overview about the primary constants used for the in silico tablet
dissolution simulations and the constants calculated according to Eq. 4.4.
Table 4.1. Comparison of the constants used for the F-CAD simulations and the calculated
values. For the polymeric excipients (e.g. Polyox®, Methocel®) the calculation
of the C1-values according to Eq. 4.4 was not possible.
Component C1-constant Calculated C1-constant
Lipophilic mini-tablet formulation:
Ca eine 700 765; (230 (1))
FCC 500 2
Hydrophobized FCC 100 000 æ Œ
Lubritab® 7 000 000 (2) æ Œ
Hydrophilic tablet formulation:
Ca eine 800 998
Citric acid 10 20
FCC (in water) 4 000 3 368 569
FCC (in 0.1 N HCl) 1 800 11
1 C1-value calculated according to Eq. 4.4.
2 Minimum C1-value required to prevent reduction of the number of voxels during dissolution simulation.
In the case of the hydrophilic tablet formulation, the primary constant of ca eine, which
was applied for the F-CAD simulation, was in accordance with the calculated value. On the
contrary, a three-times higher C1, ca eine-value than the estimated one was used for the in
silico simulation of the lipophilic mini-tablet matrices. We hypothesized that melting of the
co-formulated lipophilic excipient during the granulation process resulted in a hydrophobization
of ca eine, i.e. immersion of the ca eine crystals (or with regard to the F-CAD simulation of the
ca eine voxels) in a lipophilic matrix. This led to a significant di erence in di usion behavior
of the component between unrestricted and porous medium due to elongated flow pathways.
The change in di usion behavior of the material was included in the C1-value calculation by
adapting the voxel surface area, resulting in an estimated C1-constant of 765 for ca eine.
In a saturated porous medium, the e ective di usion coe cient De  can be represented by
the following equation [191]:
(4.9) De  =
D · ” ·„
·
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where, D is di usion coe cient, ” is constrictivity factor taking into an account the constricted
transport paths in a porous medium, „ is e ective transport-through porosity, and · is tortuosity
factor to account for the reduction in di usive flux due to the tortuous path lengths compared
to straight paths in an unrestricted medium.
We introduced an F-CAD component type for porous material (type ID 80) to be capable of
assessing the performance of FCC during in silico tablet dissolution. In the case of component
type 80, the secondary constant (C2) defines the rate of liquid sorption into the porous material.
The penetration of dissolution medium into FCC is an important parameter for the evaluation of
the flotation performance as the wetting of the porous material results in a density increase [57].
In order to simulate the behavior of FCC in dissolution media with di erent pH-values, the
C1-constant was accordingly adapted. In terms of the Noyes-Whitney equation (Eq. 4.2), the
C1-value can be described as a reciprocal of the constant term.
Under acidic conditions, a reaction-based erosion of FCC (calcium carbonate) occurs:
(4.10) CaCO3(s) + 2HCl(aq)æCaCl2(aq) + H2CO3(aq)
(4.11) H2CO3(aq)æH2O(l) + CO2(g)
(4.12) CaCO3 + 2H+æCa2+ + H2O + CO2
FCC dissociates in solution by:
(4.13) CaCO3⌦Ca2++CO32- Ksp = [Ca2+][CO32-] = 4.8 ·10-9 [167]
(4.14) H2O + H2CO3⌦H3O+ + HCO3- Ka1 =
[H3O+][HCO3-]
[H2CO3]
= 2.5 ·10-4 [96]
(4.15) H2O + HCO3-⌦H3O+ + CO32- Ka2 =
[H3O+][CO32-]
[HCO3-]
= 4.69 ·10-11 [238]
The molar solubility of FCC at pH 1.2 can be calculated, as follows:
(4.16) dm
dt
= A ·D
h
·CspH=1.2 with CspH=1.2 =
Û
Ksp
–2
where, fraction of dissociation – is –2 = [CO3
2-]
FA
= Ka1·Ka2[H3O+]2+Ka1·[H3O+]+Ka1·Ka2 and FA is
formal concentration.
The calculated C1, FCC-values for the hydrophilic and lipophilic formulations (Table 4.1)
indicate immediate dissolution of FCC in an acidic medium. But, the C1, FCC-values obtained
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according to Eq. 4.4 represent the number of iterations which are needed to dissolve an FCC
component voxel being surrounded by 26 “liquid” voxels respecting the three-dimensional
Moore neighborhood. For the F-CAD simulation, the impact of co-formulated excipients on the
dissolution behavior was included in the C1, FCC-values. They account for the average length of
the di usion pathway which dissolved FCC needs to travel in order to reach the bulk solution.
Due to the slower dissolving tablet matrix, the di usion pathway of FCC was assumed to be
obstructed and prolonged.
As calcium carbonate is practically insoluble in water, it results for the C1-constant of FCC:
(4.17) dm
dt
= A ·D
h
·CspH Ø 7 with CspH Ø 7æ 0
(4.18) C1 =
m
dm
∆C1 = mA·D
h ·Cs ·dt
with dt = 1
(4.19) C1, FCC = lim
Csæ0
m
A·D
h ·Cs
= Œ
For FCC in water, a high C1-constant of approx. 3 000 000 was calculated by applying
Eq. 4.4. The value was in accordance with the conclusion drawn from Eq. 4.19 which implies
that in dissolution media with neutral pH the primary constant of FCC goes to infinity due
to its low solubility (CaCO3 solubility in water at 25 ¶C: 0.013 g/L [227]). The C1-value
used for the dissolution simulations of the hydrophilic tablet formulation in water was about
840-fold smaller than the calculated value. It has to be taken into account that the hydrophilic
formulation contained citric acid which promoted the erosion of FCC and reduced its primary
constant. For FCC in water, as well as for hydrophobized FCC, it has to be kept in mind that
not only dissolution of FCC occurred, but also erosion processes took place in vitro. However,
the detachment of FCC particles from the tablet matrix - without dissolving FCC voxels -
cannot be simulated in silico. It can only be mimicked and controlled by the primary constant
of the component voxels, i.e. the reduction of the C1, FCC-value to simulate a faster state change
of the cellular automaton from to solid to “liquid”.
For the computer simulation of the lipophilic FCC-based tablet formulations, an additional
type of FCC - hydrophobized FCC - was introduced. We assumed that hydrophobized FCC
had a solubility equal to the lipophilic component Lubritab® which formed a hydrophobization
layer around the FCC particles.
Lubritab® is practically insoluble in water; accordingly, it follows for the primary constant
of Lubritab® and hydrophobized FCC:
(4.20) dm
dt
= A ·D
h
·Cs with Csæ 0
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According to Eq. 4.18, it results:
(4.21) C1, Lubritab® = limCsæ0
m
A·D
h ·Cs
= Œ ; C1, Hydrophobized FCC = lim
Csæ0
m
A·D
h ·Cs
= Œ
It was hypothesized that a re-arrangement of the lipophilic material took place during the in
vitro drug release measurement. In consequence, pre-hydrophobized FCC became accessible for
the acidic dissolution medium. This assumption may provide an explanation for the variation
between applied and calculated primary constant of hydrophobized FCC. As mentioned above,
the primary constant of hydrophobized FCC did not only reflect the reciprocal solubility per
unit of time. The value also took into consideration the detachment of hydrophobized FCC
particles from the tablet matrices during dissolution.
4.4 Quality by Design
The Food and Drug Administration (FDA) issued a guidance for industry “Q8R2 Pharmaceu-
tical Development” describing the principles of Quality by Design (QbD). It has been stated
that quality should be built-in or should be by design and cannot be tested into the product.
In pharmaceutical formulation design and process development, the starting point of the QbD
approach is to define the quality target product profile (QTTP) dealing with quality, safety,
and e cacy (i.e. route of administration, characteristics of the dosage form, bioavailability,
strength, stability). Furthermore, the potential critical quality attributes (CQA) of the drug
product, of the drug substance, and of the excipients, which may have an influence on the final
product quality, need to be identified and understood. The QbD approach includes the selection
of appropriate pharmaceutical manufacturing processes. To design, monitor, and control the
production processes by in-line or on-line measurements of critical process parameters (CPP),
which may e ect the CQA, process analytical technology (PAT) is applied [69]. The in silico
dissolution simulation model is considered to be a valuable additional element for the pharma-
ceutical QbD approach: it allows to gain an enhanced knowledge of raw material characteristics
and product quality attributes as well as an improved understanding of process parameters;
thus, it facilitates to establish an appropriate control strategy.
4.5 Characterization of floating behavior
To facilitate the analysis and comparison of floating kinetics of FDDS, we proposed to display
the floating force of dosage forms as a function of drug release. Based on the literature data
of resultant-weight measurements and on our results of the floating performance analysis of
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FCC-based tablets, a classification system was introduced. It describes five floating model
behavior which are commonly observed among FDDS.
So far, there exists no proposal for a floating behavior which is considered to be “optimal”
for floating GRDDS. In general, a short or no floating lag time is targeted to reduce the risk of
premature, uncontrolled stomach emptying of the delivery device. The development of FDDS
is, in most cases, aimed to achieve the longest possible buoyancy time.
From our point view, the unidirectional design and optimization of floating formulations to
achieve the longest flotation time seemed not appropriate. In the context of the classification
system for FDDS, we defined an “ideal” floating behavior which took into account the drug
release behavior (3.2 In vitro and in silico evaluation of floating gastroretentive
drug delivery systems). The “ideal” floating behavior was characterized as follows: the
dosage form features no floating lag time, maintains its floating force until complete drug
release, and finally, exhibits a floating force decrease to zero.
4.6 Gastric retention potential of floating systems in human
The in vitro and in silico analytical methods for FDDS allowed a detailed characterization
of the drug release and the floating behavior of dosage forms. But, they were not capable of
replacing the in vivo evaluation of the GI transit behavior and they could not predict the
gastric retention potential of the FDDS in humans. Thus, it implied that an excellent in vitro
floating performance in the experimental setup did not necessarily result in a prolonged in vivo
GRT. Additionally, it has to be kept in mind that the in vivo evaluation in animals does not
allow to draw a conclusion about the gastric retention potential of a FDDS in humans. The
reasons are significant species di erences regarding GI tract anatomy and physiology between
humans and commonly-used laboratory animals. A clinical evaluation in humans is obligatory
to assess the gastric retention potential of floating dosage forms.
Instead of using imaging techniques to track the GI transit of the dosage forms, we applied
an enteric-coating concept for determination of the stomach residence time of our floating
tablet formulation. The enteric-coating was only for analytical purpose and was not of relevance
for the flotation mechanism of the dosage form. In comparison to the marker-based imaging
methods, our approach featured the advantage that a modification of the floating system due to
the co-formulation of marker substances was not required. The addition of a labeling substance
in su ciently large amounts to the “original” floating formulation e ects the characteristics
of the dosage form (e.g. density, floating kinetics). Consequently, it may influence the in vivo
gastric retention capability of the FDDS.
The in vivo behavior of the enteric-coated tablets could be depicted in the floating behavior
classification graph by two points. The enteric-coated FCC-based floating tablet featured an
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inherently low density. Therefore, it was supposed to float immediately on the stomach contents
after oral administration. This property complied with our requirements for “ideal” floating
properties. Under acidic conditions in the human stomach, the pH-dependent tablet coating
remained intact. Thus, the reaction-based erosion of the tablet and the release of the marker
substance ca eine were prevented. At zero percent drug release, the enteric-coated floating
compact exhibited a positive resultant force. We hypothesized that the enteric-coated dosage
form maintained its floating capability while being retained in the stomach. Following stomach
emptying, the pH-dependent enteric coating dissolved due to the elevated pH in the intestinal
environment. As a consequence, the markers substance ca eine was released from the dosage
form. We assumed that the FCC-based tablets had a resultant force close to zero or below
zero at 100% drug released. The shown performance was close to the defined “ideal” floating
characteristics.
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Conclusion and outlook
Despite the research performed in the field of gastroretentive drug delivery during the pastdecades, the development, the manufacture, the analysis, and the optimization of floating
drug delivery platforms remain a challenging task. In the context of this thesis, the novel
pharmaceutical excipient FCC, an innovative in vitro evaluation method, a computer-based
simulation model, and an in vivo clinical study design were combined in a tool box in order
to facilitate the formulation development of FDDS and to design robust floating formulations
“right-first-time”.
5.1 Functionalized calcium carbonate - a pharmaceutical
excipient with an inherently high porosity
FCC is a microporous to mesoporous material with characteristic lamellar structures that form
a porous meshwork. The lamellae provide a large contact area allowing to tightly interlock the
particles. Due to its unique properties, the excipient is applicable and advantageous for the
compaction of tablets featuring an inherently low density less than unity accompanied by a
su ciently high tensile strength. The design of floating tablets and mini-tablets revealed that
FCC is an enabling excipient for the manufacture, also on larger scale, of innovative instantly
floating drug delivery platforms [77].
At present, it is worked on the registration of FCC as pharmaceutical excipient. The market
launch of FCC as a new generation of mineral excipient is planned to take place in the year 2015.
The commercially available pharmaceutical excipient will be registered and sold under the
brand name “Omyapharm” [160]. The encouraging results of our research group provide a first
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evidence for the successful applicability of FCC in pharmaceutical industry [57, 175, 215, 216].
5.2 Floating drug delivery platforms based on functionalized
calcium carbonate
In the context of this thesis, two types of FCC-based floating tablet formulations were designed
and investigated. The production of the hydrophilic and lipophilic formulations was done by
batch-wise wet granulation and continuous melt granulation, respectively.
Ca eine was selected as a model drug substance in order to characterize the drug release
mechanism of the delivery platforms. For further optimization of the FCC-based floating tablets,
it is recommended to replace the model drug substance by an API which benefits from a
gastroretentive delivery approach.
The hydrophilic FCC-based FDDS presented a surface-eroding drug delivery platform with
a linear decrease in floating capability while releasing the API in an erosion-controlled manner.
The degradation process at the tablet surface was faster than the di usion of the simulated
gastric fluids into the porous tablet matrix. The pH-dependent flotation mechanism can be
described as a gas-generating erosion mechanism with polymers as imbibition-inhibiting and
gas-entrapping components. Concerning the administration to humans, we concluded that the
hydrophilic formulation type does not have the risk of retention in the human stomach beyond
the targeted GRT; hence, the accumulation of delivery devices in the GI tract following multiple
administrations is rendered almost impossible.
On the basis of FCC as matrix-forming material combined with a lipophilic meltable
ingredient, we designed floating tablets and multiple-unit floating mini-tablets. The degree of
FCC hydrophobization and the arrangement of the components within the tablet matrices
were critical attributes for the design of robust lipophilic-excipient-FCC matrix formulations.
They influenced tablet properties such as breaking strength, dissolution behavior, and flotation
performance. There seems to be a negligible risk for the dosage units to accumulate in the
gastric region as the in silico simulations of the mini-tablet matrices suggested a resultant
floating force close to zero at 100% drug released. FCC, due to its porous structural organization,
may function as release-controlling excipient for hydrophobic matrix systems. It enables to
overcome the shortcoming of incomplete API release which is often observed in the case of
hydrophobic matrix delivery platforms.
To sum up, the formulation of porous material - such as FCC - with diverse types of
excipients renders possible the manufacture of instantly floating systems with di erent flotation
and drug release characteristics.
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5.3 Techniques for the analysis of floating systems
The applied approach of combining in vitro and in silico methods o ered the possibility to
compare and to characterize in detail the floating systems. This point was considered to be of
fundamental importance for the e cient preparation of innovative FDDS with targeted drug
release profiles and floating performance as well as for the understanding of the underlying
mechanisms.
In order to overcome the shortcomings associated with the conventional dissolution methods,
we proposed and applied a custom-built stomach model which was based on a horizontally-
moving water bath shaker. The horizontal movement was beneficial as it kept the FDDS
moistened during the in vitro drug release measurement and mimicked the GI tract motility.
Additionally, our experimental setup enabled the simultaneous investigation of drug release
and flotation behavior (i.e. visual assessment of floating lag time and total floating time).
The necessity of using in silico simulations resulted from the fact that the available in vitro
techniques do not allow for a simultaneous assessment of drug release and quantification of the
resultant force. For the future formulation development in the field of FDDS, the construction
of a test setup to perform this combined evaluation would be a great benefit.
In the context of the thesis, the three-dimensional cellular-automata-based computer model
was successfully applied to quantify the floating potential of tablets. Furthermore, the computer
simulations will advance the further optimization of the invented FCC-based hydrophilic and
lipophilic floating drug delivery platforms. They render possible to vary the amount of drug
substance and to substitute the used model drug ca eine by other APIs with an unmet medical
need for a gastroretentive delivery approach. The impact of formulation changes on tablet
dissolution and resultant floating force can be first studied in silico without the need of carrying
out all respective experiments in vitro in the laboratory.
5.4 Evaluation of floating systems in human
Our approach (i.e. pH-dependent enteric coating and ca eine as marker substance) presents
a simple method to study in human the stomach residence time of non-e ervescent floating
tablets with an inherent density less than unity. The results of the pilot experiment, performed
in three human volunteers, provided an indication for the in vivo gastric retention potential of
floating tablets based on FCC and for the applicability of the flotation concept, in general, to
achieve an extended stomach residence time.
The primary objective of the self-experiment was to investigate, on the example of enteric-
coated FCC-based tablets, whether a mechanism of flotation results in a prolonged GRT of
dosage forms in comparison to non-floating devices. However, the setup of the in vivo study
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did not provide any information regarding the GI performance and drug release behavior of
uncoated FCC-based floating tablets.
The encouraging findings of the pilot study seem to justify a follow-up with clinical trials in
humans. Thus, for follow-up clinical evaluations the enteric tablet coating will be omitted in
order to analyze drug concentrations at predetermined time points in endoscopically-collected
gastric juice samples. It is suggested to replace the model/marker drug substance by an API
which features an unmet medical need for a gastroretentive delivery approach. The preferred
dosage forms to be evaluated in follow-up clinical trials regarding their gastroretentive potential
are multiple-unit FDDS. They have a reduced risk of “all-or-nothing” gastric emptying and,
hence, a lower intra-individual and inter-individual variability in drug bioavailability. In the
context of a clinical study, factors that may influence the gastric retention potential of FDDS
(e.g. liquid intake, composition of food, body position, physiological conditions) need to be
investigated.
5.5 Classification system for floating systems
Our classification system was found to be a valuable element of the established FDDS formulation
design tool box. It links two important response variables of floating systems - namely drug
release and resultant force - which are often considered independent from each other. However,
it has to be kept in mind that the classification system is for illustrative purpose and displays
model floating behavior; more complex floating behavior may be experimentally observed. The
classification system is not limited to the distinguished five types of flotation and a larger
number of categories is possible.
We defined “ideal” floating kinetics, taking into consideration the anatomical and physiolog-
ical conditions and organization of the human stomach, as follows:
• The floating system exhibits immediate flotation to reduce the risk of an uncontrolled
and premature gastric emptying from the stomach.
• While the API is released, the floating system maintains its resultant floating force.
• After complete drug release, the floating system shows a “switch-o ” e ect regarding
flotation capability to trigger the stomach emptying of the device.
Nevertheless, the classification system is not only a theoretical concept. The practical
relevance of our considerations was demonstrated by applying the classification system for the
formulation development and optimization of FCC-based mini-tablets. Mini-tablet formulations
which exhibited a floating behavior close to the described “ideal” floating characteristics were
identified in the experimental setup. In addition, our definition of “ideal” floating kinetics was
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supported by the results of the in vivo pilot experiment.
The approaches proposed and applied in the context of the thesis were summarized in a
FDDS formulation design tool box to promote the formulation development of floating systems.
As elaborated in the introduction, there are several APIs which may profit from a prolonged
GRT. The FDDS formulation design tool box, which includes floating drug delivery platforms
based on FCC, provides the opportunity to reconsider and extend the existing therapies and to
design innovative and feasible treatments using the concept of floating gastroretentive drug
delivery.
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